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Abstract
This thesis examines the clinical, pathological and biochemical diversity of 
progressive supranuclear palsy (PSP).
The material and patients used for these studies involved 23 clinically diagnosed 
living patients and 127 pathologically confirmed cases of PSP, archived at the Queen 
Square Brain Bank (QSBB). Differences between ‘classic’ PSP and ‘atypical’ PSP were 
identified, and a number of clinical features that separate them from other bradykinetic 
rigid syndromes were explored.
• In addition to the clinical phenotype associated with PSP-tau pathology initially 
described by Richardson in 1963 (Richardson’s syndrome, RS) two other 
distinct clinical syndromes were identified: PSP-Parkinsonism (PSP-P) and pure 
akinesia with gait freezing (PAGF).
• The following clinical features, in addition to the operational diagnostic criteria, 
were supportive of underlying PSP-tau pathology in patients presenting with 
Parkinsonism: an absence of drug induced dyskinesias, autonomic failure and 
visual hallucinations; the presence of falls within 6 years of disease onset; UPSIT
scores above the 12th percentile for gender and age; and abnormalities in
auditory startle response and auditory blink reflex.
• PSP-tau pathology always involved the subthalamic nucleus (STN), globus 
pallidus (GP) and substantia nigra (SN), but involvement outside these 
structures was variable and could be sub-divided into at least three different 
patterns.
• Severe tau pathology in PSP-P and PAGF was restricted to the GP, STN and SN.
• Co-existent pathological diagnoses did not differ between RS, PSP-P and PAGF.
• The ratio of pathological 4-repeat:3-repeat tau in PSP was variable. In RS the 
mean ratio was higher than in PSP-P (2.84 vs. 1.63 (p<0.003).
• Mutations of MAPT did not account for the diversity of clinical features
The proposed clinical and pathological sub-classification of PSP will be helpful in 
clinical practice. Pathological and biochemical correlates raise the possibility that PSP-P
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and PAGF may represent discrete nosological entities. Further research may ultimately 
lead to their absolute distinction from Richardson’s syndrome and related tauopathies.
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The clinical and pathological features currently used to diagnose PSP are based on 
the seminal descriptions of Richardson, Steele and Olszewski. The Canadian authors 
predicted that with greater awareness of the condition, clinical heterogeneity would be 
found.
“Atypical PSP” refers to patients in whom typical PSP-tau pathology is found at 
autopsy, but whose clinical features have deviated from Richardson’s classic description. 
The lack of clear-cut clinicopathological correlations has made accurate definition of 
these patients difficult in clinical practice.
Despite its ambiguity, a number of authors have reported pathological, 
biochemical and genetic differences between “atypical” patients and those whose clinical 
syndrome mirrored Richardson’s original description.
The research undertaken for this thesis was designed to explore “atypical” PSP in 
detail. Specifically the aims were:
(1) to look for patterns of clinical symptoms that are present in pathologically 
defined PSP;
(2) to look for patterns of pathological changes in PSP and correlate them with 
clinical phenotypes;
(3) to examine the biochemical profiles of insoluble PSP-tau and correlate them 
with clinical phenotypes;
(4) to compare the tau genetic background in clinical phenotypes of PSP; and
(5) to determine the clinical features which are most helpful in identifying 
“atypical” PSP in life.
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In the early 1960s Richardson recognised a clinical syndrome he designated PSP. 
It was unique amongst the known bradykinetic rigid syndromes and was 
characterised by nuchal rigidity, ophthalmoplegia, pseudobulbar palsy, dementia, 
and gait disturbance. His colleagues Steele and Olszewski identified 
pathological changes that were consistent throughout these patients, identifying 
what are now considered the pathological hallmarks for PSP. Because of the 
difficulties with confirming the clinical diagnosis of PSP, the gold standard for 
diagnosing PSP has become pathological. Subsequently, what was originally a 
clinical designation became synonymous with a pathological entity. In the 
decades following the original observations, improvements in pathological 
methodology have allowed for clearer characterisation of the neuronal and glial 
accumulation of insoluble tau that is seen pathologically in PSP. Advances in 
clinical aspects of the disease have been hampered by diagnostic criteria with low 
sensitivity or specificity, vagaries with atypical clinical phenotypes and the lack 
of a sensitive and specific clinical tool to improve diagnosis. Despite this PSP is 
recognised throughout the world, and appears to be the second most common 
cause of bradykinetic rigid syndromes. Early, accurate diagnosis is a priority for 
patients, but improvements in clinical differentiation from other bradykinetic 
rigid syndromes and tauopathies is needed to improve this.
“There is a disease which I  really described in patients first seen at Sunnybrook 
Hospital in the late 50s and 60s that strangely enough hadn't been recognized 
before. It is a chronic, progressive brain disease in which they have a certain defect 
of eye movements, as well as a rigidity and stiffness. I  gave it the name progressive 
supranuclear palsy (PSP). The first patient which I'd seen and realized was 
something new and different died and I  had the brain. Shortly after Olszewski 
came here I  said; uNow I  do hope you will study this brain for me. It is a very 
unique and special brain of a condition that hasn't been written up before." He got 
John Steele who was a fellow to spend most of his year working at it and we 
published on this**
(J. C. Richardson, interview by the Hannah Institute for the History of Medicine Archives, University of 
Toronto)
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Progressive supranuclear palsy
In 1955, Dr J. Clifford Richardson was visited by a good friend and 52 year old 
business executive because of clumsiness, trouble in seeing, and mild forgetfulness. 
During the next 4 years, Richardson was puzzled as his friend progressively developed an 
unusual constellation of signs which included supranuclear ophthalmoplegia affecting 
chiefly vertical gaze, pseudobulbar palsy, dysarthria, dystonic rigidity of the neck, and 
mild dementia.
As he was observing the evolution of this illness, Richardson serendipitously 
identified similar symptoms in three other middle-aged Canadian veterans who were 
admitted to the Neurology Service at Sunnybrook Military Hospital for long term care. 
The first was a West Indian labourer, who immigrated to Canada in 1913 and developed 
unsteady walking in 1954. The second patient was a truck driver who came from 
England when he was a child and who was well until his personality changed and he 
started to fall at the age of 49. The third veteran had come from the Ukraine in 1913 and 
worked as a labourer until 1956 when he developed difficulty with vision, his speech 
became slurred, and he had trouble in swallowing. Richardson recognised that despite 
different presentations, these four patients had the same hitherto unrecognised disorder.
During the next few years, Richardson came across three further patients with 
what also appeared to be the same condition. Though all were Canadians, they were of 
different ethnicities, socioeconomic status, and occupations. None had family members 
with neurodegenerative disease and none had a history of preceding encephalitis or toxic 
exposure to account for their cerebral symptoms.
By the early 1960s, five of Richardson’s seven patients had died. 
Neuropathologists Linell and Tom at the Banting Institute examined their brains and 
confidently diagnosed them as having post encephalitic Parkinsonism (PEP), a post- 
infectious disease with neurofibrillary degeneration occurring in the wake of the 
encephalitis lethargica pandemic of 1915-1925. They were both quite familiar with the 
pathological findings of PEP and they were also aware of a case report, of a Flemish 
patient with identical symptoms and pathological changes that the eminent neurologist 
Ludo van Bogaert had also attributed to PEP. (Chavany et al., 1951) However, 
Richardson found himself at odds with this conclusion. He pointed out that none of the
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patients had a history of preceding encephalitis. Furthermore, by the 1950s PEP after von 
Economo’s encephalitis lethargica was declining and uncommon, and most tellingly the 
clinical syndrome he identified was quite unlike that of classical PEP, and was unfamiliar 
to Canadian neurologists.
In 1962, Richardson recommended that Dr John Steele assist Professor Jerzy 
Olszewski, the new Professor of Neuropathology in Toronto, to thoroughly re-evaluate 
the pathology of his cases. At the beginning of their project in July 1962, Olszewski 
decided that they would each make presentations during 1963, and publish their work in 
1964, in the Archives of Neurology with the order of authorship as Steele, Richardson 
and Olszewski.
In June 1963, at the American Neurological Association meeting in Atlantic City, 
Richardson presented the first clinical report of eight cases of “Heterogeneous System 
Degeneration” with supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia 
and dementia. (Richardson et al., 1963) He observed that this hitherto unrecognised 
disorder presented in the seventh and eighth decades of life and was relentlessly 
progressive with death occurring within nine years.
Professors Houston Merritt, Robert Schwab, and Derek Denny-Brown were the 
discussants. They congratulated Richardson for his detailed observations about this 
interesting condition which Denny-Brown thought must be quite rare since none of those 
attending, except McNaughton, knew of similar cases. Because there were no hereditary 
factors, Merritt thought it was likely that some toxic influence was responsible. The 
neuroepidemiologist Kurland commented on the unusual concentration of cases from 
Toronto and he also wondered if they could have been exposed, in common, to some 
regional and toxic environmental factor. In answer, Richardson observed that the group 
of cases reported from Toronto was a small one. The patients came from various parts of 
Ontario and there was nothing peculiar about their diet or exposures. One patient lived in 
Montreal and Van Bogaert's case, which seemed to be the same disease, came from 
Belgium. (Chavany et al., 1951; Richardson et a l , 1963)
In 1959 Olszewski had taken up the position of Professor of Neuropathology at 
the Sunnybrook Unit, after establishing himself as pathologist and anatomist through the 
publication of classic atlases while at McGill University. (Klatzo, 1964) In the 12
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months following Richardson’s invitation to review his archived cases, Olszewski 
described the anatomy and histopathology of the disease and the detailed localization of 
the lesions in four cases. These findings were presented by Olszewski to the American 
Association of Neuropathologists in 1963, where he described extensive subcortical 
neurofibrillary degeneration in the globus pallidus, subthalamic nucleus, substantia nigra 
and dentate nucleus. Dr Asao Hirano, a neuropathologist at Montefiore Hospital, was 
present at that meeting. He had previously published pathological findings of 
amyotrophic lateral sclerosis (ALS) and the parkinsonism-dementia complex (PDC) 
occurring among Chamorros on the island of Guam, (Hirano et a l , 1961) and in the 
discussion following Olszewski’s paper commented on the pathological similarities 
between ALS/PDC and heterogeneous system degeneration.
The following year Richardson and Olszewski, together with Steele, published 
their seminal paper titled “Progressive supranuclear palsy” (PSP) describing the clinical 
and pathological features of the disease. They argued that PSP had a distinct clinical 
picture despite the pathological similarities to PDC and PEP. (Steele et al., 1964) The 
highly specific clinical picture Richardson had observed was, with considerable foresight, 
dependent on the similar localisation of lesions amongst their cases. Furthermore they 
predicted that “it is possible that further observations may broaden the clinical spectrum 
of the disease. In other cases, the distribution of pathological changes may be different, 
and thereby the clinical picture would be modified.” (Steele et al., 1964).
In their 1963 reports, Richardson and Olszewski had called the condition 
heterogeneous system degeneration, a term first used by Verhaart for a similar case he 
described in 1958. (Verhaart, 1958) But because they were not certain the disease was a 
primary degeneration or that it was related to other system degenerations, it was agreed 
that they should choose another term. They briefly considered “Can’t look down 
disease”, “Toronto disease”, and neurosurgeon Morley suggested the eponym ROT (for 
Richardson, Olszewski and Tom). In the summer of 1963, Richardson proposed that it be 
called progressive supranuclear palsy, a clinical designation and the name by which the 
disease is now known, particularly in Europe. Some also refer to it as the Steele- 
Richardson-Olszewski syndrome, an eponym which was first used by the Montreal 
neurologist Andre Barbeau in 1965. (Barbeau, 1965)
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In 1972, Steele completed the 1964 report by confirming PSP pathology in the 
two patients who were still alive at the time of the original reports. He emphasized credit 
for the identification of the clinical syndrome must go to Richardson. (Steele, 1972)
By the 1970s, Richardson knew that the nosological entity he had first identified 
as an unusual syndrome in the 1950s was a unique, universal and not uncommon 
neurological disease of middle and later life. Of 73 patients with PSP reported between 
1951 and 1972, 51 had been male and of diverse ethnic and racial origin. With one 
exception (David et al., 1968), no similar disorder existed in their families and their past 
health had usually been good. Careful enquiry seemed to exclude anything in their life 
habits or circumstances which might have predisposed them to the disease. In none had 
there been known exposure to noxious or toxic agents or any antecedent illness to suggest 
encephalitis. The many reports available by 1972 indicated that the disease was not 
restricted to geographic or climatic regions. (Steele, 1972)
Contrary to predictions of clinical and pathological heterogeneity made by Steele, 
Richardson and Olszewski in 1964, the 59 patients reported by others between 1964 and 
1972 had, with minor exceptions, presented with similar symptoms and signs and pursued 
a similar course. (Steele, 1972; Steele, 1975)
Interest in bradykinetic rigid syndromes, including Parkinson’s disease (PD), PEP 
and PSP, increased with the widespread availability of L-dopa in the 1970s. In addition 
to the clinical features described by Richardson, PSP was found to be characterised by 
poor response to L-dopa medication. (Klawans and Ringel, 1971) Recognition and 
differentiation of PD, Rebeiz’s corticodentatonigral degeneration with neuronal 
achromasia (corticobasal degeneration, CBD), multiple system atrophy (Graham and 
Oppenheimer, 1969) and a more refined characterisation of PSP allowed for the 
identification of unusual cases of PSP without Richardson’s classic features. Reports of 
pathologically diagnosed cases included presentations of pure akinesia without rigidity 
(Matsuo et al., 1991; Vemy et al., 1996a), isolated dementia (Davis et a l , 1985; Masliah 
et al., 1991; Josephs et a l , 2005), parkinsonism without dementia (Davis et a l, 1985; 
Vemy et a l, 1996a; Birdi et a l, 2002) as well as a number of cases dying without 
recorded evidence of the distinctive supranuclear ophthalmoplegia (Pfaffenbach et a l , 
1972; Dubas et a l, 1983; Davis et a l, 1985; Daniel et a l, 1995) were reported.
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In 1996 diagnostic criteria were published following a meeting sponsored by the 
National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP 
(SPSP). The NINDS-SPSP consensus statement for the diagnosis of PSP was largely 
based on the seminal clinical descriptions by Richardson and colleagues, (Litvan et a l ,
2003), despite the expanding literature on, what had become loosely termed clinically 
“atypical PSP”. The NINDS-SPSP criteria for possible PSP required the presence of a 
gradually progressive disorder with onset at age 40 or later, either vertical supranuclear 
gaze palsy or both slowing of vertical saccades and prominent postural instability with 
falls in the first year after onset, as well as no evidence of other diseases that could 
explain these features. Probable PSP required vertical supranuclear gaze palsy, 
prominent postural instability, and falls in the first year of onset, as well as the other 
features of possible PSP. Definite PSP required a history of probable or possible PSP and 
histopathologic evidence of typical PSP. The recognition of clinical heterogeneity in 
pathologically diagnosed cases of PSP has lead to the adoption of an imprecise clinical 
classification, which includes typical and atypical clinical subgroups. The arbitrary 
definitions of atypical clinical PSP have varied and are often applied retrospectively.
20
What is PSP?
Richardson’s original designation of PSP was as a clinical entity. Despite this, in 
the past 3 decades “PSP” has come to be defined by the pathological changes originally 
described by Steele and Olszewski, probably because of the clinical heterogeneity. The 
diagnosis of PSP is made by the identification of tau-positive neurofibrillary tangles and 
neuropil threads at high density in pallidum, subthalamic nucleus, substantia nigra or 
pons and in lower density in other subcortical structures. In addition to neuronal tau 
deposits, PSP-tau also forms insoluble deposits in glial cells which are characteristically 
star-shaped tufted astrocytes and comma shaped coiled bodies. The pathological 
signature of PSP is the tufted astrocyte, which is rare in other tauopathies. (Litvan et a l , 
1996b; Lowe et al., 2002)
The original pathological observations are reflected in the current 
neuropathological diagnostic criteria, published in 1996. (Hauw et a l , 1994; Litvan et al., 
1996b) These criteria, allowed for an “atypical” pathological group in cases where the 
severity or distribution of abnormalities deviated from the original description, in 
particular where substantial cortical tau pathology occurred. Steele and Olszewski had 
reported that “no pathological evidence of frontal, cortical, or white matter involvement 
of consequence”. (Steele et al., 1964) When applied using traditional histopathological 
staining and sampling methods the current criteria are unable to reliably differentiate PSP 
from PEP. (Geddes et al., 1993; Litvan et a l, 1996b) The differentiation between typical 
and atypical pathological PSP has also proved difficult because involvement of the 
cerebral cortex has now been widely reported in PSP, particularly the frontal and primary 
motor cortex. In many cases the degree of cortical involvement and pathological features 
overlap considerably with other diseases including PDC Guam and CBD. (Braak et a l, 
1992; Hof et a l, 1992; Geddes et a l, 1993; Vemy et a l, 1996a; Bergeron et a l, 1997; 
Takanashi et a l, 2002; Tsuboi et a l, 2005)
The clinical diagnosis of PSP relies on the identification of a gradually 
progressive disorder beginning over the age of 40 years, with early falls, a fronto-limbic 
dementia, a vertical supranuclear gaze paresis and axial rigidity, with poor response to L- 
dopa and an absence of rest tremor. The NINDS/SPSP criteria (table 1.1) incorporate
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these clinical features and were published quoting a sensitivity of 83% for possible PSP 
and specificity of 100% for probable PSP categories. (Litvan et a l, 1996a) When these 
criteria were applied retrospectively to a different series of patients clinically and 
pathologically diagnosis with PSP, similar values were found (sensitivity of 85% for 
possible PSP and positive predictive value (PPV) of 84% for probable PSP). (Osaki et 
a l, 2004) However, when applied at the first clinic visit, early in the disease, the 
sensitivity was reduced to 21% for possible PSP and 4% for probable PSP. (Osaki et al., 
2004) These data support the clinical view that the early diagnosis of PSP can be 
difficult. (Daniel et a l, 1995; Vemy et al., 1996b; Litvan et al., 1996c; Santacruz et a l, 
1998; Schrag et al., 1999; Nath et al., 2001) Pathologically diagnosed PSP is frequently 
mistaken for PD, cerebrovascular disease/multi infarct state, MSA, CBD and even AD. 
(Jackson et a l, 1983; Rajput et a l, 1991; Hughes et al., 1992a; Jellinger, 1995; Santacruz 
etal., 1998; Lopez et al., 1999)
Possible Prohable
Gradually progressive disorder 
Onset at age 40 or older
Either vertical (upward or downward gaze) supranuclear palsy* or both 
slowing of vertical saccades and prominent postural instability with 
falls in the first year of the disease onset 
No evidence of other diseases that could explain the foregoing features, as 
indicated by mandatory exclusion criteria
Gradually progressive disorder 
Onset at age 40 or older
Vertical (upward or downward gaze) supranuclear palsy’ and 
prominent postural instability with falls in the first year of 
the disease onset 
No evidence of other diseases that could explain the foregoing 
features, as indicated by mandatory exclusion criteria
Table 1.1 NINDS-SPSP clinical criteria for the diagnosis of PSP (Litvan et al., 1996a)
In one study of 60 clinically diagnosed cases of PSP, 13 (22%) did not have PSP- 
tau pathology. (Osaki et al., 2004) These cases had PD dementia, PD and AD, MSA, 
Pick’s disease (PiD), frontotemporal dementia with Parkinsonism associated with 
chromosome 17 (FTDP-17) and vascular disease. (Osaki et a l, 2004) Vascular PSP has 
been described in the multi-infarct state (Tanner et al., 1987; Dubinsky and Jankovic, 
1987; Josephs et al., 2002), following hypoxic brain injury (Mokri et a l, 2004; Kim et 
al., 2005), CADASIL (Van Gerpen et a l, 2003), primary antiphospholipid antibody 
syndrome (Reitblat et a l, 2003) and cerebral amyloid angiopathy (Dubinsky and 
Jankovic, 1987). Subtle clinical differences exist between many of these reported cases 
and pathologically proven PSP, including sudden deterioration, early memory
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impairment and late falls. Other diseases which can closely resemble PSP include 
frontotemporal dementia with ubiquitin-only inclusions (Paviour et al., 2004), FTDP-17 
(Morris et al., 2003), Whipple’s disease (Verbuch -Heller et al., 1999), striato-dentate- 
pallidal calcification (Watanabe et al., 2003), brain tumour (Siderowf et al., 1998), 
obstructive hydrocephalus (Curran and Lang, 1994), neurosyphilis (Murialdo et al., 2000) 
and progressive subcortical gliosis secondary to prion disease (Will et al., 1988; Revesz 
et al., 1995). A single case report exists of a reversible, neuroleptic-induced PSP-like 
syndrome (Campdelacreu et al., 2004). Other multisystem neurodegenerative disorders 
in which supranuclear ophthalmoplegia occurs include Kufor Rakeb disease (Williams et 
a l, 2005), Niemann-Pick type C (Neville et al., 1973), Joseph’s disease (Rosenberg et 
al., 1976) and Lewy body pathology (Feamley et al., 1991; de Bruin et a l, 1992), 
although clinical confusion with PSP would be unusual in most of these conditions.
Early, definitive diagnosis may be beneficial on many levels in neurodegenerative 
disease, and is demanded by most patients, but there is little literature on the impact of 
timely diagnosis. In PSP the mean time to definitive diagnosis in one North American 
study was found to be 33.4 months in men and 24.1 months in women. (Santacruz et al.,
1998) Patient contributions to PSP advocacy newsletters frequently report frustration at 
delayed diagnosis and relief when a definitive diagnosis is finally made.(PSP (Europe) 
Association Newsletter) In PD “satisfaction with the explanation of the condition at 
diagnosis” is the second most significant predictor of health related quality of life, after 
depression, having significantly more impact than disease severity or medication use. 
(The Global Parkinson's Disease Survey (GPDS) Steering Committee, 2002)
Only with a definitive diagnosis can issues such as prognosis and planning for the 
future, therapeutic options and genetic counselling be appropriately dealt with. 
Community resource allocation and discussion of end-of-life issues also cannot be dealt 
with adequately without “a name for the disease”. Caregivers and relatives, as well as 
patients, need to be able to “identify” with a specific disease. (Groves and Forrest, 2005) 
This is particularly apposite to PSP where deterioration in function can be marked 
in the first 12 months. (Litvan et al., 1996c; Nath et al., 2003) PSP, in common with 
other neurodegenerative bradykinetic rigid syndromes is often referred to as atypical 
Parkinsonism, Parkinson’s-plus or simply ‘bradykinetic rigid syndrome’. (Jankovic,
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1989; Schrag et a l , 2000; Diroma et a l , 2003; Tolosa et a l, 2006) This terminology, 
although having the benefits of honesty where uncertainty exists, is unhelpful in 
providing patients and their caregiver’s much insight into prognosis. Furthermore it may 
heighten the alienation that is common in the early stages of a chronic neurodegenerative 
disease. (Groves and Forrest, 2005) No support groups for “atypical Parkinsonism” exist 
and internet searches using these terms are more likely to yield unhelpful results.
Clinical acumen is essential for the accurate diagnosis of PSP due to the absence 
of biomarkers. Even when considered in the early differential diagnosis, efforts to make 
a definitive diagnosis are frequently impaired by the clinical heterogeneity at presentation 
reflected in the poor sensitivity of the most stringent diagnostic criteria. (Osaki et al.,
2004) Falls within the first 12 months of disease are central to the NINDS/SPSP 
diagnostic criteria. In the data used to prepare these criteria, the mean time to first fall 
was 6 months, but the range exceeded 150 months, making “late” falls the single biggest 
factor limiting the sensitivity of the criteria. (Wenning et a l , 1999) Vertical supranuclear 
gaze palsy is also a prerequisite for the diagnosis, but some patients develop it many 
years after disease onset and occasionally never. (Imai et a l , 1987; Daniel et a l , 1995; 
Litvan et a l , 1996a; Birdi et a l , 2002) An absence of improvement with L-dopa 
treatment is one of the supportive criteria for the diagnosis of PSP, however, even in the 
NINDS/SPSP cohort 20% of patients had some initial response, and in other reports up to 
a third of patients with pathologically diagnosed PSP can improve with L-dopa. (Vemy et 
a l , 1996b; Litvan et a l, 1997; Birdi et a l, 2002)
Richardson was surprised that the clinical syndrome he reported from Toronto had 
not been reported earlier and in 1963 suggested that “a good many cases of the same 
disease will be identified in other areas”. (Richardson et a l, 1963) True estimates of PSP 
prevalence are difficult as they are affected by the same issues that limit accurate, early 
diagnosis. In addition, methods of case finding and population size can result in 20-fold 
variations in crude prevalence rate estimates. (Nath et al., 2001) The best studies of 
prevalence are community-based, derived from primary care, utilising sensitive inclusion 
criteria, personal examination and validated diagnostic criteria. Two studies in the UK 
that satisfy these requirements report a crude prevalence rate of 6.5 per 100,000 and an 
age adjusted prevalence of 5.0 per 100,000. (Schrag et a l, 1999; Nath et a l, 2001)
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Another study using similar methodology estimated crude and age adjusted prevalence in 
Yonago, Japan to be 5.8 and 5.0 per 100,000 respectively. (Kawashima et al., 2004) In 
Northwest Italy and the Faroe Islands, in studies designed primarily to determine the 
prevalence of PD, the prevalence of PSP has been estimated as 3.2 and 4.6 per 100,000 
respectively. Overall these rates are similar to prevalence rates reported in motor neurone 
disease, where disease duration is shorter, (Roman, 1996) and more than 25 times less 
than rates in PD, where disease duration is almost twice that in PSP. (Porter et al., 2006)
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The pathological distinction of PSP from other neurodegenerative diseases 
characterised by accumulation of tau protein is not as clear cut as originally 
argued. Tauopathies encompass more than 20 clinicopathological entities 
including PSP, Alzheimer’s disease, the most common tauopathy, Pick’s disease,
CBD, PEP and PDC-Guam. Important clinical, pathological, biochemical and 
genetic similarities exist within this spectrum of diseases and have helped to 
advance our understanding of the aetiological factors that initiate 
neurodegeneration and tau accumulation. This has enhanced the need for 
identification of the genetic and biochemical characteristics of PSP.
Introduction
Aggregation of proteins is now recognised as a salient feature of a large number 
of neurodegenerative disease (disorders of protein misfolding). It is now possible to 
classify neurodegenerative diseases not only by their clinical characteristics and 
histological features, but also by the characteristics of the proteins that accumulate in 
neuronal, glial and muscle cells. The microtubule associated protein tau is ubiquitous in 
the adult brain. Its normal function is to promote microtubule assembly from tubulin 
subunits and also to stabilise microtubules, which are important structural building blocks 
and transporters in neuronal cells. Normal tau protein binds to microtubules in axons, but 
in certain neurodegenerative diseases it is redistributed to the cell body where it 
accumulates to form insoluble, fibrillary deposits. (Goedert, 2004) The group of diseases 
characterised by accumulation of tau resulting in formation of neurofibrillary tangles and, 
in some, also glial filamentous inclusions, are collectively known as tauopathies.
Neurofibrillary tangles were recognised as pathological features of 
neurodegeneration by Alzheimer in 1907. However, it was not until the 1960s that the 
composition of these insoluble proteinaceous deposits began to be unravelled, when 
paired helical filaments were identified by electron microscopy. (Kidd, 1963) Two 
decades later the identification of tau protein, as the major component of these filaments, 
allowed for immunohistochemical recognition of tau in a number of other 
neurodegenerative conditions. Its importance in the aetiopathogenesis of
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neurodegeneration was firmly established by the discovery of a number of families with 
autosomal dominant ffontotemporal dementia and Parkinsonism with mutations in the tau 
gene and tau-positive inclusions in neuronal and in several variants of the disease, also 
glial cells (Hutton et a l , 1998). In other tauopathies the molecular events that initiate 
conformational changes in normal tau protein leading to aggregated protein, filament 
formation, neuronal dysfunction and finally cell death are largely unknown.
More than 20 different degenerative disorders are known at present to be 
characterised by neurofibrillary tangle formation.(Table 2.1) Most cause dementia or 
degeneration of the motor system, including Alzheimer’s disease, the most common of 
the tauopathies, PSP, CBD, FTDP-17, PiD, PEP, dementia pugilistica, Down’s syndrome, 
PDC Guam and argyrophilic grain disease. The presence of insoluble tau inclusions and 
neuronal loss in all of these diseases implies a common mechanism involved in cell 
injury and death.
Tauopathies can be divided according to coexistent pathological features. (Table 
2.1) In primary tauopathies tau accumulation is the only finding that accompanies the 
neuronal loss and gliosis. In secondary tauopathies such as AD, the pathological 
accumulation of insoluble tau occurs in combination with another pathological process, 
such as amyloid deposition.
Molecular biology
Tau protein is the most abundant microtubule-associated protein in the brain. It was 
designated the Greek letter T (x, tau) for its ability to induce tubule formation through 
assembly of tubulin. (Weingarten et a l , 1975) In the adult human brain it exists as six 
isoforms, differing by the presence or absence of 29- or 59-amino acid inserts located in 
the amino terminal end and a 31-amino acid repeat in the microtubule-binding domain. 
The isoforms can be further sub-divided depending on whether this microtubule binding 
domain harbours 3-repeat or 4-repeat sequences. In normal adult brain there are similar 
levels of 3-repeat tau (3R) and 4-repeat tau (4R), but in neurodegenerative disorders this 
ratio is altered.
The gene encoding tau is on the long arm of chromosome 17, and is made up of 13 
exons. (Figure 2.1) Exon 10 codes for the alternatively spliced amino acid repeat
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sequence in the binding domain, and mutations here most often cause disease by altering 
the ratio of 3R and 4R tau. (Hutton et al., 1998) Some of the identified mutations reduce 
the ability o f tau to interact with microtubules (Hasegawa et al., 1998) while others 
promote the assembly o f tau into filaments associated with disease. (Nacharaju et al.,
1999) A number of commonly occurring haplotypes of the tau gene are associated with 
other tauopathies, and although the precise mechanisms are yet to be determined the 
central importance of tau for these diseases is beyond doubt. (Pittman et al., 2005)
MAPT genomic structure
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Figure 2.1 Microtubule associated protein tau, and six tau isoforms produced by
alternatively spliced exons 2, 3 and 10 with western blot of recombinant tau and 
insoluble tau from PSP
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Primary tauopathies
Progressive supranuclear 
palsy
Richardson’s syndrome
PSP-P
Argyrophilic grain d isease 
Corticobasal degeneration
Pick’s disease
FTDP-17
Post encephalitic 
Parkinsonism
PDC Guam
Guadeloupean Parkinsonism
Secondary tauopathies 
Associated with amyloid 
deposition
Alzheimer’s disease
Down’s syndrome 
Dementia pugilistica
Familial British dementia 
Familial Danish Dementia 
in association with other 
pathology 
Myotonic dystrophy 
Hallevorden-Spatz disease
Niemann Pick Type C
Pattern of 
dementia
Frontal
dysexecutive
Late frontal 
dysexecutive
Limbic dementia 
Parietal, 
frontal 
dysexecutive 
Frontal 
dysexecutive 
PNFA, SD 
Frontal behavioural
Rare
Frontal
dysexecutive,
cortical
Frontal
dysexecutive
Amnestic, cortical
Amnestic, cortical 
Amnestic, cortical
Amnestic, cortical
Frontal behavioural 
Mental retardation
Mental retardation, 
psychosis
Movement
disorder
Axial rigidity, 
postural instability, 
bradykinesia, 
ophthalmoplegia 
Asymmetric onset, 
axial rigidity, 
tremor, late falls 
No
Asymmetric 
Parkinsonism 
alien limb 
Rare
Symmetric rigidity 
and bradykinesia, 
ophthalmoplegia
Symmetric rigidity 
and bradykinesia, 
ophthalmoplegia 
Symmetric rigidity 
and bradykinesia, 
ophthalmoplegia 
Symmetric rigidity 
and bradykinesia, 
ophthalmoplegia
Rare
No
Parkinsonism
No
No
Gait disturbance, 
extrapyramidal 
syndrome 
Dystonia, ataxia, 
ophthalmoplegia
L-dopa
response
-/+
- /+
- /+
3R:4R
1:2-4
1:1-2
1:2
1:2
3:1
1:2
1:1
2:1
1:1
1:1
1:2
1:1
1:1
1:1
2:1
Associated
genes
MAPT H1
MAPT H1
MAPT H1 
MAPT H1
Multiple 
mutations/ 
deletions of 
MAPT
APP, PS1, 
PS2 
Trisomy 21 
ApoE4 risk 
factor 
BRI2
DMPK
PANK2
NPC1
NPC2
Table 2.1 Most prevalent tauopathies. PNFA progressive non-fluent aphasia; SD semantic 
dementia; FTDP-17 frontotemporal dementia with Parkinsonism associated with 
chromosome 17; APP amyloid precursor protein; PS presenilin; Apo E 
Apolipoprotein E e4; DMPK dystonia myotonica protein kinase; PANK 
pantothenate kinase; NPC Niemann Pick type C
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PSP
Tau-positive neurofibrillary tangles and neuropil threads occur in high density in 
specific subcortical structures, and to varying degrees in the cerebral cortex. The 
pathological signature of PSP is the tufted astrocyte, which is rare in the other 
tauopathies. (Litvan et al., 1996b; Lowe et al., 2002)
The factors which lead to tau accumulation and selective vulnerability of the basal 
ganglia and upper brainstem in PSP are not clear. Insoluble tau exists predominantly as 
straight tubules, which have a slightly thinner diameter than the predominantly paired 
helical filaments of AD. (Roy et al., 1974) PSP tau also forms insoluble deposits in glial 
cells which are characteristically star-shaped tufted astrocytes (figure 2.2) and comma 
shaped coiled bodies. Typically 4R tau is present in the glial and neuronal deposits, 
which are expressed as a doublet band pattern on western immunoblotting of 
phosphorylated tau. (de Silva et a l, 2003) Triplet patterns have also been reported in 
some cases, reflecting relatively more 3R tau and overlap with the triplet banding that is 
characteristic of AD. (Hanger et al., 2002; Morris et al., 2002a) Unlike AD, there is no 
clear pattern of pathological progression in PSP.
PSP is a sporadic disorder, but genetic susceptibility has been found in association 
with the HIc haplotype of the tau gene (microtubule associated protein tau, MAPT). 
(Pittman et al., 2005) However, mutations of MAPT have been identified in patients with 
clinical and pathological features similar to sporadic PSP.
Corticobasal degeneration
The syndrome of CBD was first recognised as a discrete nosological entity in the 
late 1960s. (Rebeiz et al., 1967) Subsequent clinicopathological reports have expanded 
the clinical phenotype and have frustrated attempts to produce consensus diagnostic 
criteria. The classic presentation is unilateral limb rigidity with myoclonus, dystonia and 
cortical sensory loss which can ultimately lead to the alien limb syndrome. The alien 
limb may present with abnormal limb movement with seemingly purposeful actions, 
levitation and an associated feeling of not owning the limb and results from parietal lobe 
degeneration. Other clinical presentations are common, and include non-fluent aphasia, a 
frontal lobe behavioural syndrome and apraxia with levodopa non-responsive
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Parkinsonism. Disease onset is in the sixth or seventh decade and disease duration is less 
than 10 years. The disease is rare, the incidence is estimated as being less than 1 per 
100,000 per year, and so is 10 times less common than PSP. (Litvan et al., 2000) CBD is 
defined pathologically by the presence of swollen neurons, also known as achromatic or 
ballooned neurons or Pick cells and prominent diffuse cortical glial tau pathology, 
including neuropil threads, coiled bodies and astrocytic plaques, (figure 2.2)
Many of the features o f pathological tau accumulation in CBD are shared with 
PSP. There are similarities in tau biochemistry; both accumulate predominantly 4R tau in 
neuronal and glial pathology, although in CBD the tau in both is made of predominantly 
twisted, helical filaments similar to AD. (Feany and Dickson, 1995) As well as in PSP, 
the tau Hlc susceptibility haplotype is also strongly associated with CBD pathology. 
(Pittman et al., 2005) CBD is differentiated from PSP pathologically by the presence of 
ballooned neurones, which are only weakly immunoreactive to tau, and tau-positive 
astrocytic plaques. In general, tau pathology in CBD favours a more cortical distribution 
than in PSP, though substantial overlap exists. (Feany and Dickson, 1995; Tsuboi et al., 
2005)
Figure 2.2 A, tufted astrocyte (x 40); B, astrocytic plaque (x 20); C, neurofibrillary tangle 
(x 40); D Pick bodies (x 40). AT8 anti-tau antibody.
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Frontotemporal dementia with Parkinsonism associated with chromosome 17
This condition comprises a group of familial, autosomal dominant, progressive 
adult onset neurodegenerative syndromes in which behavioural, cognitive and motor 
disturbances are caused by mutations in the tau gene, of which more than 30 have now 
been identified in over 100 families. (Goedert and Jakes, 2005) The clinical 
manifestations are protean but can be predicted, to some extent, by the site of the 
mutation in the tau gene. Changes in personality and behaviour dominate the early 
clinical picture in many patients, with social disinhibition, aggressive outbursts, 
compulsive behaviour, gambling, hyper-religiosity and a pathological liking for sweet 
foods. There is progressive speech disturbance with non fluent aphasia and later 
deterioration to mutism in some cases. Some patients present with atypical Parkinsonism 
with symmetrical bradykinesia, axial and limb rigidity, supranuclear ophthalmoplegia 
and no response to levodopa. A diagnosis of FTDP 17 is suspected when these 
neurological symptoms develop between the third and fifth decade, particularly if there 
are early progressive speech problems or a positive family history suggestive of an 
autosomal dominant neurodegenerative condition. (Foster et a l, 1997) Refractory 
seizures also sometimes occur.
The pathological features of FTDP 17, including the distribution and type of tau 
deposits, overlap substantially with PSP, AD, CBD and PiD. A molecular genetic 
analysis of the gene is essential to confirm the diagnosis.
The known mutations in the tau gene result in structurally abnormal tau protein 
(missense mutations or deletions), an alteration in the ratio of tau isoforms (exon 10 
mutations) or both. These mutations cause abnormal filament formation and 
accumulation of tau in neurons, or, in several variants, in neuronal and glial cells in the 
cerebral cortex and subcortical and brainstem nuclei. Morphology and tau isoform 
composition in FTDP 17 are variable and the mechanisms by which these protein 
alterations cause neuronal death remain unknown. (Goedert and Jakes, 2005)
Parkinsonism dementia complex of Guam
In Hirano’s 1961 report of an endemic disease in the Chamorro people on the 
western Pacific island of Guam, he described a condition characterised by Parkinsonism
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and dementia in the fifth and sixth decade of life. (Hirano et al., 1961) Subsequent 
reports have emphasised the marked clinical heterogeneity and the wide spectrum of 
disease which includes a PSP-like progressive, symmetric akinetic rigid state with early 
gait and speech disturbance with a poor response to levodopa, frontolimbic dementia, 
oculomotor paresis, pigmentary retinal lesions, asymmetric apraxia with dystonia and 
motor neurone disease. (Steele, 2005) Reports of families support phenotypic 
predispositions by age: those with the youngest age of onset develop motor neurone 
disease; those of middle age develop a Parkinsonian syndrome closely resembling PSP; 
and the oldest develop dementia. A similar condition on the Japanese peninsula of Kii 
has been described. (Kuzuhara et al., 2001) The annual incidence of Parkinsonism- 
dementia complex (PDC) of Guam is changing, and has been decreasing since records 
began in the mid 20th century. The maximum incidence was about 60 per 100,000 for 
men and 20 per 100,000 for women. (Steele, 2005) Most new cases now have a 
dementing syndrome.
Tau positive neurofibrillary tangles populate the cortex and basal ganglia 
structures in PDC Guam, but neuropil threads and coiled bodies are sparse compared to 
PSP and CBD. (Wakayama et a l , 1993) The neurofibrillary tangles are predominantly 
composed of paired helical filaments although straight filaments have also been 
described. (Oyanagi et al., 1994) The topographical distribution of tau pathology reflects 
the distribution of atrophy and neuronal loss, and regional differences are found in 4R:3R 
tau ratios, in some cases similar to PSP (Winton et al., 2006) though no clear 
clinicopathological correlations with the different phenotypes that have been identified. 
(Steele, 2005)
Exciting insights into the pathogenesis of tauopathies have been predicted from 
the PDC Guam geographical isolate because of its high prevalence and diminishing 
incidence. However, more than four decades of research have failed to uncover its 
aetiology. No clear genetic susceptibility has been identified. (Morris et al., 2004) 
Current efforts to identify an environmental cause are focussed on the effects of 
cumulative neurotoxins in the diet or infectious agents. (Steele, 2005)
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Pick’s disease
In 1892 Pick described focal frontal lobar atrophy in patients with aphasia, 
behavioural change and dementia. (Pick, 1892) The pathological heterogeneity in frontal 
lobe dementias meant that it was more than a century after the initial description before 
the pathological hallmarks and diagnostic criteria for his eponymous disease were agreed. 
(McKhann et al., 2001) Clinically Pick’s disease (PiD) is characterised by the onset of 
behavioural changes and aphasia in the sixth or seventh decade that progress over 10 to 
15 years. (McKhann et al., 2001) Features of frontal lobe dysfunction include changes in 
personality and social behaviour, including apathy, prominent and distressing social 
disinhibition, stereotypic behaviours, alterations in food preference and loss of attention 
to personal hygiene and appearance as well as frontal dysexecutive features including 
poor planning, forethought, reasoning and organization. A progressive non-fluent 
aphasia characterised by prominent speech production deficits leading to mutism is the 
commonest language disturbance encountered. (Hodges et a l, 2004) Rarely PSP can 
present with an identical phenotype, and in some cases never develop motor or 
oculomotor abnormalities. (Josephs et al., 2006a) Semantic dementia, defined by loss of 
language comprehension and visual agnosia with preserved verbal fluency may also 
occur. There is no reliable data on the epidemiology of PiD, but clinic based, 
pathological series suggest a prevalence of less than 1 per 100,000 in those in their 60s. 
(Rosso et al., 2003) Pathologically it is characterised by sharply circumscribed and 
asymmetrical lobar atrophy of the frontal and temporal lobes with superficial spongiosis. 
The diagnosis can be made by identification of tau-positive spherical cytoplasmic 
inclusions known as Pick bodies (figure 2.2) throughout the frontal and temporal cortices 
and in particular in the hippocampus. (Bergeron et al., 2003) In contrast to PSP, CBD 
and other forms of FTD, the substantia nigra remains relatively well pigmented.
Insoluble tau accumulation develops mainly in neuronal cells and to a lesser 
degree in glial cells as thorn shaped astrocytes and coiled bodies. 3R tau is the 
predominant isoform in PiD inclusions, but 4R tau has been seen in some cases and in a 
few 4R is the most abundant isoform. (Zhukareva et al., 2002) The accumulated 
filamentous material appears as predominantly paired helical filaments on electron
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microscopy, similar to AD but in some cases there are only straight filaments, similar to 
PSP. (Zhukareva et a l, 2002)
PiD is considered a sporadic disease although mutations in the tau gene have been 
shown to cause frontotemporal dementia associated with pathology that is 
indistinguishable from sporadic PiD. (Bronner et al., 2005) This apparent genetic 
heterogeneity along with the pathological and clinical heterogeneity has caused some 
confusion about how to precisely define PiD. The widely accepted definition of PiD is: a 
sporadic 3R tauopathy, characterised by the presence of Pick bodies. Some consider PiD 
as nothing more than another connotation for the presence of Pick bodies and it has been 
suggested that the term PiD should be used only in clinical practice and dropped for 
pathological diagnosis where classification of 3R, 4R or mixed type of tauopathy may be 
more useful terms. (Bronner et a l , 2005)
Postencephalitic Parkinsonism
Epidemic encephalitis lethargica (EL), is an infectious or post-infectious disorder, 
first described fully by von Economo in Vienna after the First World War. Otherwise 
known as “sleepy sickness” the illness had a high mortality and one of the common late 
complications in the survivors was postencephalitic Parkinsonism (PEP). No aetiology 
for EL has been identified and the condition, at least in its epidemic form, has all but 
disappeared. (Reid et a l, 2001) Similar clinical phenotypes have been reported since and 
are thought to be due to autoimmunity against deep grey matter neurons. (Howard and 
Lees, 1987; Reid et a l, 2001) PEP following epidemic EL was characterised clinically 
by Parkinsonism usually with rest tremor and no, or very slow, disease progression, and 
oculogyric dystonic spasms. Mortality was high initially, but those who survived often 
lived to old age and in these patients response to levodopa was usually good but with 
early emergence of dyskinesias, fluctuations and psychiatric side effects. The diagnosis 
hinges on a prior history of acute EL and contemporary, sporadic cases need to be 
carefully compared with the seminal descriptions of the epidemic form and alternative 
explanations excluded. (Ravenholt and Foege, 1982)
PEP is a multisystem tauopathy characterised by widespread neuronal loss along 
with neuronal and glial tau accumulation and severe degradation of the dopaminergic
35
substantia nigra. It shares histological features with PSP, CBD and PDC Guam, but 
ultrastructurally the neurofibrillary tangles of PEP are similar to AD. No genetic 
associations have been identified in PEP.
Alzheimer’s disease
AD is the most common cause of dementia accounting for between 50% and 80% 
of all dementia and is defined by an insidious decline in cognition from a previous higher 
level. (Knopman, 2003) Diagnostic criteria require that two or more cognitive domains 
are affected including memory impairment and at least one of language, visuospatial 
function, executive function (including abstract reasoning and concentration) and praxis 
(ability to execute skilled motor activities in the absence of weakness). (American 
Psychiatric Association, 2000) Early involvement of memory and the absence of early 
eye movement abnormalities and bradykinesia distinguish it from PSP. The prevalence 
increases with age, doubling with every five year increment over 65 years old. (Hy and 
Keller, 2000) Pathologically AD is diagnosed by semi-quantitative analysis of senile 
plaques composed of extracellular Ap-amyloid peptide deposits and neurofibrillary 
tangles composed of intraneuronal tau deposits. (Figure 2.2) To a certain extent these 
changes occur in normal ageing, in the absence of dementia, so the definitive 
pathological diagnosis of AD requires clinical correlation.
Tau accumulation in AD is likely to be a consequence of Aj3-amyloidogenic 
neuronal damage rather than a primary event, differentiating this process from PSP which 
is considered a primary tauopathy. (Gotz et a l , 2001) Ap-amyloid deposition is central 
in the pathogenesis of AD and the balance between biogenesis and catabolism appears to 
be the critical factor. In addition to neuronal fibrillary tangles, insoluble tau in AD also 
exists as neuropil threads (derived from dendritic processes) and dystrophic neurites in 
senile plaques. (Braak et al., 1986) Biochemical analysis of this tau reveals all six 
isoforms and the filaments in neurofibrillary tangles exist as paired helical filaments or 
twisted ribbons. (Pollanen et a l, 1997; Mailliot et a l, 1998)
Tau mutations have not been reported to cause AD. Inherited forms of AD 
include the highly penetrant, autosomal dominant mutations in amyloid precursor protein 
and presenilin 1 and 2 genes, which will lead to an increase in Ap-amyloid deposition. In
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these families tau pathology is abundant and indistinguishable from sporadic late onset 
AD, reflecting the importance of Ap-amyloid deposition in the generation of tau 
accumulation. The apolipoprotein E e4 allele acts as a genetic risk modifier in sporadic 
AD, by decreasing the age of onset of disease. (Meyer et al., 1998) In patients with the e4 
allele tau load is higher than those without. (Ohm et a l , 1999)
Other tauopathies
The dementia associated with Down’s syndrome occurs 10 to 20 years earlier than 
in AD, but otherwise is clinically and pathologically the same. (Wisniewski et a l, 1985) 
Dementia pugilistica, which occurs following traumatic brain injury in boxers, is also 
characterised by Ap-amyloid deposition and widespread neurofibrillary tau deposition 
with the same isoform profile as AD. However, personality changes, cerebellar and 
extra-pyramidal signs are common giving it a distinct clinical picture. (Schmidt et a l,
2001) Argyrophilic grain disease is a newly recognised nosological entity which may 
account for 5% of all dementias. Pathologically it is defined as a 4R tauopathy with 
prominent cortical and subcortical granular changes in the neuropil and can coexist with 
PSP-tau pathology. (Togo et a l, 2002) Patients are most likely to present with memory 
disturbance and personality change, similar to mild Alzheimer type dementia or limbic 
dementia. (Tolnay et a l, 2002) Another geographical isolate of atypical Parkinsonism 
exists in the French Antilles. Clinically these patients share many features with PDC 
Guam, and atypical PSP, with predominantly 4R tau pathology similar to that seen in 
PSP. Local herbal teas made from soursop and sweetsop (annonaceae) leaves containing 
high levels of alkaloid neurotoxins may be responsible. (Caparros-Lefebvre and Lees, 
2005) Neuronal tau deposits are also known to occur in some other genetically 
determined neurodegenerative conditions including Hallevorden-Spatz syndrome, 
Niemann Pick disease type C and myotonic dystrophy, where cognitive deterioration can 
occur either early or later in life and neuronal cell death occurs due to disease specific 
mechanisms.
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“...establish first the morbid phenomena, seek then to explain them from the 
physiological point of view, when ever the actual state of science permits it The 
inverse method, which consists of starting from anatomy and physiology in order 
to deduce from them the conditions of the disease, is full of dangers and beset 
with risks ”
(J. M. Charcot. Maladies des vieillards. In: Oeuvres competes de JM Charcot. Tome VII. Paris:
Lecrosnier et Bab£, 1890. [Translated into English by W.S. Tuke. Clinical lectures on senile and chronic 
disease by J.M. Charcot. London: The New Sydenham Society)
Description of disease in neurology has relied heavily on the anatomicoclinical 
method perfected by Charcot in the 19th century. He systematically categorised the 
clinical features of his patients and their detailed pathological findings at autopsy, 
revealing clinical and pathological correlations to an extent that had previously not been 
possible, and paving the way for a new nosological approach to nervous disease. (Goetz,
2002) This standard of disease definition was successful throughout the twentieth 
century and allowed for the characterisation of many neurological disorders, including 
PSP. (Steele et al., 1964) However, the limitations of definitions that relied on strict 
anatomical and clinical associations became increasingly apparent, due to increasing 
recognition of clinical overlaps between different diseases. When these clinical 
conundrums were encountered in the late twentieth century, for example between PD and 
PSP, “the post mortem room (became) the temple of truth” (Caine, 2005), pathological 
examination became the source of definitive diagnosis and histological characteristics 
became the definition of disease, almost regardless of the clinical history. (Litvan et al., 
1996a)
With this increasing reliance on pathological findings for disease definition, the 
clinical description became slowly less important and consequently the name given to the 
disease has become less pertinent to a patient’s experience. For example the current 
definitions of clinical PSP and pathological PSP embrace different subsets of patients.
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(Litvan et a l, 1996a; Litvan et a l, 1996b; Morris et a l, 2002a; Osaki et a l, 2004) and 
these uncertainties render the desire to provide patients with an early accurate diagnosis 
difficult. The current criteria are designed with clinical research in mind, and are usually 
unsatisfactory in providing guidelines for definitive, early diagnosis in patients who are 
later proven to have PSP-tau pathology. (Litvan et a l, 1996a; Osaki et a l, 2004)
The designation of PSP was originally for a clinical entity. Assuming that 
Richardson’s definition is definitive, a number of cases with the PSP syndrome will not 
share the same underlying disease process. This has been estimated as being up to 25% 
of cases, with the alternative pathologies including Lewy body disease, MSA, 
ffontotemporal lobar dementia with ubiquitin-only-immunoreactive neuronal changes, 
AD, vascular disease and prion disease. (Hughes et a l, 2002; Josephs and Dickson, 2003; 
Paviour et a l , 2004) To gain insight into the nature of the disease and to plan clinical 
trials in cases with the same underlying pathology, relying on descriptions of the clinical 
syndrome of PSP has substantial limitations.
The post mortem identification of PSP-tau pathology implies a certain disease 
experience in the patient. This assumption is not always correct and alternative clinical 
syndromes are consistently encountered in PSP pathological series. (Daniel et a l, 1995; 
Morris et a l, 2002a) In addition, substantial pathological overlap occurs with other 
distinct clinical syndromes, including PEP and PDC Guam, and clear boundaries to 
separate these diseases solely on pathological grounds do not exist. (Geddes et a l, 1993; 
Litvan et a l, 1996b) From the patient’s perspective a pathological definition of PSP does 
not help define their disease and any definition that relies on post mortem features 
effectively excludes the patient from any benefits that come with knowledge of the 
diagnosis.
Contemporary definitions of PSP reflect the shift towards pathological gold- 
standards (Josephs and Dickson, 2003), at the expense of defining the clinical syndrome 
as it applies to patients in the clinic. Charcot warned that such an approach was “full of 
dangers and beset with risks” suggesting that neglecting “morbid phenomena” in favour 
of anatomy and physiology ignores the essential characteristics of disease. (Charcot, 
1890) From the patient’s perspective, disease definition should reflect the accepted 
wisdom about a clinical entity, leading to interaction with their doctor relating to
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prognosis, disease course, therapeutics, research, and end-of-life issues. The nature of 
the underlying pathology is of less importance. To achieve a more advantageous 
perspective of PSP for science and patients, the diagnostic emphasis needs to revert to 
clinical features. To enable this, clearer definitions of the clinical entity described first by 
Richardson, are needed and additional clinical syndromes need to be dissected out from 
what has been referred to in the literature as “atypical PSP”. Even with the future 
identification of definitive biomarkers that accurately predict the underlying pathology, 
the clinical aspects of the disease will remain central to the patient’s disease experience 
and require careful attention.
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Pathologically defined PSP encompasses more than the classic clinical 
syndrome originally described by Richardson. The hypothesis of this body of work 
is that classic and atypical forms of PSP represent different points on a spectrum of 
PSP-tau disease and together these clinical differences explain some of the 
pathological, biochemical and genetic diversity observed in PSP.
Questions and approaches
The questions raised and approaches taken to investigate the main hypothesis and 
issues related to PSP are summarised below:
A) What are the clinical differences between classic and atypical PSP?
i. Do patients with atypical PSP share common clinical features?
To address these questions the clinical case notes from the series of pathologically 
diagnosed cases of PSP, archived at the Queen Square Brain Bank for Neurological 
Disorders (QSBB), were examined. Data regarding the clinical features of these patients 
were analysed using factor analysis which identified groups of related clinical features. 
Patients were then retrospectively dichotomised according to clinical groups and 
compared. A further, PSP-specific clinical syndrome was identified from an exhaustive 
search through the clinical case notes of all patients archived at the QSBB, including 
those with pathologically diagnosed PD, MSA, CBD, AD and VP.
B) What is the diversity in regional tau pathology in PSP?
i. Do clinical features correlate with PSP-tau pathology?
ii. Do additional pathologies contribute to clinical features in PSP?
The topographical distribution of PSP-tau lesions was studied in 42 cases of 
pathologically diagnosed PSP. PSP-tau pathology was assessed using AT8, RD4 and 
RD3 anti-tau antibodies in 20 different brain regions. The severity and distribution of
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these lesions was compared between groups of patients with different clinical syndromes. 
These cases were systematically screened for the presence of Alzheimer pathology, Lewy 
body pathology and vascular disease, and clinical groups were compared.
C) What is the diversity in the isoform composition of insoluble tau aggregates 
in PSP?
i. Do clinical features correlate with isoform composition?
Tissue homogenates from the basal pons of 69 cases of PSP archived at QSBB were 
prepared. The composition of the insoluble tau isolated from this region was analysed by 
dephosphorylation of the guanidine-solubilised deposits followed by electrophoresis. 
The isoform profiles were compared to those of the soluble tau and compared between 
clinical groups.
D) Do known genetic risk factors influence clinical features in PSP?
The HI haplotype of the tau gene is associated with PSP and is considered a 
genetic risk factor. The association of the PSP-susceptibility haplotype in pathologically 
diagnosed PSP was examined in the whole QSBB PSP series and then in each different 
PSP subgroup. DNA from this series was then screened for mutations in exons 1 and 10 
of MAPT. The association between APOE genotype and PSP was also examined.
E) What are the clinical features that separate atypical PSP from other 
bradykinetic rigid syndromes?
Tests of olfactory function, the presence of visual hallucinations and 
abnormalities in the auditory startle response have been proposed as useful clinical 
discriminators between PD, PSP and other bradykinetic rigid syndromes. A group of 
clinic patients, diagnosed with PSP, atypical Parkinsonism or PD at the National Hospital 
for Neurology and Neurosurgery, were tested using a standardised smell identification 
test, a novel visual hallucination inventory and a modified auditory startle protocol. 
Clinical features were also examined in patients archived at the QSBB to identify the 
specificity and positive predictive value of these features in pathologically diagnosed
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patients. In addition the natural history of falls and visual hallucinations was established 
in different pathological groups.
F) What does clinical diversity in PSP mean to patients and future research?
The anatomoclinical method of disease definition relies on correlations between 
clinical and then pathological features. The potential benefits of these newly recognised 
correlations are discussed. Power calculations were performed using data from QSBB 
archived patients, where different PSP subgroups were compared to estimate sample sizes 
needed to power clinical research trials.
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The cases Richardson presented to the American Neurological Association in 
1963 had a remarkably consistent clinical picture. (Richardson et al., 1963) Since then a 
number of other clinical presentations of PSP-tau pathology have been described.
In 1974 Imai described pure akinesia without response to levodopa. (Imai and 
Narabayashi, 1974) The cases described were distinguished by freezing of gait, writing 
and speech with kinesie paradoxale but without limb rigidity or tremor. At presentation 
these patients were cognitively intact, had no eye movement abnormalities and, in many, 
there was a long disease duration without the development of other Parkinsonian features. 
(Mizusawa et al., 1993)
PSP has been reported in several patients with isolated dementia. (Davis et al., 
1985; Bergeron et al., 1998; Mochizuki et al., 2003; Josephs et al., 2005) When marked 
cognitive changes predominate early in the disease, PSP may rarely be confused with 
AD. However, in PSP, specific cognitive and behavioural changes are associated with 
subcortical damage and corresponding frontal lobe deafferentation leading to a 
characteristic dysexecutive syndrome which occurs in 50-80% of patients at some stage 
of the illness. (Millar et al., 2006) A number of patients have also been described with 
progressive Parkinsonism but without dementia, further adding to the clinical 
heterogeneity. (Davis et a l, 1985; Mizusawa et al., 1993; Vemy et al., 1996a; Birdi et 
al., 2002)
Supranuclear down gaze palsy is one of the most distinctive clinical features of 
PSP. Slow vertical saccades are often the first neuro-ophthalmological abnormality in 
PSP (Rottach et al., 1996), and precede the gaze paresis. (Litvan et al., 1996a) However 
a number of cases have been reported to have PSP pathology without ever developing a 
vertical supranuclear gaze palsy, or abnormalities of saccadic eye movement. 
(Pfaffenbach et al., 1972; Dubas et al., 1983; Davis et a l, 1985; Daniel et a l, 1995; Birdi 
et al., 2002; Josephs et al., 2005)
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A pill rolling, 4-6 Hz rest tremor is considered to be a highly characteristic feature 
of PD (Gibb and Lees, 1988) and was absent in the early reports of PSP. (Richardson et 
al., 1963; Steele et a l , 1964; Steele, 1972) However, rest tremor has subsequently been 
reported as a presenting feature in a number of patients in three different PSP 
pathological series. (Daniel et al., 1995; Vemy et al., 1996a; Birdi et al., 2002)
The corticobasal syndrome is characterised by asymmetric Parkinsonism, apraxia, 
alien limb phenomena and cortical sensory loss. (Boeve et al., 1999) Although this 
syndrome is classically attributed to CBD, a number of pathological entities, including 
PSP can cause an identical phenotype. (Boeve et al., 1999; Motoi et al., 2004; Tsuboi et 
a l, 2005)
Attempts have been made to embrace these broader clinical features in the clinical 
diagnosis of PSP with typical and atypical clinical subgroups. The arbitrary definitions of 
these subgroups have varied and have usually been applied retrospectively. They 
include: the presence or absence of supranuclear gaze palsy (Daniel et al., 1995; Birdi et 
al., 2002); the presence or absence of a diagnosis of PSP in life (Morris et al., 2002a; 
Gibb et al., 2004); the application of retrospective diagnostic criteria (Morris et al., 
2002a); and the presence or absence of early bulbar signs or falls. (Nath et al., 2003) 
Several authors have found genetic, prognostic or pathological differences between these 
clinical sub-groups. (Daniel et al., 1995; Vemy et al., 1996a; Morris et a l, 2002a; Nath 
et al., 2003)
The clinical features that have been reported to have the greatest prognostic 
significance in PSP are the classic clinical hallmarks of the disease described in 
Richardson’s original report (Richardson et al., 1963) and are included in the operational 
diagnostic criteria. (Litvan et al., 1996a) Accordingly the absence of supranuclear 
vertical gaze palsy, early falls and early bulbar dysfunction, with a positive response to 
levodopa conveys a better prognosis, but patients presenting in this way are much less 
likely to be diagnosed as PSP, and would have been excluded by the astute eye of 
Richardson.
45
itation in pathologically diaj
The clinical diagnosis of progressive supranuclear palsy (PSP) relies on the 
identification of characteristic signs and symptoms. The apparent clinical 
dichotomy between classic PSP and atypical PSP has been examined in this 
thesis. In 103 consecutive cases of pathologically confirmed PSP two clinical 
phenotypes have been identified by factor analysis, which have been named 
Richardson’s syndrome (RS) and PSP-Parkinsonism (P). Cases of RS made up 
54% of all cases, and were characterised by postural instability and falls, 
supranuclear vertical gaze palsy and cognitive dysfunction in the first two years. 
A second group of 33 (32%) were characterised by asymmetric onset, tremor, a 
moderate initial therapeutic response to levodopa and were frequently confused 
with Parkinson’s disease (PSP-P). Fourteen cases (14%) could not be separated 
according to these criteria. In RS two thirds of cases were men whereas the sex 
distribution in PSP-P was even. Disease duration in RS was significantly shorter 
(5.9 vs. 9.1 years,p<0.001) and age at death earlier (72.1 vs. 75.5 years,p=0.01) 
than in PSP-P. A third distinct phenotype was identified in post-hoc analysis of 
these cases and others archived at the QSBB. A clinical syndrome of pure 
akinesia with gait freezing (PAGF), first described by Imai, was identified in 
seven cases that fulfilled proposed criteria. The mean age at onset was 61 years 
(range 44-78) and mean disease duration was 13 years (5-21). Akinesia of gait, 
speech and poverty of facial expression were common early features. Most 
patients were wheel chair dependent in the second half of their disease, and eye 
movement abnormalities typically occurred after 9 years of disease. The classic 
clinical description of PSP, which includes supranuclear gaze palsy, early falls 
and dementia does not adequately describe one third of cases in this series of 
pathologically confirmed cases. We propose that PSP-P and PAGF represents 
two discrete clinical syndromes that need to be distinguished from classical PSP 
(Richardson’s syndrome).
6.1. Analysis of clinical features in PSP
Aims
The apparent clinical and pathological dichotomy between classic PSP and 
atypical PSP has led to the examination of the effect of different clinical factors on 
phenotype in an attempt to identify distinct subgroups that might exist alongside the 
clinical entity originally described by Richardson. The characteristics of these clinical 
subgroups were examined in an attempt to further clarify the nosology of this condition 
and more clearly define prognostic factors.
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Materials and Methods
Patients
One hundred and three consecutive cases of pathologically diagnosed PSP, 
donated from all over the UK between 1988 and 2002 and stored in the Sarah Koe PSP 
Research Centre (SKRC) at the Institute of Neurology, UCL were reviewed. The 
diagnosis was made according to the NINDS-SPSP pathological criteria (Litvan et al., 
1996b), and was retrospectively applied to those cases acquired prior to the publication of 
the criteria. All patients had been assessed during life by a hospital specialist 
(neurologist or geriatrician).
Clinical data collection
A systematic chart review was performed on all the case notes. Specifically the 
comprehensive case notes of the family doctor and all of the correspondence between the 
family doctor and the medical specialist were reviewed. When available medical 
inpatient notes, inpatient consultations and emergency room admission notes were also 
scrutinised. A clinical data sheet was designed to record the presence or absence of 
clinical features either early in the disease course (within two years of first symptom 
onset) or at anytime during the disease. Symptoms were recorded as being absent if not 
reported, and clinical signs were recorded separately as unknown if they were not 
specifically mentioned in the notes. Where conflicting clinical features were reported the 
findings of the neurologist were used.
Definitions were: Age of onset: Age, in years, at the time of the first reported 
symptom considered to be attributable to PSP or Parkinsonism. Duration: Time between 
the age of onset and the age at death. Falls: The presence of any report of falls. 
Bradykinesia: The presence of any mention of bradykinesia or motor slowing. Cognitive 
decline: The presence of any perceived cognitive decline, either by the patient, patient’s 
relative or the treating doctor. This included annotation of difficulty in concentration, 
reports of intellectual functional decline and comments by the family of mental slowing 
but did not include affective disorders. No patients underwent formal neuropsychological 
testing in the first twelve months of their disease. Speech disturbance: The recording of
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any alteration in speech quality compared to speech prior to disease onset. Dysphagia: A 
record of any swallowing abnormality. Asymmetric Onset: If there was a clear difference 
between the signs on the left and the right asymmetry was recorded as being present. 
This included asymmetry of tremor, rigidity, bradykinesia or functional decline. It did 
not include specific tasks such as writing and using tools. Tremor: The recording of any 
tremor. Rigidity: The recording of axial or peripheral muscle rigidity, extra-pyramidal 
and pyramidal rigidity was not differentiated. Impaired Postural Reflexes: The presence 
of this sign was only recorded if specifically mentioned in the clinical notes. 
Supranuclear Gaze Palsv: The specific recording of restricted range of eye movement in 
the vertical plane. Impaired Saccadic or Pursuit Movements: The specific recording of 
abnormal saccadic or smooth pursuit eye movements. Other visual symptoms: The 
recording of other visual symptoms not explained by the presence of gaze palsy or 
impaired saccadic or pursuit movements, which evolved during the disease course. 
Symptoms include painful eyes, dry eyes, visual blurring, diplopia, blepharospasm and 
apraxia of eyelid opening. Extra axial-dvstonia: The presence of dystonia in any body 
part apart from trunk and neck. Pyramidal signs: Pathologically brisk reflexes and/or 
extensor plantar response(s). Autonomic dysfunction: Either abnormal autonomic 
function testing or documentation of any two of: urinary urgency, frequency and nocturia 
without hesitancy; chronic constipation; postural hypotension; sweating abnormalities; 
erectile dysfunction. Dyskinesia: The presence of chorea associated with levodopa 
therapy. Response to levodopa: The patient and clinician’s interpretation of improvement 
was assessed from the case notes and in some cases from the completed Parkinson’s 
Disease Society Brain Bank (PDSBB) annual assessment forms. A self reported 
improvement of more than 30% coincident with the introduction of levodopa was 
recorded as being a positive response. This degree of response was graded by a 4 point 
scale modified from the PDSBB annual assessment forms: 1 - nil, or slight response 
(<30% improvement), 2 - moderate response (30-50% improvement), 3 - good response 
(51-70% improvement) and 4 - excellent response (71-100% improvement).
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Statistical methods
A complete data set of clinical variables each coded as present or absent was 
available from 29 cases only and these were entered into a principal components analysis 
in order to summarise the information. Other cases had missing data on one or more 
variables and could not be included in this analysis. Statistical analysis was performed 
using SPSS for Windows (version 12.0.1). The principal components analysis was 
performed using clinical data from the first two years of disease. We selected the first 
two principal components and performed a “Varimax” rotation on these components (this 
rotation maximises the number of variables that have high loadings on each factor). The 
loadings of each variable on both of these components were plotted against each other. 
The plot was examined and two groups of variables in different areas of the plot were 
selected. A between groups, hierarchical cluster analysis using squared Euclidean 
distance measures was performed to check that these sets of clinical features grouped 
together. Those cases that exhibited a greater number of the characteristics from set 1 
than from set 2 were deemed to fall within group 1, and vica versa for group 2. A cross 
tabulation was used to examine how many cases had a similar number of characteristics 
from the two variable sets. This was then applied to the cases that were excluded from the 
principal components analysis. Where there were missing data, we scaled up the number 
of positive results found (e.g. multiplied by 5/3 where status on 3 out of 5 characteristics 
was known). Clinical characteristics of the patients were compared between the two 
groups, and significance was calculated using Student’s t-test for normally distributed 
data, and chi-square or Fisher’s exact test for binary data.
Results
Clinical features
Clinical data was available for 103 pathologically confirmed cases of PSP, of 
which 65 were male (63%). The clinical diagnosis of PSP was made during life in 71 
cases (69%), 24 (23%) were diagnosed with PD, 2 (2%) with atypical PD, 2 (2%) with 
MSA, 1 (1%) with CBD and in 3 a final clinical diagnosis was not established. 
Neurologists made the final clinical diagnosis in 87% of cases and correctly diagnosed
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PSP in 72%. The mean age of onset was 66.4 years (standard deviation (SD) 12) age at 
death 73.5 years (SD 7.5), and disease duration was 7.0 years (SD 3.7).
The clinical features of these patients are summarised in table 6.1. There was an 
asymmetric onset in 28% of cases. Slowness of movement or bradykinesia was the most 
commonly reported feature early in the disease, occurring in 75% of cases. Falls (60%), 
tremor (20%), cognitive decline (29%), speech disturbance (39%), and non specific 
visual symptoms (21%) were early features. Rigidity and impaired postural reflexes were 
found in nearly half of the patients early on in the disease course. Later in the disease 
more clinical information was recorded. Bradykinesia was present in 98% of cases, 
rigidity in 98% and falls in 94%. Postural reflexes were impaired in 98% of cases, after 
the first two years of illness, and other signs included speech disturbance (87%), 
dysphagia (69%), cognitive decline (74%), tremor (23%), pyramidal signs (19%) and 
extra-axial dystonia (26%). Cerebellar signs (1%), autonomic dysfunction (2%), and 
cortical sensory loss (1%) were rare. Alien limb phenomenon was not reported.
Examination of the eye signs was not recorded in detail, beyond a statement of 
“cranial nerve examination normal” in more than half of the cases early in the disease. 
Supranuclear gaze palsy was present early in the disease in 38%, and pursuit or saccadic 
eye movements were abnormal in 44% of cases where the examination was recorded 
completely. By contrast later in the disease, 91% of these cases were recorded as having 
supranuclear gaze palsy though clinical examination was incompletely recorded in 21%.
A trial of levodopa or dopamine agonist medications was recorded in 91 of 103 cases 
(88%). The trial was not recorded or was not performed in the remainder. In 32% of 
cases there was a better than 30% improvement in symptoms coincident with the 
initiation of the medication. The duration of treatment, and continued efficacy were not 
measured. In four cases dyskinesias were recorded (4% of those treated).
Statistical analysis
The first two components from the principal component analysis performed on 
data from the first two years of disease explained 42% of the variance seen in all cases. 
The loading of each variable on one component was plotted against its loading on the 
other component. (Figure 6.1) This suggested that the variables fell into two approximate
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groups (characteristic set 1 with high positive loadings on component 1 and characteristic 
set 2 with positive loadings on component 2 and negative loadings on component 1). The 
variables grouped together in each characteristic set were: set 1 -  falls, cognitive decline, 
supranuclear gaze palsy, abnormal saccadic/pursuit movements, postural instability; set 2 
-  tremor, bradykinesia, asymmetrical onset, extra axial dystonia, response to levodopa. 
A cluster analysis of clinical variables confirmed this grouping of variables as reasonable. 
(Figure 6.2) This suggests that sufficient information was incorporated into the first two 
components of variance in order to determine groupings of characteristics between 
patients.
The frequency of the two sets of characteristics in the 29 cases with a complete
data set is summarised in table 6.2A. Fourteen cases (48%) had more features in
characteristic set 1 than set 2, and were deemed to belong to group 1. Nine cases (31%) 
had more features in characteristic set 2, and were deemed to belong to group 2. Six 
cases (21%) had an equal number of features in each characteristic set.
The frequency of the two sets of characteristics in the 71 cases with incomplete
data is shown in table 6.2B. Five cases (7.4%) had an equal number of features in each 
characteristic set. Three cases were excluded from the analysis because of insufficient 
clinical information. The low percentage of cases that were unclassified according to this 
division suggests that the identified characteristics are reasonable at distinguishing two 
groups. The two groups share few variables from each characteristic set, suggesting that 
they are clinically distinct.
The 66 cases that were not included in the principal components analysis, and 
were able to be separated into two groups with the cross tabulation, were compared 
according to the presence or absence of early clinical features (table 6.3). The co­
occurrence of clinical features appeared to be similar to the cases with a complete data 
set, included in the principal components analysis. Early bradykinesia occurred in around 
three quarters of cases in both groups and did not differentiate them.
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First 2 years Throughout disease
Clinical Feature Presentearly
Absent
early
Not
recorded
Present 
in total 
cohort 
%
Present
ever
Absent
ever
Never
recorded
Present 
in total 
cohort 
%
Falls 61 40 2 60 93 8 2 94
Bradykinesia 74 25 4 75 99 0 4 98
Tremor 20 79 4 20 23 76 4 23
Cognitive decline 28 68 7 29 72 25 6 74
Non-specific visual 
symptoms 20 77 6 21 48 49 6 50
Rigidity 43 53 7 42 95 2 6 98
Dysphagia 6 89 8 6 64 29 10 69
Speech disturbance 38 60 5 39 83 12 8 87
Impaired postural reflexes 49 30 24 62 84 2 17 98
Supranuclear gaze palsy 19 31 53 38 75 7 21 91
Abnormal pursuit or 
saccades 21 27 55 44 70 6 27 92
Extra-axial dystonia 7 89 7 7 25 70 8 26
Pyramidal signs 8 88 7 8 18 79 6 19
Cerebellar signs 0 10 3 0 1 98 3 1
Autonomic dysfunction 0 100 3 0 2 97 3 2
Cortical sensory loss 0 97 4 0 1 97 4 1
Asymmetric Onset 26 67 10 28
L-dopa response 29 62 12 32
L-dopa induced dyskinesia 4 92 7 4
Table 6.1 Clinical features in 103 pathologically confirmed cases of PSP
52
RIGID
COG
DYST
0.0
-.5
C l
O  -10 _  
-1 0 - 5 CO 5 1.0
Component 1
Figure 6.1 Plot of factors for components 1 and 2 derived from factor analysis. 
Components grouped together (red -  RS; blue -  PSP-P).
ASYM = asymmetric onset; TREM = tremor; L-DOPA = response to 
levodopa; BRADYK = bradykinesia; DYST = limb dystonia; DYSPH = 
dysphagia; PYRAM = pyramidal tract signs; COG = cognitive dysfunction; 
DYSK = dyskinesia; VISUAL = non-specific visual symptoms; PI = postural 
instability; SNGP = supranuclear gaze palsy; S/P = abnormal saccadic or 
pursuit movements; SPEECH = speech disturbance.
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Figure 6.2 Hierarchical cluster analysis of clinical variables: dendrogram using average 
linkage (between groups).
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2A Set 2
0 1 2  3 4
Total
0
1
2
3
r  4 
® - co 5
1 1 1 2 2 7
0 2 0 0 0 2
1 0 3 2 0 6
0 0 0 0 1 1
2 2 1 1 0 6
0 6 1 0 0 7
Total 4 11 6 5 3 29
2B Set 2 Total
0 1 2 3 4
0 2 7 8 6 2 25
1 1 0 0 0 0 1
2 0 1 1 1 0 3
3 2 10 4 2 0 18
H 40)co 5
1 3 3 0 0 7
3 8 2 4 0 17
Total 9 29 18 13 2 71
Table 6.2 (A) Cross tabulation of the number of characteristics in each of two sets exhibited
by each case for initial data set, and (B) for the second data set where at least 
one variable was missing
Set 1 (RS): falls, cognitive decline, supranuclear gaze palsy, abnormal 
saccades/pursuit movements, postural instability. Set 2 (PSP-P): tremor, 
bradykinesia, asymmetric onset, non-axial dystonia, response to levodopa.
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Group 1
% reported as 
present
Group 2
% reported as 
present
p value
Symptoms
*Falls 85.7 0% <0.001°
(36/42) (0/24)
‘Cognitive decline 50.0 0 <0.001b
(19/38) (0/22)
*Tremor 9.8 39.1 0.007b
(4/41) (9/23)
Speech disturbance 32.5 26.1 0.406b
(13/40) (6/23)
Dysphagia 2.7 4.3 0.624b
(1/37) (1/23)
Other visual symptoms 23.1 4.3 0.051b
(9/39) (1/23)
Clinical signs
'Asymmetric onset 17.9 45.0 0.030°
(7/39) (9/20)
'Bradykinesia 75.6 73.9 0.880a
(31/42) (17/23)
Rigidity 39.5 52.5 0.3338
(15/38) (12/23)
'Postural Instability 84.4 7.7 <0.001b
(27/32) (1/13)
'Extra-axial dystonia 0 8.7 0.138b
(0/38) (2/21)
'Supranuclear gaze palsy 70.0 0 0.002b
(7/10) (0/9)
'Abnormal saccades/pursuits 63.6 0 0.017b
(7/11) (0/6)
Pyramidal tract signs 7.9 4.3 0.513b
(3/38) (1/23)
'Response to Levodopa ever 14.3 50.0 0.005b
(5/35) (11/22)
Table 6.3 Early clinical features in cases with an incomplete data set, * variables used in 
initial analysis; 8 chi-square analysis;b Fisher’s exact test 
Group 1: Richardson’s syndrome, Group 2: PSP-P
55
All 89 cases that could be separated into groups were compared according to 
profile (table 6.4) and the late clinical features that they displayed (table 6.5). There was 
a difference in gender distribution between the two groups. Men were over represented 
in group 1 (64.3%, 95% confidence interval (Cl): 52-77%), but gender distribution was 
equal in group 2 (51.5%, 95% Cl 33-67%). The age of disease onset was not different 
between the two groups. The ages at death and disease duration were significantly 
different: those in group 1 died at a younger age, and after shorter disease duration. Falls, 
cognitive decline and supranuclear gaze palsy continued to be significantly associated 
with group 1 later in the disease (p<0.001). Tremor was the only clinical feature 
significantly associated with group 2 later in the disease though extra-axial dystonia was 
also more frequent in that group. There was no significant difference in the frequency of 
bradykinesia, speech disturbance, postural instability, pyramidal tract signs or levodopa 
induced dyskinesias.
RS PSP-P *p value
Gender (male, %) 64.3 51.5
Age at disease onset (years) 66.1 66.4 0.872
Age at death (years) 72.1 75.5 0.041
Disease duration (years) 5.94 9.12 <0.001
Table 6.4 Patient profiles according to clinical group, * student’s t test
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Group 1 
% reported as 
present
Group 2 
% reported as 
present
p value
Symptoms
Falls 100 80.6 0.001a
(56/56) (25/31)
Cognitive decline 90.7 51.6 <0.001a
(49/54) (16/31)
Tremor 13.0 43.8 0.002b
(7/54) (14/32)
Speech disturbance 90.2 81.3 0.2428
(46/51) (26/32)
Dysphagia 75.5 56.3 0.0708
(37/49) (18/32)
Other visual symptoms 56.6 34.4 0.0478
(30/53) (11/32)
Clinical signs
Bradykinesia 98.2 96.9 0.6858
(55/56) (31/32)
Rigidity 98.1 96.8 0.6878
(53/54) (30/31)
Postural Instability 100 96 0.1428
(51/51) (23/24)
Extra-axial dystonia 21.2 42.4 0.054b
(11/51) (13/32)
Supranuclear gaze palsy 100 71.4 <0.001a
(50/50) (15/21)
Pyramidal tract signs 17.0 15.6 0.561b
(9/53) (5/32)
Levodopa induced dyskinesia 1.9 6.3 0.323b
(1/52) (2/32)
Table 6.5 Late clinical features in 89 cases separated into distinct groups,a chi-square 
analysis;b Fisher’s exact test.
Group 1: Richardson’s syndrome, Group 2: PSP-P
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Discussion
This study confirms that two distinct clinical phenotypes exist in patients with 
pathologically proven PSP. One was characterised by early falls, early cognitive 
dysfunction, abnormalities of gaze and postural instability, and the other by asymmetric 
onset, tremor, early bradykinesia, non-axial dystonia and a response to levodopa 
medications. The clinical characteristics present in this first group were similar to those 
first described in PSP by Richardson (Richardson et a l , 1963), whereas the clinical 
features in the second group resembled Parkinson’s disease. We propose naming the first 
group “Richardson’s syndrome” (RS) and the second “PSP-Parkinsonism” (PSP-P). RS 
had a shorter duration of disease and the female to male ratio was 1:1.8, whereas the 
gender distribution was equal in PSP-P (see table 6.4).
This series comprised 54% RS, 32% PSP-P, 11% had equal numbers of features 
of both subtypes and 3% lacked sufficient clinical data to be classified. These subgroups, 
defined by the clinical features present in the first two years of disease, represent two 
separate points on a spectrum of clinical features related to PSP tau pathology. The 
proportions of patients presenting with RS and PSP-P in this study may not reflect the 
proportions of these subtypes in the community because of ascertainment bias inherent in 
a brain banked population. (Maraganore et al., 1999) Furthermore this study is limited 
by its retrospective nature. Despite this, the frequency of falls (94%), bradykinesia 
(98%), speech disturbance (87%) and dysphagia (69%) in the whole group was consistent 
with data reported in other clinical and clinicopathological studies. (Maher and Lees, 
1986; Vemy et a l , 1996a; Nath et a l, 2003) In contrast to some studies we found a 
higher incidence of levodopa responsiveness (32%), extra-axial dystonia (26%) and a 
longer duration of disease. (Maher and Lees, 1986; Nath et a l, 2003) The inclusion of 
only pathologically proven cases of PSP partially accounts for this, and is a strength of 
this study, allowing us to more clearly identify atypical clinical features in cases that 
would have been automatically excluded from clinical reports relying on PSP clinical 
diagnostic criteria.
Previously, attempts have been made to define clinical subgroups in cohorts of 
PSP (Birdi et a l, 2002; Morris et a l, 2002a; Nath et a l, 2003; Gibb et a l, 2004) and to 
apply this classification in small pathologically proven series (Braak et a l, 1992; Daniel
58
et al., 1995; Vemy et al., 1996a; Vemy et al., 1996b; Bergeron et al., 1997). Daniel and 
co-workers found that in a subgroup without supranuclear gaze palsy women were over 
represented, age of onset was later and duration of disease was longer when compared to 
the group with supranuclear gaze palsy, where men were over represented. (Daniel et al., 
1995) No quantitative or qualitative pathological differences were distinguished, 
although a subsequent study on the same material showed greater neuronal loss in the 
nucleus interpositus in those with a supranuclear gaze palsy. (Revesz et al., 1996) Birdi 
and collaborators reported that patients with gait or balance difficulties at onset were less 
likely to improve on levodopa therapy, more likely to develop supranuclear gaze palsy 
and had a shorter duration of disease. (Birdi et al., 2002) Morris and colleagues 
classified pathologically confirmed cases of PSP according to the diagnosis of PSP in life 
and the retrospective application of diagnostic criteria for PSP. (Morris et al., 2002a) All 
cases in their “typical PSP” subgroup had a diagnosis of PSP in life, all retrospectively 
satisfied the diagnostic criteria, and such cases were more likely to have the PSP 
susceptibility tau haplotype (HIHI). In a series where only 60% of cases had 
pathological confirmation, Nath and co-workers found that the subgroup with early falls 
and bulbar dysfunction had a shorter survival, and those with a diagnosis of probable PSP 
according to the NINDS-SPSP criteria had a worse prognosis. (Nath et a l , 2003) The 
variations in definition between these studies make it difficult to compare clinical groups 
and even more difficult to apply clinical characteristics objectively to pathological 
cohorts. By applying the clinical distinctions identified in our study comparisons can be 
made between more homogenous clinical groups potentially enabling a better 
understanding of the spectrum of pathological changes in PSP.
The identification of RS and PSP-P goes some way to reconcile the differences 
that exist between the pathological and clinical criteria for the diagnosis of PSP. This 
study was designed to synthesise a large body of clinical data with no a priori 
assumptions. Using this data driven approach we have identified two discrete syndromes 
in patients who have pathologically diagnosed PSP. What this strategy could not identify 
were clinical syndromes with characteristics that were not included in the data collection. 
In addition it relies on consistent syndromes to occur in large enough numbers to impact 
on the principal components in the factor analysis. For example gait ignition failure was
59
not a clinical criterion that was extracted from the case notes, and cases where it may 
have been the presenting feature and other features of PSP were lacking, or developed 
later, were infrequent enough to have no significant impact on the factor analysis. 
Ascertainment bias inherent in a brain bank cohort will also inevitably skew the 
proportion of cases in each clinical group, and may not reflect proportions in the 
community. Therefore, pure akinesia may still be a third distinct clinical syndrome in 
PSP, but it occurs in sufficiently small numbers that it has not been a significant finding 
in this study. Prospective clinicopathological studies are now needed to confirm further 
these proposed subgroups and could potentially identify less common, but distinct 
clinical phenotypes.
We found no cases that exhibited any of the NINDS-SPSP mandatory exclusion 
criteria. (Litvan et al., 1996a) However, according to our data some features that are 
included in the NINDS-SPSP “supportive criteria” may be misleading. Early speech 
disturbance was found in 39% of cases, and 32% had a modest or good response to 
levodopa (PDSBB grade 2 or 3), though an excellent response to levodopa (PDSBB 
grade 4) was not recorded. While an asymmetric onset was a feature in 28%, persistent 
markedly asymmetric Parkinsonism was not seen.
The core clinical features of PSP appear to be bradykinesia, rigidity and postural 
instability and are almost always present later in the disease. Together with the 
supranuclear vertical ophthalmoplegia, dementia, dysarthria and pseudobulbar palsy they 
form the classic features of PSP. (Steele et a l , 1964) When these features appear in the 
first two years a diagnosis of RS is most likely. We have confirmed a high frequency of 
non-specific visual complaints early in the course of the disease and a predominance of 
males in the RS subgroup. (Richardson et a l, 1963)
The expanded clinical phenotype now includes a syndrome that, at least in the 
early stages, may closely resemble idiopathic PD. The presence of the PSP-P subgroup 
may account for the small proportion of cases in other clinicopathological reports where 
an incorrect antemortem diagnosis of PD was made. (Hughes et a l , 2001) The features 
which most clearly differentiate this syndrome from RS appear to be an asymmetric 
onset, extra-axial dystonia, tremor and benefit from levodopa. Early bradykinesia 
appears to be essential for the diagnosis, but does not adequately differentiate it from RS,
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especially later in the disease course. Disease duration in PSP-P is significantly longer 
than RS (table 6.4), and to our knowledge exceeds median survival in all 
clinicopathological PSP case series.
The clinical features in these two groups may give some insights into the 
pathological substrate for PSP. Axial rigidity, bradykinesia and postural instability are 
universal end points of this heterogeneous degeneration and may be related to the 
invariable pathological findings which form the basis of the diagnostic criteria. (Litvan et 
al., 1996a) Though supranuclear gaze palsy is seen in the later stages of most cases 
(table 6.5) it appears earlier in RS. This clinical finding is specifically associated with 
degeneration of some cholinergic brainstem structures (Juncos et al., 1991) and the 
nucleus raphe interpositus. (Revesz et a l , 1996) The current study suggests that early 
involvement of these areas predicts early dementia and poorer prognosis. The striatal 
cholinergic neurons that bear the dopamine receptors are affected in PSP either by 
degeneration of intrinsic striatal projection neurons or by altered regulation of D2 
receptors (Ruberg et a l, 1985; Pierot et a l, 1988; Arnold et a l, 1994; Landwehrmeyer 
and Palacios, 1994; Suzuki et a l, 2002). The partial response to levodopa in PSP-P may 
imply a different pattern of neurodegeneration where these projection neurons are 
relatively less affected. Differences in early pathological involvement of the striatum, 
pallidum or subthalamus may account for the observed marked clinical differences 
between RS and PSP-P, which appear to be two different points on a continuous 
spectrum of PSP tau pathology.
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6.2. Post-hoc analysis of QSBB database -  pure akinesia with gait freezing 
Background
In 1974 Imai described what he considered to be a hitherto unrecognised clinical 
syndrome which he termed pure akinesia without response to levodopa. (Imai and 
Narabayashi, 1974) These cases were characterised by freezing or blocking during 
walking, writing and speaking with ‘kinesie paradoxale’. Limb rigidity and rest tremor 
were conspicuous by their absence. The patients were also reported to have normal eye 
movements and no cognitive deficits. (Mizusawa et a l , 1993) They could be 
distinguished further from Parkinson’s disease (PD), by the near total lack of response to 
levodopa. (Barbeau, 1972) Phenomenologically Imai’s pure akinesia was similar to 
‘trepidant abasia’ described by Petren in the pre-levodopa era. (Petren, 1901) Since 
Imai’s description a number of similar reports have occurred describing the same clinical 
picture under different rubrics such as Petren’s gait (Baezner and Hennerici, 2005), 
(isolated) gait ignition failure (Atchison et a l, 1993) and primary progressive gait 
freezing. (Achiron et a l, 1993) The prominence of the distinctive early gait disturbance 
has been emphasised in some of the more recent reports while the absence of other 
Parkinsonian features and dementia has been relatively overlooked. This diversity in the 
clinical reports has confounded clinicopathological correlation. (Quinn et a l, 1989; Imai 
and Narabayashi, 1990)
Petren considered that diffuse arteriosclerosis was responsible for the gait 
disturbance in his pathologically examined patients. (Petren, 1901) This conclusion had 
some merit given the contemporaneous clinical and pathological associations of 
‘demarche a petits pas’ with thrombotic encephalomalacia by Brissaud. (Brissaud, 1895) 
More recently it has been suggested that patients with “pure akinesia” or “primary 
progressive gait freezing” may have an over accumulation of hyperphosphorylated tau in 
subcortical structures because of the associated late development of ophthalmoplegia, 
nuchal rigidity and dysphagia in some cases. (Imai et a l, 1993; Riley et a l, 1994; Factor 
et a l, 2002; Factor et a l, 2006) This has been supported in the handful of published 
autopsy cases where pathology compatible with PSP has been the commonest finding.
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(Homma et al., 1987; Matsuo et al., 1991; Mizusawa et al., 1993; Yoshikawa et al., 
1997; Katayama et al., 1998; Konishi et al., 2005; Factor et al., 2006) Two published 
cases have been diagnosed as pallidonigro-luysian atrophy (PNLA) (Konishi et al., 2005; 
Factor et al., 2006) a rare pathological diagnosis characterised by severe neuronal loss 
and gliosis in the globus pallidus, subthalamic nucleus and substantia nigra. (Contamin et 
al., 1971; Kawai et al., 1993) The neuropathological characteristics of PNLA have not 
been fully delineated but there is evidence that this condition substantially overlaps with 
PSP-tau pathology. (Mori et al., 2001)
Imai’s pure akinesia is distinct from both RS and PSP-P and has been suggested 
to represent a further separate clinical phenotype. (Imai et al., 1993)
Aims
The present study was undertaken to determine to what extent this clinical 
syndrome is represented in the Queen Square Brain Bank (QSBB) and whether it is 
specific for PSP-type tau pathology. Diagnostic criteria and a reclassification of the 
nomenclature is proposed to incorporate previous observations with the current findings, 
under the label of “pure akinesia with gait freezing”.
Patients and Methods
A retrospective analysis was performed using the clinical case-notes from 886 
cases of pathologically diagnosed neurodegenerative disease archived at the QSBB. 
From this 749 had sufficient clinical information and a definitive primary diagnosis for 
inclusion in the study (Lewy body Parkinsonism (LBP), n = 470; PSP, n = 125; multiple 
system atrophy (MSA), n = 84; vascular Parkinsonism (VP), n = 25; Alzheimer’s disease, 
n = 9; corticobasal degeneration (CBD), n = 9; post-encephalitic Parkinsonism (PEP), 
n=5; essential tremor (ET), n=5; Huntington’s disease(HD), n=5; other, n=12). The 
cases met the widely accepted pathological criteria for the diagnosis of these conditions. 
(Kosaka, 1990; Mirra et al., 1991; McKeith et al., 1996; Litvan et al., 1996b; Gilman et 
al., 1999; Lantos, 2000)
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Data Collection
A systematic chart review was performed as described in chapter 6.1. Patients 
with pure akinesia were selected according to criteria, modified from Imai (Imai et ah, 
1993). (Table 6.6) In the patients who satisfied these criteria, clinical features from 
disease onset to death were recorded. Where any clinical feature was present in more than 
half of all patients, the mean time from disease onset to onset of that clinical feature was 
calculated and expressed as a percentage of total disease duration.
Pure akinesia with gait freezing 
Present:
Gradual onset
Early freezing of gait or speech
Absent:
Sustained response to levodopa
Tremor
Imaging changes suggestive of lacunar infarcts or subcortical 
white matter ischaemia suggestive of Binswangefs disease
Absent in first 5 years:
Limb rigidity
Dementia
Supranuclear ophthalmoplegia
History of acute focal neurological events due to stroke______
Table 6.6 Diagnostic criteria for pure akinesia with gait freezing
Results
Seven cases (five men, two women), fulfilled criteria for pure akinesia with gait 
freezing. The primary pathological diagnosis was PSP in six and Lewy body pathology in 
the seventh. One patient with a diagnosis of PSP had previously been classified PNLA 
because of sparse neurofibrillary tangles on routine silver staining, but subsequent 
immunohistochemical analysis revealed typical PSP neuronal and glial pathology. 
Clinical descriptors of gait freezing and gait ignition failure were varied amongst these 
cases, and could not be delineated from gaits associated with other pathologies. Other 
clinical features were able to make the distinction between VP and most PD from PAGF. 
Four patients with isolated vascular disease who presented with slowing of gait and 
bradykinesia were excluded because of co-existent tremor, rigidity and dementia in four
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and history of acute stroke episode in one. In ten patients with combined vascular and 
Lewy body pathology who presented with slowing of gait and freezing PAGF was 
excluded by co-existent tremor, rigidity and response to levodopa medications. In one 
patient with shunt-responsive PSP, diagnosed as normal pressure hydrocephalus in life, 
PAGF was excluded by early cognitive dysfunction. Patients with isolated Lewy body 
disease who presented with gait disturbance were excluded by their response to levodopa 
medications, rigidity and cognitive dysfunction. Table 6.7 lists the red flags for these 
distinctions.
The clinical features of PAGF are summarised in table 6.8. The mean age at 
disease onset was 61 years (range 44-78) and mean disease duration was 13 years (range 
5-21). The natural history and evolution of clinical features in these patients is 
summarised in figure 6.3. Akinesia of gait, speech and poverty of facial expression were 
common early features. Back pain and nuchal rigidity were also reported. Most patients 
were wheel chair dependent in the second half of their disease, and eye movement 
abnormalities typically occurred after 9 years of disease.
Of the six cases with a pathological diagnosis of PSP, three had been suspected to 
have PSP, a mean of 11 years after disease onset, and three had carried a final clinical 
diagnosis of PD. Five of the cases had been classified as PSP-P in chapter 6.1. In the 
patient without PSP pathology there was a well documented history of dementia and 
visual hallucinations in the last 8 years of disease but other clinical features were not 
substantially different from the PSP cases.
Disease duration was longer in pure akinesia with gait freezing than in other 
archived cases of PSP (PSP-PAGF 11.9 vs. PSP 8.0 years, t-test p=0.034). These 
differences were significant when PSP-P AGF was compared to RS, though there was no 
significant difference when compared to PSP-P. (Table 6.8) There were no significant 
differences between these groups in age of onset or age at death. There were no 
significant differences in age of onset or death between PSP-PAGF and other 
Parkinsonian conditions, except that in cases of CBD, disease duration was shorter 
(PAGF 11.4 vs. CBD 6.8, t testp=0.01).
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PAGF Fast micrographia 
Rapid hypophonia 
Palilalia
PD Associated rigidity
Rest tremor
Response to levodopa
Quiet dysprosodic slurred speech
Visual hallucinations
VP Leg rigidity 
Tremor
Early cognitive dysfunction 
Pyramidal signs 
History of acute stroke
Table 6.7 Red flags for distinguishing PAGF from PD and VP
Case number
1 2 3 4. 5 6 7
Age at onset (yr) 68 44 63 49 71 78 55
Age at death (yr) 81 60 75 62 76 87 76
Disease duration 13 16 12 13 5 11 21
(yr)
Gender F F M M M M M
First symptom Gait
disturbance
Slowed gait Slowed gait Speech
disturbance
Slowed gait Slowed gait Gait
disturbance
Time to first fall (yr) 5 4.5 - 8 ? 8 ?
Time to wheelchair 11 - 7 7 7
(yr)
Speech Hypophonia Hypophonia Stammering, 
rapid hypophonia
Rapid
hypophonia
Hypophonia Dysarthria
Handwriting - Micrographia Micrographia Micrographia - - -
Upper limb Late No No Late Mild No Late
bradykinesia
Time to gaze 8 13 - 5 - - -
paresis (yr)
Eye signs Bleph
H&V
SNGP
Bleph 
Late SNGP
Normal Bleph 
V then H SNGP
Bleph Normal Hypometric
saccades
Cognition Normal Normal Normal Normal Normal Normal Late frontal
_________________________  dysexecutive
Table 6.8 Demographic features F, female; M, male; ?, unknown; H, horizontal; V, vertical;
SNGP, supranuclear gaze palsy; not relevant; Bleph, blepharospasm
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Age of onset P Age at death P Duration P
(range) years (range) years (range) years
PSP-PAGF 62.2 73.6 11.4(44.4-78.1) (60.9-87.0) (5.5-16.5)
PSP 65.7 NS 73.7 NS 8.0 0.034(40.1-87.5) (45.4-95.8) (1.2-23.8)
RS 66.0 NS 72.3 NS 6.3 <0.001(40.1-87.5) (45.4-95.8) (1.2-13.5)
PSP-P 65.8 NS 76.4 NS 10.5 NS(44.3-86.1) (50.1-92.6) (4.1-23.8)
LBP 61.0 NS 76.3 NS 15.1 NS(28.6-84.2) (49.8-93.4) (1.4-41)
MSA 56.4 NS 64.4 NS 7.9 NS(33.5-79) (39.4-86.4) (2.9-16.5)
CBD 66.2 NS 73.0 NS 6.8 0.01(55.6-76.1) (65.8-81.6) (3.6-10.2)
VP 71.7 NS 82.4 NS 9.9 NS(59.7-81.3) (72.4-90.8) (2.6-18.2)
Table 6.9 Mean age of onset and disease duration in PSP-PAGF vs. other bradykinetic
rigid syndromes, p, Student’s t-test p value compared to pure akinesia; NS, non­
significant.
Case histories:
Case 1 — Pathological diagnosis: PSP
This 68 year old woman presented to her local doctor with low back pain and progressive 
difficulties walking because of feelings of unsteadiness. Degenerative lumbar disc 
disease was diagnosed 3 years later, after she experienced an acute exacerbation of 
lumbar and buttock pain. Her gait disturbance deteriorated and the following year she 
was found to have marked difficulty initiating walking, but she was able to walk fluently 
once she had got started. There was mild leg rigidity and no tremor. Cognition and eye 
movements were normal. There was a mild, unsustained improvement when L-dopa was 
tried four years after disease onset. However, by the following year there was no response 
to a daily dose of 1500 mg of 1-dopa/carbidopa, and she had a quiet speech, had slowed 
up mentally and required a walking stick for support. Examination, five years after 
disease onset, revealed a slowing of vertical saccadic eye movements but no supranuclear 
gaze palsy. Over the next 2 years, however, there was gradual deterioration in the range 
of her eye movements, and she developed swallowing difficulties. Her gait became so 
unsteady that she was unable to walk without two people supporting her and at home she
67
was confined to a wheel chair. There was neither delirium nor visual hallucinations and 
her memory was normal. When re-examined at 79 years of age she had blepharospasm 
and gaze limitation in the horizontal and vertical planes. There were no frontal lobe 
release, pyramidal or cerebellar signs. When she died 2 years later she had been resident 
in a nursing home for 4 years and was dependent on others for most activities of daily 
living.
Case 2 - Pathological diagnosis: PSP
A 44 year old woman was referred to an orthopaedic surgeon following a nine month 
history of aching thigh pain, particularly at night. Over the next 2 years she developed 
facial impassivity and slowness of gait with decreased arm swing. Examination revealed 
marked neck rigidity but normal tone in the limbs and there was no rest tremor. 
Anticholinergic medications were ineffective. In the following year she developed some 
dystonic posturing of the left foot on and after walking. L-dopa/carbidopa 220 mg was 
started without improvement. She became increasingly unsteady, and she developed a 
specific difficulty in initiating walking, but was able to walk with normal stride length 
once started. By the time she was 50 she was falling frequently, and experienced gait 
freezing when walking through doorways. Amantadine 200 mg daily had no effect. The 
following year she developed a quiet slurred speech, facial freezing and micrographia but 
no other signs of Parkinsonism in the arms. She continued to fall frequently and 11 years 
after disease onset she was confined to a wheelchair when venturing out of doors and 
used a single point stick indoors. Her cognition was unaffected, and apart from 
handwriting difficulties upper limb function was normal. Selegiline and bromocriptine 
were ineffective, and the latter precipitated visual and auditory hallucinations which 
disappeared on withdrawal. She developed pyramidal signs and by 57 years of age had 
blepharospasm and some restriction of her vertical gaze. Ocular motility deteriorated 
over the next 2 years until voluntary eye movements became impossible. Terminally she 
developed laryngeal dystonia, stridor and dysphagia leading to frequent respiratory 
compromise and depression. She became delirious and died suddenly from presumed 
respiratory failure at the age of 60.
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Case 3 - Pathological diagnosis: PSP
This 63 year old man gradually developed speech disturbance and slowness of walking. 
One year later his handwriting deteriorated and he was found to have moderate 
bradykinesia in the limbs, worse on the right than the left. L-dopa/carbidopa was started 
without clear benefit up to 1000 mg per day. The bradykinesia increased and selegiline 
and bromocriptine were added but with no improvement. Within five years he had 
developed start hesitation and difficulties moving off from a standing start. Increasingly 
over the next two years he experienced gait initiation failure and freezing. He required a 
single point stick to mobilise indoors and a wheelchair outside. Cognition was 
unaffected, and, apart from micrographia, he was able to use his hands for everyday tasks 
without difficulty. Walking became impossible by 72 years of age and he became 
dependent on a wheelchair to get around. There was no rigidity in the limbs. Further 
trials with dopaminergic medication were ineffective. He developed depression after 
being diagnosed with bladder cancer and died from complications of the cancer at 75 
years of age.
Case 4 - Pathological diagnosis: PSP
This 49 year old man presented to his doctor with depression and phobic anxiety. He had 
developed speech difficulties and deterioration in his hand writing. He complained of a 
stutter and his speech would sometimes suddenly block in mid-sentence. The family also 
commented that his speech was faster and more imprecise. Three years later he had 
developed facial impassivity and walked very slowly. L-dopa/benserazide (Madopar) 
was started four years after onset with no improvement, up to 1200 mg per day. He 
tended to freeze in crowds, and over the next year developed gait initiation difficulties. 
There was no tremor or rigidity. His start hesitation and blocking increased and he was 
referred for consideration of pallidotomy. He had normal cognition and normal function 
in the arms. The right sided stereotactic pallidotomy was complicated by aphonia and 
produced no benefit to his gait. His condition deteriorated further over the following four 
years, and he developed blepharospasm and a complete supranuclear gaze palsy, initially 
in the vertical plane. In the final stages of his illness he had severe limb rigidity and died 
after 13 years of disease from presumed aspiration pneumonia.
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Case 5 - Pathological diagnosis: PSP
This 71 year old presented with a gradual onset of difficulty initiating movements and 
speech disturbance. His speech had become quiet and his handwriting much smaller. L- 
dopa/carbidopa was started and increased to 660 mg per day without noticeable effect. 
Three years later he had a rapid, monotonous, low volume speech and profound gait 
initiation problems with shortened stride length when he started walking, but good arm 
swing. There was a mild decrement in amplitude on sequential finger movements, but no 
limb rigidity, tremor or hypomimia. He then started to complain of freezing up in 
doorways and confined spaces. He developed an anterocollis and mild swallowing 
difficulties. He had no rigidity and only minimal bradykinesia in the arms right up to the 
final year of his life. His speech deteriorated to the point where he was virtually aphonic, 
only able to communicate by speaking slowly in a whisper. Though no formal 
neurological examination was performed in the last months of his life he is recorded to 
have had a staring expression with a tendency for his eyes to spontaneously close.
Case 6 - Pathological diagnosis: PSP
At 78 years of age this man gradually developed unsteadiness and slowness of gait. His 
walking progressively deteriorated, over the next three years and he was referred to a 
neurologist who recorded gait initiation problems, shuffling gait and freezing. There was 
a moderate hypophonia, but no bradykinesia, tremor or rigidity in the arms. There was 
no response to 1-dopa/carbidopa or bromocriptine. After five years disease duration he 
developed dysphagia and his speech became unintelligible. No cognitive dysfunction or 
oculomotor abnormality was described at the last clinical visit 2 months before his death 
at 87 years of age.
Case 7 - Pathological diagnosis: PD
At 50 years of age this man noticed progressive unsteadiness, poor balance and 
eventually difficulty initiating walking and turning. He had history of traumatic brain 
injury and was comatose for two weeks following. There was also a history of long and 
liberal alcohol intake. He started L-dopa/benserazide 625 mg without benefit and the
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medication was withdrawn, and there was no response to 3 mg of subcutaneous 
apomorphine. An MRI scan did not show any evidence of vascular disease or 
hydrocephalus. At lumbar puncture the cerebrospinal fluid (CSF) pressure was normal, 
and there was no improvement following three large volume CSF taps. After 10 years he 
developed some urinary hesitancy and terminal dribbling. Even after 20 years there were 
no signs of Parkinsonism in the upper limbs, only mild hypomimia and normal eye 
movements. He scored 30 on Folstein’s mini mental state examination, but on detailed 
neuropsychometric testing there was evidence of moderate under functioning of non­
verbal reasoning tasks. Subsequent treatment with selegiline and amantadine was 
ineffective. In the final years of his illness there was dystonic posturing of the right arm, 
apraxia and fluctuating cognitive state with hallucinations and daytime somnolence.
Discussion
Pure akinesia is an uncommon presentation of PSP-tau pathology and is clinically 
distinct from the more common PSP phenotypes of RS and PSP-P. The striking 
consistent clinical features are difficulties with the initiation of walking and freezing of 
gait with associated handwriting and speech difficulties. In contrast to PSP-P limb 
rigidity and tremor are absent and cognition remains intact. In common with PSP-P eye 
movement abnormalities emerge late in the disease. We have identified seven cases in a 
brain bank cohort of 753 patients with a presentation of start hesitation and freezing of 
gait. These cases resemble the patients first described by Imai (Imai and Narabayashi, 
1974) and subsequently documented in several small case series by other authors. In a 
number of later reports similar cases have been referred to as gait ignition failure or 
primary progressive gait freezing. (Yamamoto et a l, 1985; Imai et al., 1993; Atchison et 
al, 1993; Riley et a l, 1994; Factor et a l, 2002) We would like to propose “pure akinesia 
with gait freezing” as a unifying term which encompasses the salient clinical features.
Six of the patients had the pathological features of PSP, one of whom had 
previously been labelled as pallidonigro-luysian atrophy (PNLA), and a seventh had 
Lewy body pathology. A natural history of pure akinesia with gait freezing can be 
constructed from the retrospective analysis of patients in our study (figure 6.3). Start 
hesitation and a change in handwriting or, less frequently speech, are common presenting
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features. Other early complaints include unsteadiness and slowing of gait, untidy 
handwriting and mildly slurred speech. As the disorder evolves, gait ignition failure and 
freezing, rapid stuttering and hypophonia with fast ‘pallidal’ micrographia occur. Some 
patients develop axial rigidity and back pain, and later bladder instability. Supranuclear 
gaze paresis and blepharospasm are late and inconsistent features. Death usually occurs 
more than a decade after disease onset by which time some patients have developed 
additional upper limb bradykinesia and swallowing problems. (Petren, 1901; Achiron et 
a l , 1993; Atchison et a l ,  1993; Factor et a l ,  2002; Factor et a l ,  2006)
Micrographia (3) I 
U n ste a d in e ss  (6) I 
S lo w n e ss  o f gait (4) I 
H ypom im ia(5) I 
Back pain (3) I 
Gait iniation failure (6) I 
Hypophonia (6) I 
Nuchal rigidity (3) I 
Bladder instability (3) I 
G aze p a resis  (4) I 
W heelchair (6) I 
B lep h arosp asm  (4) I
0
Figure 6.3 Natural history of PSP-PAGF, summarised clinical features from 6 patients 
showing mean time from disease onset (expressed as percentage of total 
disease duration, x) to onset of clinical feature (y)
Amongst the patients with a pathological diagnosis of PSP in this series, pure 
akinesia with gait freezing (PSP-PAGF) can be differentiated from RS by the absence of 
a frontal dysexecutive syndrome, eye movement abnormalities and falls within the first 
two years o f disease. In chapter 4.1 patients with PSP-PAGF were grouped together with 
PSP-P. PSP-PAGF can, however, be further separated from PSP-P by the presence of
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gait ignition failure, rapid hypophonia or micrographia and the absence of levodopa 
response and tremor. The duration of disease is similar to PSP-P but is longer than in RS.
An association between PAGF and PSP-tau pathology was first suggested after 
the recognition of late eye movement abnormalities. (Imai et a l , 1987) Abnormalities of 
vertical downward saccadic eye movements are considered to be most specific for the 
diagnosis of PSP and, in RS eye movement abnormalities often occur within the first two 
years of disease. (Litvan et al., 1996a) In a clinically diagnosed group of patients with 
pure akinesia, eye movement recordings showed slowness of vertical saccades that was 
proportional to disease duration and hence likely to be a product of the underlying 
pathological process postulated to be PSP-tau pathology. (Riley et a l, 1994) Although 
the patients included in our study were not subject to standardised examination, five were 
recorded as having eye movement abnormalities a mean of 8 years after disease onset. In 
four, blepharospasm also occurred late in the disease. This late emergence of eye 
movement and eye-lid abnormalities contributed to the inaccuracy of clinical diagnosis. 
The earliest eye movement abnormalities in PSP are postulated to result from 
degeneration affecting the rostral interstitial nucleus of the fasciculus longitudinalis 
medialis, followed by progression into the interstitial nucleus of Cajal and the central 
mesencephalic reticular formation. (Revesz et a l, 1996; Rottach et a l, 1996; Bhidayasiri 
et a l, 2001) The neuroanatomical basis for akinesia is less completely understood. The 
globus pallidus and the frontal cortex have been associated with lesional and imaging 
studies with akinesia. (Taniwaki et a l, 1992; Kondo et a l, 1994; Imai, 1996; Ohno et 
a l, 1997; Kim et a l, 2001; Yener et a l, 2005) Pathological studies have consistently 
shown involvement of the globus pallidus and substantia nigra and in most cases the 
subthalamic nucleus, (Homma et a l, 1987; Matsuo et a l, 1991; Mizusawa, 1993; 
Yoritaka et a l, 1997; Katayama et a l, 1998; Konishi et a l, 2005) and a number of cases 
of secondary pure akinesia have been attributed to structural lesions in the globus 
pallidus. (Suzuki et a l, 1984; Pramstaller et a l, 1999)
Lower-body Parkinsonism has been linked to a vascular aetiology for more than a 
century (Brissaud, 1895), and accounts for around 4% of all Parkinsonism. (Foltynie et 
a l, 2002) However, the clinical diagnosis of VP is often inaccurate (Hughes et a l, 
1992b; Jellinger, 2002), and clinical correlates of VP are limited to few large autopsy
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series. (Hughes et a l,  1992b; Jellinger, 2001; Zijlmans et al., 2004a) In the current series 
no patient with pathologically diagnosed VP, or PD with added vascular pathology, 
satisfied the criteria for PAGF. A number of patients with VP presented with early gait 
freezing, marche a petits pas, micrographia and hypophonia, but the presence of tremor, 
dementia response, limb rigidity and a sustained response to dopaminergic medications, 
excluded them from PAGF according to our criteria. Furthermore these additional clinical 
features are typical for VP, suggesting that the clinical diagnostic criteria would exclude 
most VP from a diagnosis of PAGF. (Winikates and Jankovic, 1999; Zijlmans et al., 
2004b) Lewy body pathology only accounted for one patient in our series, and is 
differentiated from the other cases only by the late onset of dementia and visual 
hallucinations. Postural instability and gait disturbance are poor prognostic features in 
PD, and suggest an early progression to dementia. (Bum et a l , 2006; Alves et al., 2006) 
In general these patients are unlikely to be classified as PAGF because of responsiveness 
to dopaminergic medications and rigidity which tends to be more severe than in PD 
patients with tremor dominance. (Giladi et al., 2001)
The goal in defining any disease is “to gain insight into its nature, with the 
implicit assumption that disease exists as an ideal form”. (Nesse, 2001) The proposed 
diagnostic criteria for pure akinesia with gait freezing emphasises the absence of limb 
rigidity and rest tremor and the absence of any substantial, sustained response to 
levodopa. Some of the published cases of pure akinesia, primary progressive gait 
freezing, gait initiation failure and Petren’s gait would be reclassified using these criteria, 
presumably as vascular Parkinsonism or PD. A number of rare causes have been reported 
to cause secondary pure akinesia, involving brain regions known to be affected in PSP. 
Sarcoma in the caudate, globus pallidus and thalamus (Suzuki et al., 1984), primary 
central nervous system lymphoma involving the globus pallidus bilaterally (Pramstaller et 
al., 1999), pheochromocytoma (Nakagawa et al., 1987) and genetically proven 
Hallevorden-Spatz syndrome (Molinuevo et a l, 2003) have caused similar symptoms, 
but the tempo of disease and imaging characteristics would have excluded PSP-tau 
pathology in these cases.
The findings suggest that PSP pathology is the most common underlying 
pathological process in patients with pure akinesia with gait freezing. A clinically
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identical syndrome can also be associated with Lewy body disease, although the presence 
of rigidity and dementia with visual hallucinations might separate these cases in the later 
stages of the disease. The proposed diagnostic criteria for pure akinesia and gait freezing 
will improve the clinical and pathological homogeneity, and hence clinical utility of this 
clinical syndrome.
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Introduction
The diagnosis of PSP can only be made with absolute conviction after post 
mortem confirmation. (Litvan et al., 1996a; Osaki et al., 2004) Clinical variability in 
disease accounts for the low specificity and sensitivity of diagnostic criteria. (Osaki et al., 
2004) The different clinical expressions of PSP-tau pathology suggest that there might 
be regional variability of pathological change. Several pathologists have addressed this 
issue by examining the distribution and severity of pathological changes in series of cases 
where the minimum pathological criteria for PSP are satisfied. Unfortunately the 
accompanying clinical descriptions in these series are often incomplete and the definition 
from report to report of “atypical” PSP varies.
Regional pathology in PSP
In one series Braak et al., demonstrated that patients with early, severe dementia 
have relatively more cortical pathology. (Braak et al., 1992) They found a correlation 
between dementia and severity of cortical lesions and emphasised the need to consider 
PSP as disease with significant regional heterogeneity. In the same year Hof et al., 
quantitatively analysed the brains of 6 patients with PSP to determine the distribution of 
cortical neurofibrillary tangles. (Hof et al., 1992) A variable distribution of pathology 
and different densities of neurofibrillary tangles in the prefrontal, primary motor and 
temporal cortices were found. However, pathological changes in the granule cell layer of 
the dentate gyrus were uniform.
Later Vermersch et al., eloquently mapped the pattern of neurofibrillary 
degeneration in one patient using biochemical and immunohistochemical methods. 
(Vermersch et al., 1994) The greatest tau load was detected in the motor strip and 
prefrontal areas. Vemy et al., examined in detail the distribution of tangle formation and 
neuronal loss in 10 cases of PSP. (Vemy et al., 1996a) Using morphometric analysis, the 
mean density of NFTs was calculated using contiguous microscopic fields, transferred to
fit a 10-level standard scale. They performed a factorial analysis, using these results, and 
were able to identify two subgroups that could be divided on clinical and pathological 
grounds. A group with mild involvement of the pedunculopontine nucleus invariably had 
associated mild cortical involvement and a number of clinical signs that they considered 
unusual, including rest tremor at presentation, blepharospasm and facial dystonia, 
myoclonus on startle and postural tremor in different patients. The subcortical structures 
involved had a preferentially ‘pallido-luyso-nigral’ distribution. The second group all 
had typical clinical signs and more severe involvement of the pedunculopontine nucleus 
and cortex, and more widespread involvement of subcortical structures. The sample size 
was too small to be conclusive about a true difference between these groups.
The presence or absence of a described vertical supranuclear gaze palsy was used 
to define clinical groups by Revesz and colleagues at the National Hospital for 
Neurology, Queen Square. (Revesz et al., 1996) They identified changes in the degree 
of nerve cell loss and neurofibrillary tangle deposition in the nucleus raphe interpositus 
(nRI) which contains the omnipause neurons. The classic clinical group with 
supranuclear gaze palsy had the most severe changes in the nRI, which has a role in the 
initiation of saccadic eye movements.
The neuropathological characteristics of 3 patients with “clinically atypical” PSP 
were reported by Bergeron et al. (Bergeron et al., 1997) These patients had developed a 
corticobasal syndrome, with apraxia, focal dystonia and arm levitation late in the disease. 
Neuronal loss and gliosis, tau immunoreactive threads, neuronal tau inclusions and tau 
immunoreactive astrocytes in the cerebral cortex, subcortical structures and cerebellum 
were found and pathological changes were most severe in the frontal lobes. Bigio et al., 
found similar changes in two groups, where the atypical PSP group was defined as 
having severe dementia at death. (Bigio et al., 1999) Using a manual semi quantitative 4- 
grade scale they found a positive association between severity of cortical tau pathology 
and dementia.
Takanashi et al., compared the globus pallidus and frontal lobes of six cases of 
PSP and five of CBD, using a 4-grade scale to measure the expression of pathological 
tau. (Takanashi et al., 2002) They found very few changes in the frontal cortices in five 
of the six (83%) PSP cases, but the clinical details of were not reported.
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Variability has been reported in the substantia nigra (SN) pars reticulata lesions in 
six cases of PSP. (Halliday et al., 2000) The topography and degree of cell loss within 
was analysed using serial section analyses and unbiased quantitative techniques. 
Significantly more reticulata neuronal loss was reported in the 4 cases with gaze palsy.
Halliday and her colleagues have also examined the globus pallidus (GP), 
subthalamic nucleus (STN) and SN in PSP and PD. (Hardman et al., 1997a; Hardman et 
a l, 1997b; Hardman and Halliday, 1999a; Hardman and Halliday, 1999b) Neuronal 
numbers were calculated using an unbiased fractionator technique following 
immunostaining. The density of NFTs and neuropil threads was quantified to obtain 
severity index on a 4-grade scale and neurones were counted in each nucleus. 
Significant, but variable neuronal loss was found in the GP extema of the PSP cases, but 
not PD. All other regions examined in the PSP cases had substantial (>60%) neuronal 
loss.
Regional variability has also been noted in the cerebellar cortex of 13 cases of 
PSP. (Piao et a l, 2002) Tau positive pre-tangles were found in the cerebellar cortex in 
the absence of NFTs in 9/13 (69%), but no clinical correlations were suggested.
Substantial regional variability in NFT and pre-tangle distribution was reported in 
another study. (Li et al., 1998) Tau positive neurons (NFT & pre-tangles) were counted 
in five cortical (superior frontal, precentral, entorhinal and transentorhinal cortices and 
the hippocampus) and five subcortical (amygdala, Meynert nucleus, hypothalamus, 
pallidum, subthalamus) regions in eight cases. In these regions up to three fold 
differences in the density NFT were reported. The group of patients with the highest 
number of pre-tangles, was designated ‘atypical PSP’ on the basis that pre-tangles are 
rare in PSP, but common in CBD. In their ‘typical’ group, with few pre-tangle neurons, 
NFTs were most abundant in the STN, GP, Meynert nucleus, central nucleus and 
hypothalamus.
In a post mortem imaging study using nine pathologically confirmed cases of 
PSP, regional brain atrophy (Cordato et al., 2000) was greatest in the GP interna, the 
amygdala, frontal lobes and parietal lobes compared with controls and PD. Interestingly 
the degree of atrophy of the GPi and amygdala correlated with increasing tangle 
formation in the precentral gyrus.
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Regional analysis of tau isoform accumulation in PSP
Delacourte and colleagues demonstrated selective vulnerability of neuronal 
subsets in PiD and AD that corresponded to the expression of specific tau isoform 
patterns. (Delacourte et a l,  1996; Delacourte et al., 1998) They suggested that tau 
accumulation could perform as a biochemical marker for “neuronal subsets and their 
specifically related degenerative processes”. (Delacourte et al., 1996) Later in their 
seminal paper on the biochemical pathway of AD, they used these methods to 
demonstrate a hierarchical ‘collapse’ of subsets of neurons using paired helical filament 
(PHF)-tau as a marker. (Delacourte et al., 1999)
In PSP tau deposition was first mapped biochemically in 1994. Vermersch 
sampled several subcortical regions, brain stem regions, and all cortical areas using 
Brodmann classification. (Vermersch et al., 1994) These were analyzed using an anti- 
PHF-tau antibody and western blotting, and band intensity was measured by 
computerised densitometry. Abnormal doublet tau was found in all cortical and 
subcortical regions. The largest amount of tau was detected in the motor strip and 
prefrontal areas.
Regional analysis of tau expression was later performed using tau real time -  
polymerase chain reaction (PCR) in 15 cases of PSP using tissue taken from the frontal 
cortex, cerebellar cortex and brainstem (including midbrain and medulla). (Chambers et 
a l, 1999) An increase in 4R tau mRNA in the brainstem was found in these cases, but 
not in the frontal cortex or cerebellum. Weak expression of 3R mRNA in the cerebellar 
cortex was also noted.
Takanashi et al., performed the first comparative study of quantitative analysis of 
tau mRNA isoforms in pathologically diagnosed cases of PSP, CBD and controls. 
(Takanashi et a l, 2002) There was no difference in total amounts of 4R and 3R tau 
between the three groups, but a high ratio of 4R/3R tau mRNA was reported in the globus 
pallidus of PSP and CBD cases, and in the frontal lobes of CBD cases only.
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Conclusion
Pathological heterogeneity has been reported in PSP within the accepted 
pathological diagnostic criteria. The differences are found in: the degree of neuronal loss 
in the frontal lobe, temporal lobe, pontine base, periaqueductal grey matter, nRI, SN pars 
reticulata, GP, dentate nucleus and cerebellar cortex; and there is also variability in the 
distribution of NFTs and pre-tangles in the superior frontal-precentral cortex, amygdaloid 
central nucleus, GP, STN and dentate nucleus. The clinical importance of these changes 
is unclear. This heterogeneity does, however, provide the framework on which a 
structured neuropathological examination can be performed in a group of patients who 
have been carefully clinically examined in life.
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Pathological tau lesions were analysed in 42 cases of pathologically diagnosed 
PSP (23 RS, 13 PSP-P and 6 PAGF) using specific antibodies for 
hyperphosphorylated tau (AT8, RD4 and RD3). The severity of tau-positive 
lesions (neurofibrillary tangles, tufted astrocytes, coiled bodies and neuropil 
threads) was graded in 20 brain regions. The mean overall severity of AT8 
positive lesions was higher in RS than in PSP-P (p<0.001) and in PAGF 
(p<0.001). In all three clinical syndromes tau pathology was most severe in the 
subthalamic nucleus (STN), substantia nigra (SN) and globus pallidus interna 
(GPi). In RS, tau-pathology was significantly more severe than PSP-P in all 
regions (p<0.05) except the STN and putamen, and more severe than PAGF in 
the parietal cortex, pons, dentate nucleus and cerebellar white matter (p<0.05). 
Three patterns of distribution of pathological tau were identified by cluster 
analysis: in cluster 1 the burden of tau accumulation was highest in the STN, 
SN and GPi, and relatively spared the other regions, accounting for most cases 
of PSP-P; in cluster 2, in addition to the basal ganglia, there was moderately 
severe tau pathology in the pons, cerebellar white matter and some cortical 
regions; and in cluster 3 there was moderately severe tau pathology in most 
cortical regions and basal ganglia and more severe pathology in the pons, 
dentate nucleus and cerebellar white matter. Clusters 2 and 3 accounted for the 
majority of RS patients. The incidence of Alzheimer’s type pathology, Lewy 
bodies and vascular pathology did not differ between clinical groups. The 
findings of this study suggest that the ‘atypical’ clinical features of PSP-P and 
PAGF are underpinned by PSP-tau pathology that is less severe and less 
widespread than in RS.
“...if  I  were to describe in a single word the services rendered to us by... 
pathological anatomy...I should say that it has taught the physician to think 
anatomically”
(J. M. Charcot. Maladies des vieillards. In: Oeuvres com petes de JM Charcot. Tome VII. Paris: 
Lecrosnier et Bab6, 1890. [Translated into English by W.S. Tuke. Clinical lectures on senile and chronic 
disease by J.M. Charcot. London: The New Sydenham Society)
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Aims
To examine the distribution of PSP tau pathology, specifically with a view to 
determine what extent pathological variability might explain the clinical differences 
between RS, PSP-P and PAGF.
Materials and Methods
We selected 42 cases, from 102 pathologically diagnosed as PSP, that were 
archived at the QSBB between 1992 and 2002. A systematic case note review and 
clinical classification (RS, PSP-P and PAGF) was performed as described in chapter 5. 
The analysis started with the most recently archived 21 cases comprising 13 cases of RS, 
seven of PSP-P and one of PAGF. A further 21 were selected according to clinical 
phenotype. This second group comprised nine cases of RS and seven cases of PSP-P 
randomly selected from the remaining 81 cases and five cases of PAGF.
Pathological Methods
Diagnostic procedures
Consent for brain donation was obtained from the patient prior to death and 
consent for post mortem examination was obtained from the next of kin after death. 
After removal the brain was divided in the midline and one half was frozen and stored at 
-80°C. The other half was fixed in 10% formalin and sliced in the coronal plane. The 
routine analysis of post mortem material at QSBB included removal of tissue blocks from 
the frontal, temporal, parietal and occipital neocortices, in addition to basal ganglia, 
thalamus, amygdala, hippocampus, midbrain, pons, medulla and cerebellum. All brain 
areas were processed in paraffin wax using standard protocols. Routine sections were cut 
at 7pm and stained with routine methods including haematoxylin and eosin (H&E), luxol 
fast blue/cresyl violet (LFB/CV), tau or silver impregnation (modified Bielschowsky’s 
method). Preliminary PSP pathological diagnostic criteria were applied (Litvan et a l , 
1996b) which insist on the presence of neurofibrillary tangles (NFT), gliosis and nerve 
cell loss in the subthalamic nucleus (STN), pallidum, substantia nigra (SN), dentate 
nucleus, inferior olive and oculomotor nuclear complex.
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Immunohistochemistry
In each case selected for this study, 7 pm tissue sections were taken from the 
anterior and posterior frontal cortex, parietal and temporal cortices, midbrain, griseum 
pontis, and cerebellum for immunohistochemical analysis with the AT8 (tau phospho- 
epitope Ser202/Thr205; Autogen Bioclear, Caine, UK), and three-repeat specific (RD3, 
Upstate, Dundee, UK) and four-repeat-specific (RD4, Upstate, Dundee, UK) anti-tau 
antibodies. Tissue sections were coded with a novel identifier to allow for examination 
blinded to clinical details. The sections which were stained with RD3 and RD4 required 
pre-treatment pressure cooking in sodium citrate buffer (pH 6) for 10 minutes. They 
were then incubated with RD3 (1:1000) or RD4 (1:100) at room temperature for 1 hour, 
followed by biotinylated antimouse IgG (1:200, Dako, Cambridgeshire, UK) for 30 
minutes. They were then further incubated in ABC (Avidin-Biotin complex, Dako) for 
30 minutes at room temperature. Colour was developed with glucose oxidase nickel 
diaminobenzidine and the sections counterstained with Mayers haematoxylin for 1 
minute. For AT8 immunohistochemistry, tissue sections were pre-treated in a microwave 
oven in sodium citrate buffer for 20 min. Sections were incubated with AT8 (1:600) at 
room temperature for 1 hour followed by biotinylated anti mouse antibody (1:200, Dako) 
for 30 min. The remaining steps were as described above.
In addition, tissue sections were taken from the midbrain for a-synuclein 
immunohistochemistry and temporal, parietal and frontal cortical areas for A(3- 
immunohistochemistry. For a-synuclein and Ap-immunohistochemistry, sections were 
pre-treated with formic acid for 15 minutes and then pressure cooked as described above. 
Sections were incubated with a-synuclein (Vector laboratories) 1:50 or Ap (1:100, Dako) 
for 1 hour at room temperature followed by biotinylated anti mouse antibody (1:200) for 
30 minutes.
Regional pathological examination and quantification
In each case quantitative tau pathology assessment was carried out by one rater 
blinded to clinical details (DRW), in 20 brain regions: grey and white matter in anterior 
and posterior frontal lobes, parietal lobe and temporal lobe; globus pallidus intemus and 
extemus; dorsolateral and ventromedial putamen (Ozawa et a l, 2004); caudate nucleus;
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medial, ventromedial and dorsolateral SN (Ozawa et al., 2004); STN; pontine base; 
dentate nucleus; and cerebellar white matter. In each region AT8, RD4 and RD3 positive 
neurofibrillary tangles, tufted astrocytes, and oligodendroglial coiled bodies were counted 
in seven randomly placed high powered microscopic fields (x20 magnification), and 
neuropil threads were counted within a 10x10 graticule (x20 magnification).
The distribution of absolute numbers of tau lesions in the first 21 cases made 
comparison between cases and the identification of patterns of tau pathology difficult 
because of the weighting of cases with very high scores. To make further comparisons 
possible a five point grading scale was developed for each region. The distribution of 
absolute counts for tau pathology, in each region, were examined and plotted along the x- 
axis and ranges for grades 0 to 4 were assigned on the y-axis. Grade 0 was reserved for 
when tau-positive pathology was absent. If the distribution of counts fitted a logarithmic 
curve the upper limit of grade 4 was set as the highest number counted, grade 1 the 
lowest count above zero and other grades on a log scale along the y-axis. If the 
distribution of counts suggested that a linear model was more appropriate the upper limit 
of grade 4 was set at the highest value counted and grades 1-3 were set at 25%, 50% and 
75% of this highest value. In regions where the range included less than four values, 
absolute counts were used.
To assess repeatability, counting of the four pathological inclusions (NFT, TA, 
CB and threads) was repeated in all regions of 10% of cases, selected to represent a range 
of severities, by the same rater. The repeatability of measures was calculated for each 
pathological lesion in each region by calculating the intra-rater SD as follows: (standard 
deviation (Ravi-Rav2)W2. The mean SD was calculated for each lesion in each region for 
all four repeated cases, as well as the mean SD of all lesions in each region and the mean 
total severity of each case.
Histopathological examination
Tissue was examined independently by two neuropathologists (TR and JH) in a 
standardised way using Bielschowsky’s silver impregnation and Consortium to Establish 
A Registry for Alzheimer’s Disease (CERAD) neuropathological criteria for Alzheimer’s 
disease were applied. (Mirra et al., 1991) Immunohistochemistry was used to assess
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vascular (cerebral amyloid angiopathy) and parenchymal AP-peptide deposition. (Revesz 
et al., 2003) Tau immunohistochemistry was used in the hippocampal formation to 
identify the presence of tau-positive grains. (Togo et al., 2002) The frontal lobe, 
lentiform nucleus and pons were examined for vascular pathology (small vessel 
atherosclerosis, lipohyalinosis, microaneurysm and arteriolosclerosis) and its sequelae 
(lacunes; perivascular rarefaction; diffuse white matter attenuation (Binswanger’s type). 
Vascular pathology was graded as mild (occasional vessels affected), moderate (a 
significant proportion of the small vessels affected; little or no sequelae noted) or severe 
(a significant proportion of the small vessels affected; obvious sequelae). The presence 
of associated Lewy body pathology in the substantia nigra was assessed using a- 
synuclein immunohistochemistry.
Statistical Methods
Spearman’s correlation calculation was used to determine the relationship 
between disease duration, age of onset and age at death and the mean grade of severity of 
each lesion. The relationship between disease duration and regional severity of each 
pathological lesion was also investigated.
Cases were classified according to clinical type and overall pathological severity 
was compared between these groups by calculating the mean grade of tau pathology in all 
regions for each clinical group. Univariable analyses using x2 for categorical and two- 
tailed t test or the Mann Whitney U test, as appropriate, for continuous variables were 
applied.
A complete data set of pathological variables was available from 34 cases (21 RS, 
12 PSP-P and 1 PAGF). To identify patterns of distribution of tau pathology in these 
cases, a between groups, hierarchical cluster analyses, using squared Euclidean distance 
measures was performed. ‘Relative’ mean pathological grades for each region were 
calculated and used as variables. These values allow for patterns of regional tau 
distribution to be identified by correcting for overall tau severity, and were calculated by 
combining the mean grades for NFT, tufted astrocyte, coiled body and thread pathology 
in that region and dividing by the mean grade for all regions in that case. Data from the 
temporal lobe grey matter was excluded to remove any influence of co-existent
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Alzheimer pathology on the analysis. In order to minimise the number of variables in the 
analysis the relative mean grades for the ventromedial and dorsolateral putamen were 
combined and the sub-regions of the SN were combined. Groups of cases with a similar 
distribution of tau pathology were identified by examination of the dendrogram solution 
which graphically shows the similarities of cases from the resolution of the cluster 
combine. The demographics, clinical features, additional pathologies and severity of tau 
pathology between the identified clusters were compared. Statistical analysis was 
performed using SPSS for Windows (version 12.0.1).
Results
Demographics
Forty-two patients (62% men) were included in the study. The mean age of onset 
was 66.5 years (range 44.4-87.5), the mean age at death was 75.6 years (60.9-95.8) and 
the mean disease duration was 9.1 years (1.2-17.3). Mean disease duration was longer in 
patients classified as PSP-P and PAGF, and diagnostic accuracy was lower. (Table 8.1) 
There was a significant negative correlation between age of disease onset and disease 
duration (Pearson correlation -0.557, p<0.001). (Figure 8.1)
All RS PSP-P PAGF
n 42 23 13 6
Male: Female 26:16 14:9 9:4 4:2
Age at onset years 66.5 67.5 66.7 62.2
(range) (44.4-87.5) (56.4-87.5) (51.2-82.1) (44.4-70)
Age at death years 75.6 74.7 76.8 73.6
(range) (60.9-95.8) (65.8-95.8) (66.5-87.9) (60.9-81.4)
Disease duration years 9.1 7.1 10.2* 11.4*
(range) (1.2-17.3) (1.2-15.6) (3.7-17.3) (5.5-16.5)
PSP as final clinical diagnosis % 67 91 43* 50*
Time from symptom onset to final 5.1 3.8 5.2 10.7*
diagnosis of PSP years (range) (0.6-14.5) (0.6-7.5) (0.5-8.7) (5.5-14.5)
Table 8.1 Demographic details of patients included, * (Student’s t-test, p<0.05 vs. RS)
86
90-
80-
70-
50-
40-
0 5 10 15 20Dil duration
Figure 8.1 Disease duration vs. age at disease onset 
Additional pathology
Additional pathological findings are listed in table 8.2. There were no significant 
differences in the occurrence of AD pathology, Lewy body pathology or vascular 
pathology between groups. Tau-positive grains were more common in PSP-P (46%) than 
in RS (18%, Fisher’s exact, p=0.084), but not in PAGF (0, Fisher’s exact, p=0.126).
RS PSP-P PAGF
Number 23 13 6
CERAD
Negative 10 (45) 6(46) 2(33)
Positive 13(55) 7(54) 4(67)
Sparse 5(21) 3(23) 2(33)
Moderate 7(30) 3(23) 2(33)
Frequent 1(4) 1(8) 0
Tau-positive grains 4(18) 6(46) 0
Lewy body pathology 1(4) 0 0
Ischaemic vascular pathology 7(30) 6(46) 0
Mild 6(26) 5(38) 0
Moderate 0 1(8) 0
Severe 1(4) 0 0
Amyloid angiopathy 3(13) 3(23) 1(17)
Table 8.2 Additional pathological diagnoses (%)
Distribution o f  PSP-tau pathology
The distributions of absolute counts of AT8 positive tau pathology and graded 
severity are illustrated in figure 8.2. There was no significant difference in the 
distribution of AT8 and RD4 positive lesions in the first 21 cases. The mean ratio of
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AT8:RD4 was 3.25. RD3 positive lesions were not identified in any cases. All further 
analysis was performed using only AT8 positive lesions. AT8 positive NFT were most 
abundant in the STN, SN, pontine base, GPi and dentate nucleus. (Figure 8.2A) AT8 
positive TA were most abundant in the cortical grey matter and striatum. (Figure 8.2C) 
The range of values for CB and threads was greater than NFT and TA, and they were 
most abundant in the STN, SN and GPi. (Figures 8.2E and 8.2G) The distribution of 
these findings remained after the grading scale was applied, confirming this scale as 
reasonable. (Figures 8.2B, D, F, H and Figure 8.3)
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Figure 8.2A Regional NFT counts (21 cases) Figure 8.2B Regional NFT grades (all cases)
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Figure 8.2C Regional TA counts (21 cases) Figure 8.2D Regional TA grades (all cases)
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Figure 8.2E Regional CB counts (21 cases) Figure 8.2F Regional CB grades (all cases)
Figure 8.2G Regional thread counts (21 cases) Figure 8.2H Regional thread grades (all cases)
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Figure 8.3 Tau lesion severity in the posterior frontal cortex: NFT, neurofibrillary tangle; TA 
tufted astrocyte; CB, coiled body; Thr, thread pathology; Grades 1 (least severe) 
to 4 (most severe)
Bar represents 50 pm on all panels. (x20 magnification)
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Figure 8.4 Microphotographic illustrations showing the difference in tau-load between cases 
of PSP-PAGF (A, C, E) and RS (B, D, F).
(A & B) subthalamic nucleus, (C & D) posterior frontal cortex, (E & F) cerebellar 
dentate nucleus tau immunohistochemistry (AT8 antibody).
Bar on A represents 30 pm on all panels. (x20 magnification)
No correlation was identified between overall mean grade of severity for each 
pathological lesion (NFT, TA, CB and threads) and disease duration, age at onset or age 
at death. Analysis by region revealed a significant negative correlation between disease 
duration and NFT in the SNM using graded data (Spearman’s rho -0.474, p=0.026) as 
well as raw count data (Spearman’s rho -0.384, p=0.014). There were no significant 
linear correlations between grade of severity and NFT in the other regions or in any 
regions for TA, CB or threads. There were no significant correlations between any PSP 
pathological lesions and age at disease onset or age at death.
Repeatability
The intra-rater SD was 0.012, implying that 95% of severity grades fell within 
0.024 either side o f the measured mean, and variability of grading was thus less than 2%. 
The repeatability within each region differed according to size o f region and variability of 
random sampling points. The minimum intra-rater SD was 0.003 (<1% variability) in 
medial SN and the maximum intra-rater SD was 0.14 (14% variability) in caudate. 
Overall the grading scale was highly repeatable.
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Tau pathology according to clinical phenotype
The overall severity o f AT8 positive lesions was significantly higher in RS 
(median grade 1.1; SD 0.36) than PSP-P (0.5; SD 0.23; Mann-Whitney U, p<0.001) and 
PAGF (0.4; SD 0.47; Mann-Whitney U, p<0.001). (Figure 8.5) Mean regional severity 
was always highest in RS, and significantly higher than PSP-P in all areas (Mann- 
Whitney U, p<0.05) except the dorsolateral putamen (Mann-Whitney U, p=0.15) and 
STN (Mann-Whitney U, p=0.77) (figure 8.6). Tau pathology was significantly more 
severe in RS than PAGF in the parietal grey matter (Mann-Whitney U, p=0.022), griseum 
pontis (Mann-Whitney U, p=0.003), dentate nucleus (Mann-Whitney U, p=0.010) and 
cerebellar white matter (Mann-Whitney U, p=0.023). (Figure 8.6)
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Figure 8.5 Overall tau severity according to clinical group: median, quartiles, outliers
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Figure 8.6 Regional tau severity according to clinical group
Patterns o f  tau distribution
Three clusters o f  cases could be identified on the distance matrix and dendrogram 
of the cluster combine o f the cluster analysis, and five individual cases could be deemed 
not to belong to any cluster. (Figure 8.7) The cases in cluster 1, the largest group (group 
1, n=18; 44% RS, 56% PSP-P) were characterised by relatively more tau pathology in the 
GPi, STN and SN, than in the cortical regions, griseum pontis and cerebellar white 
matter. The median overall tau grade of this group was 0.48 (interquartile range (IQR) 
0.18-0.88). In the second cluster (group 2, n=4; 100% RS) cases had relatively more tau 
pathology in the posterior frontal grey matter, putamen, GPi, caudate, STN and SN than 
in the temporal white matter, dentate nucleus and cerebellar white matter. The median 
overall tau grade o f this group was 0.86 (IQR 0.5-1.29), and was significantly higher than 
group 1 (Mann Whitney U, p<0.001). In the third cluster (group 3, n=7; 86% RS, 14% 
PAGF) cases were characterised by relatively more severe tau pathology in the frontal 
cortical regions, GPi, STN, SN as well as the griseum pontis and cerebellar white matter, 
and the median overall tau grade (1.14, IQR 0.68-1.63) was significantly higher than in 
the other groups. (Table 8.3) Median regional severity significantly differed between 
groups (see figure 8.8). In group 1, cortical pathology was significantly less than in 
groups 2 and 3. The severity o f tau pathology in the STN and SN was similar between all 
groups but in the griseum pontis and cerebellar white matter it was more severe in group 
3 than groups 1 and 2. In group 2 the caudate was significantly more severely affected 
than in groups 1 and 3.
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Figure 8.7 Hierarchical cluster analysis of cases: dendrogram using average linkage 
(between groups).
Figure 8.8 Distribution of tau pathology according to cluster: median values in cluster 1
(black) cluster 2 (grey) and cluster 3 (white); f  p<0.05, cluster 1 vs. 2; * p<0.05, 
cluster 1 vs. 3; § p<0.05, cluster 2 vs. 3.
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There were no significant differences in mean disease duration or age at disease 
onset between groups. (Table 8.3) The only clinical feature that was significantly 
different between these groups was speech disturbance in the first two years of disease, 
which was present in 4 (100%) patients in cluster 2, but only 6 in cluster 1 (33%, Fisher’s 
exact, p=0.029) and 2 in cluster 3 (29%, Fisher’s exact, p=0.045).
Cluster 1 Cluster 2 Cluster 3 Not
grouped
Number 18 4 7 5
RS 8 4 6 3
(%) (38) (19) (29) (14)
PSP-P 10 0 0 2
(%) (83) (17)
PAGF 0 0 1 0
(%) (100)
Median tau grade 0.48 f* 0.86 t§ 1.14 *§
(IQR) (0.18-0.88) (0.5-1.29) (0.68-1.63)
Age at onset, years 65.0 70.0 67.5
(range) (51.2-76.6) (56.4-87.5) (58.1-74.3)
Disease duration, years 9.4 7.5 6.3
(range) (1.2-17.3) (5.0-10.8) (4.0-7.2)
Early speech disturbance % 33* 100*§ 29§
Table 8.3 Demographics of cluster groups, t  p<0.05, cluster 1 vs. 2; * p<0.05, cluster 1 vs.
3; § p<0.05, cluster 2 vs. 3
Cases in cluster 1 were separated according to clinical type (RS and PSP-P) and 
compared. There was no significant difference in age at disease onset or age at death 
between these groups, but disease duration was significantly longer in PSP-P (11.6 years) 
than in RS (5.6 years, Student’s t-test p=0.003). Amongst the cases in cluster 1 the 
median overall tau severity was higher in RS (grade 0.62, IQR 0.29-1.10) than PSP-P 
(grade 0.37, IQR 0.17-0.69, Mann Whitney U p=0.12). The regional severity was 
significantly higher in RS than in PSP-P in the parietal white matter, GPi and medial SN 
(figure 8.9).
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Figure 8.9 Distribution of tau pathology in cluster 1 according to clinical phenotype: median 
value in RS (black) and PSP-P (white); * Mann Whitney U p<0.05, RS vs. PSP-P
Discussion
This study confirms that PSP-P and PAGF exist as clinical manifestations of PSP- 
tau pathology, and are characterised by the typical pathological hallmarks of PSP. We 
have documented substantial variability in the distribution and severity of pathological 
tau accumulation in PSP and have found that co-existent additional pathological 
diagnoses do not differ between RS, PSP-P and PAGF, implying that variability in tau 
pathology is the principal factor separating these clinical syndromes.
Pathological tau accumulation was found to be most severe in RS, and its 
distribution throughout the brain was more widespread than in PSP-P and PAGF. The 
tau pathology in RS was predominantly subcortical affecting the STN, SN and GPi but 
also involved the cerebral cortex and was consistently more widespread and severe than 
in the other clinical types. In PSP-P severe tau pathology tended to be restricted to 
pallido-luyso-nigral structures, with less involvement of the cerebral cortices, griseum 
pontis, dentate nucleus and cerebellar white matter. In PAGF tau pathology was less 
severe than in other types, and also had a more restricted distribution than RS.
Three distinct patterns of pathological tau distribution were identified by cluster 
analysis. In the most frequently encountered pattern, the burden of tau accumulation was
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highest in the STN, SN and GPi, and relatively spared the cortical regions, caudate, 
griseum pontis and cerebellar white matter. This pattern of distribution was common to 
RS and PSP-P, emphasising the overlap between these conditions. However, the severity 
of tau accumulation was significantly lower in PSP-P than in RS, suggesting the 
separation of these two syndromes along the spectrum of PSP-tau changes. A second 
pattern, only seen in RS, had more severe pathology in the caudate, putamen and 
posterior frontal lobes, while the third type had more severe pathology in the griseum 
pontis and cerebellar white matter and all cortical regions, in particular the frontal cortex.
Pathological features additional to PSP-tau lesions were present in very few 
patients. When Lewy body pathology coexists with PSP it is considered to represent a 
different disease process, which could potentially influence the clinical phenotype. 
(Uchikado et al., 2006) Reports of previous pathological series have found coexistent 
Lewy body pathology in approximately 10% of patients with PSP, which is similar to age 
matched control brains. (Gearing et al., 1994; Tsuboi et al., 2001; Uchikado et a l, 2006) 
The frequency of Lewy body pathology in this series was substantially lower (2.4%). 
There were no significant differences in the degree of Alzheimer type pathology between 
the three clinical phenotypes. Co-existent argyrophilic grain disease (AGD) has been 
previously reported in PSP, but the frequency of this association is uncertain. (Martinez- 
Lage and Munoz, 1997; Tolnay et a l, 2002; Togo and Dickson, 2002; Tsuboi et al., 
2005) Tau-positive grains o f considerable degree were identified in ten cases (23%) and 
were more frequent in PSP-P than RS, although this difference did not reach significance. 
In pure AGD, patients are most likely to present with memory disturbance and 
personality change (Tolnay et al., 2002) and its coexistence with PD has been linked 
occasionally with ophthalmoplegia and cognitive disturbance. (Seno et al., 2000) Mild 
ischaemic vascular pathology was present in a minority of patients (31%), and did not 
differ between clinical types.
No differences were found between the distribution of AT8 and RD4 antibody 
stains. RD4 positive NFTs, threads, CB and TA were present in all cases, whereas RD3 
immunoreactive structures were absent in the material examined, which did not include 
entorhinal and transentorhinal cortical regions. Previous immunoblot analysis of 
insoluble tau from the basal pons in PSP demonstrated the presence of varying degrees of
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3-repeat tau. (Gibb et al., 2004) Despite this, we were unable to identify any staining 
using RD3, which is a sensitive and specific antibody to 3-repeat isoforms, (de Silva et 
al, 2003) This discrepancy is possibly due to levels being below the detection threshold 
of RD3 or masking of the 3R-tau epitope in tissue. On an immunoblot, 3-repeat tau may 
be more concentrated or exposed as a result of denaturation explaining the discrepancy, 
(de Silva et al., 2003)
The relationship between neuronal loss, tau accumulation and neuronal 
dysfunction in tauopathies is incompletely understood. (Daniel et a l, 1995; Halliday et 
al, 2000) However, there is some evidence that the extent and severity of tau pathology 
reflects clinical features. Cognitive dysfunction has been associated with increasing 
cortical tau pathology (Braak et a l, 1992; Bergeron et al., 1998; Bigio et a l, 1999; 
Tsuboi et al., 2005) and more severe tau pathology in the nucleus raphe interpositus has 
been correlated with supranuclear gaze palsy. (Revesz et al., 1996) In contrast to these 
findings there is a reduction in the density of NFT in the SN with ongoing subcortical 
atrophy, suggesting that in certain regions tau severity correlates weakly with neuronal 
loss. (Halliday et al., 2000) We have also identified a significant reduction in NFT 
correlated with increased disease duration in this region, but not in other regions. 
Overall, however, our findings suggest that the distribution and severity of pathological 
tau is an adequate measure of regional brain dysfunction that is not consistently affected 
by age or disease duration, and is therefore an appropriate marker for attempting to 
establish clinicopathological correlations.
Clinicopathological correlations
This study confirms previous observations that the STN and SN are the most 
severely affected structures in PSP. (Steele et al., 1964; Hauw et al., 1994; Daniel et a l, 
1995) The pattern of tau distribution outside these structures is similar to that reported by 
Vemy and colleagues who mapped the distribution of tangle formation and neuronal loss 
in 10 cases. (Vemy et al., 1996a) One group with typical clinical signs had widespread 
involvement of subcortical structures, and more severe involvement of the 
pedunculopontine nucleus and cortex than a second group with unusual clinical features 
and mild involvement of the pedunculopontine nucleus and cerebral cortex. Similar to
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cluster one in the present study, this group had more severe involvement of the 
subcortical structures in a pallido-luyso-nigral distribution. These findings suggest that 
there is a consistent regional vulnerability to PSP-tau pathology in the STN, SN and GP 
and that clinical differences are related to differences in the distribution of pathological 
changes outside the basal ganglia.
We found no convincing evidence that age or disease duration affected PSP-tau 
pathology. NFTs in the SN were the only pathological lesion inversely related to disease 
duration. One previous report, using semiquantitative data and a 4 point rating scale, 
found an inverse relationship between disease duration and oligodendroglial pathology, 
particularly in the globus pallidus. (Josephs et al., 2006b) In the present study we applied 
a region and lesion specific 5 point rating scale with high intra-rater reliability, and failed 
to confirm this finding. This discrepancy emphasises that the regional pathological 
variability in PSP means that no single set of parameters for rating tau lesion severity will 
be sufficiently sensitive in all brain regions and that any single rating scale will be subject 
to substantial ceiling and floor effects.
In RS gaze palsy, dementia, postural instability and falls occur early in the 
disease. The postural instability in PSP is thought to be caused by lesions in a number of 
brain regions, and in particular the pons. (Agid et al., 1987) In RS the severity of 
deposition of abnormal tau in the griseum pontis was similar to that in the STN and SN, 
implying similarities in the vulnerability of these structures to tau degeneration. In 
contrast, the griseum pontis was relatively less affected in PSP-P, and it is possible that 
early pathological changes in the caudal brainstem are important in the occurrence of 
early postural instability seen in RS. (Agid et al., 1987) Anatomical regions believed to 
be involved with gaze fixation and ocular motility include the dentate nucleus and 
pontine base where tau pathology was most severe in RS, and again similar in severity to 
changes in the STN and SN. In PSP-P and PAGF these regions were relatively spared 
compared to the STN and SN. In previous studies brain stem, structures including the 
rostral interstitial nucleus of the medial longitudinal fascicle, superior colliculus, and 
nucleus raphe interpositus, were more severely affected in patients with supranuclear 
gaze palsy and had more severe pathology than those with “atypical” PSP where gaze 
palsies occurred late in the course of the illness or not at all. (Daniel et al., 1995; Revesz
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et a l , 1996) The frontal cortex was consistently most severely affected in RS, which 
may reflect the early cognitive and neurobehavioral changes seen in this syndrome. In 
contrast, in PSP-P where cognitive dysfunction occurs late or not at all, the relative tau 
burden in cortical regions was very low.
In the early stages of PSP-P the clinical features are reminiscent of Parkinson’s 
disease. The asymmetry at disease onset argues for less widespread pathology early and 
the restricted pattern of pathological involvement at death indicates that tau pathology 
continues to be more limited in extent and severity than in RS. The majority of patients 
with PSP-P have an initially good therapeutic response to levodopa medications, although 
secondary non-responsiveness later in the course of the illness is common. (Birdi et a l , 
2002) The balance of pathological dysfunction in the motor loops of the basal ganglia is 
likely to be responsible for this difference with RS. It has been suggested that in PSP 
dopaminergic medications are relatively ineffective because of loss of post synaptic 
striatal dopamine receptors and cholinergic intemeurons in the putamen. The absolute 
severity of tau pathology in the putamen is lowest in PSP-P, which would be in keeping 
with this notion. In addition, the less severe tau pathology in the cortical regions and the 
griseum pontis in PSP-P may represent involvement of these structures later in the course 
of the disease and explain the delayed appearance of falls, frontolimbic dementia and 
gaze palsies.
The clinical presentation of PAGF is quite distinct from RS and PSP-P and the tau 
burden is considerably lower than RS (see figure 8.4), particularly in the pedunculo- 
pontine region and parietal lobes. The small number of PAGF cases in this series limited 
the effect that this type had on the cluster analysis. However univariate analysis of the 
mean regional tau pathology suggested a pattern of predominantly posterior frontal lobe 
involvement together with involvement of the STN and SN. Interestingly previous 
SPECT studies in patients with (pure) gait initiation failure (Atchison et a l , 1993), 
which we consider to be the same clinical syndrome as PAGF, implicate the 
supplementary motor areas of the posterior frontal lobe. Other reports suggest that the 
globus pallidus is responsible for the akinesia in PAGF, but isolated, severe pallidal 
lesions were not seen in this series, and have not been reported in other pathologically 
examined cases of PSP-PAGF. In PAGF the evolution of clinical features, other than gait
100
disturbance, is slow compared to RS. The late evolution of gaze palsy in PAGF may be 
related to the relatively mild pathology in the griseum pontis and dentate nucleus, 
structures important in the generation of saccadic eye movements examined in this study. 
Clinically significant cognitive dysfunction is also rare but mild or moderate pathological 
involvement in the frontal cortex was a common finding, although lower than in RS.
Vascular pathology was not a significant finding in patients with PAGF. Lewy 
body pathology has previously been reported in a clinically identical syndrome classified 
as primary progressive gait freezing, however, the authors suggested that the presence of 
rigidity differentiated this patient from “pure akinesia”. (Factor et al., 2006) In the 
present series one patient with Lewy body pathology developed dementia and visual 
hallucinations in the last eight years of a 25 year disease (chapter 5). Pallidonigro- 
luysian atrophy (PNLA) has been reported rarely in the literature, but is consistently 
associated with bradykinesia and occasionally rigidity and catatonia. (Takahashi et al., 
1977; Kawai et a l , 1993; Mori et al., 2001; Konishi et a l , 2005) Sparse neurofibrillary 
tangle pathology has been reported and PNLA has been defined by these minimal 
findings on conventional silver staining in the presence of severe gliosis and cell loss. 
(Contamin et al., 1971) A recent report has identified more severe neuronal and glial tau- 
pathology in PNLA identified by the application of modem immunohistochemical 
techniques. (Mori et a l , 2001) Immunoblotting of phosphorylated tau from this case 
showed a predominance of 4R tau, raising the possibility that PNLA is a form of 
‘minimal change’ PSP-tau pathology.
Neuropathological classification
Specific histological criteria have been proposed for PSP to allow for its 
distinction from other disorders in which neurofibrillary tangles occur. (Hauw et a l , 
1994) The proposed NINDS-SPSP pathological criteria stipulate that a minimum number 
of subcortical regions need to be examined to make the pathological diagnosis in the 
context of a compatible clinical history. The criteria rely on the presence of numerous 
NFT and threads in the brainstem and basal ganglia, including two or more of these 
lesions per high powered field (h.p.f.) in the pallidum, STN, SN and griseum pontis, as 
well as one or more lesion per h.p.f. in three of the striatum, oculomotor complex,
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medulla and dentate nucleus. The predominance of tau pathology in this distribution in 
PSP is supported by our findings. (Figures 8.6 and 8.8)
Criteria for “atypical” pathological PSP have also been proposed and defined by 
the presence of fewer NFT and threads in the same five regions as with PSP. The criteria 
for atypical PSP also stipulate that the distribution of cortical NFT could be either absent 
or of high density in the entorhinal, prefrontal, precentral and other associative cortices. 
Subsequent revisions to the criteria excluded the atypical classification because of 
practical difficulty in reliably distinguishing it. (Litvan et al., 1996b) The authors raised 
concern about the value and validity of an atypical pathological classification in the 
absence of any absolute histologic differences in clinically atypical cases (Daniel et al., 
1995; Litvan et al., 1996b) However, the patterns of tau distribution identified by cluster 
analysis and the regional variability identified in the current study suggest that such a 
distinction is possible and may be clinically meaningful. Using these data it is possible to 
construct a framework for considering variability in PSP pathology. Such a framework 
could include the following classifications: typical PSP (RS in cluster 1), where 
pathology is most severe in the GP, STN, SN but also involves the griseum pontis, 
dentate nucleus and cerebellar white matter and cortical structures; minimal change PSP 
(PAGF and PSP-P in cluster 1), where pathology is restricted to the GPi, STN and SN, 
and relatively spares the cortex, griseum pontis and cerebellar white matter; limited 
cortical PSP (RS, cluster 2), where the most severe pathology exists in the GP, STN, SN 
and caudate nucleus, there is moderate pathology in the griseum pontis and cerebellar 
white matter and some cortical regions with tau lesions of moderate severity; and 
widespread PSP (RS, cluster 3), where there is moderately severe tau pathology within 
the parietal and anterior and posterior frontal cortices, griseum pontis, dentate nucleus 
and cerebellar white matter in addition to the GPi, STN and SN.
Conclusion
We have confirmed that PSP-P and PAGF are clinical syndromes with PSP-tau 
pathology, and are characterised by all of the typical pathological hallmarks of PSP. The 
findings of this study argue that the clinical differences between “clinically atypical” PSP 
(PSP-P and PAGF) and RS are underpinned by tau pathology that is less severe and less
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widespread than in RS and are not due to co-existent additional pathological disease. The 
cluster analysis demonstrated that the distribution of tau pathology in PSP-P was similar 
to RS, but was consistently milder. Furthermore, only in RS was severe cortical, pontine 
and cerebellar white matter tau pathology present. A pathological sub-classification to 
incorporate these observations, including the extent and distribution of PSP-tau, should 
provide a plausible framework for determining further clinicopathological correlations. 
The factors which contribute to the pathological and clinical differences between these 
groups remain to be determined.
103
PSP and other tauopathies are characterised by neuronal, and in some cases 
glial, accumulation of tau. Accumulations of insoluble tau contain different 
ratios of the six tau isoforms. Disease specific tau isoform profiles are 
examined using western blot analysis of brain tissue homogenates. In the 
preparatory experiment two methods of tissue preparation were compared to 
determine the most efficient and efficacious method for examining insoluble 
tau in PSP. The subsequent experiment used the ‘Hanger’ method to examine 
the diversity of tau isoform profiles amongst 69 cases of pathologically 
diagnosed PSP. The isoform composition of insoluble tangle-tau isolated from 
the basal pons differed significantly between RS and PSP-P. In RS the mean 
ratio of 4-repeat:3-repeat tau was 2.84 and in PSP-P it was 1.63 (p<0.003). The 
differences in tau deposition provide a tantalising clue that the molecular 
processes the lead to neurodegeneration in PSP may vary between these two 
clinical phenotypes.
Introduction
In the CNS, the tau protein occurs as six isoforms ranging from 352 to 440 amino 
acids, with molecular weights from 45 to 65 kDa (figure 2.1). These isoforms contain 
either three or four repeat domains (3R-tau or 4R-tau), according to the absence or 
presence of 31 amino acid microtubule-binding repeat. This is the result of the alternative 
splicing of the tau gene (MAPT) exon 10, which codes for the second of four 
microtubule-binding repeat domains of the tau protein, the other 3 being encoded by 
exons 9, 11 and 12. Both 3R and 4R-tau variants are further separated according to the 
presence or absence of 2 different amino acid sequences encoded by MAPT exons 2 and 
3, at the amino-terminal end, thus giving rise to the six isoforms designated 0N3R, 1N3R, 
2N3R, 0N4R, 1N4R and 2N4R (ON, IN and 2N indicating the presence of 0, 1 or 2 of the 
amino-terminal inserts).
Phosphorylation regulates the microtubule binding capacity of tau and probably 
modifies its biochemical properties by making the tau molecule longer and stiffer 
(Hagestedt et a l , 1989) Increased phosphorylation, or hyperphosphorylation, occurs in 
neurodegenerative disorders but it is unclear whether this occurs before or after 
filamentous aggregation. In AD, which is the best studied ‘secondary’ tauopathy, the
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paired helical filaments (PHF) that form characteristic NFTs are known to be comprised 
of insoluble, fibrillar tau (PHF-tau). PHF-tau deposited in AD differs from normal, 
soluble tau by its hyperphosphorylated state, which also has the effect of reducing its 
electrophoretic mobility. (Flament et a l , 1989; Hanger et a l , 1991) The biochemical 
characterisation of these insoluble aggregates by SDS-PAGE and tau-immunoblotting 
reveals patterns involving all of the constituent isoforms. On western blots, AD PHF-tau 
runs in three major bands, corresponding to proteins at 55, 64 and 69 kDa, and a fourth 
minor tau species at 74 kDa. The characteristics of insoluble tau inclusions have been 
examined in different tauopathies and other tau isoform patterns have been identified in 
PiD (Delacourte et a l , 1996; Lieberman et a l , 1998; Zhukareva et a l , 2002), CBD 
(Ksiezak-Reding et a l , 1994), PSP (Vermersch et a l , 1994; Morris et a l , 2002a; 
Mochizuki et a l , 2003), PDC Guam (Buee-Scherrer et a l, 1995; Winton et a l, 2006), 
and FTDP-17. (Hutton et a l, 1998) Selective tau deposition in these apparently distinct 
clinical and pathological entities differ by the relative amounts 4R and 3R-tau. (Goedert 
et a l, 1998; Mailliot et a l, 1998) Results are often expressed only in terms of triplet or 
doublet banding patterns derived from hyperphosphorylated tau, which only gives 
imprecise estimations of the levels of individual tau isoforms. (Hong et al., 1998; Buee 
and Delacourte, 1999) However, Goedert and co-workers demonstrated that 
dephosphorylation of PHF-tau proteins, using Escherichia coli alkaline phosphatase, 
reveals all six tau isoforms as separate bands according to their respective molecular 
weights, allowing for precise identification of each isoform (figure 2.1). (Goedert and 
Jakes, 1990)
Several recent refinements in the methodology for the isolation of insoluble 
pathological tau have improved the sensitivity and specificity of tau isoform detection by 
western blot analysis. (Gibb et a l, 2004) In the late 1980s Rubenstein and co-workers 
developed a technique using 1% N-lauroylsarcosine, sodium salt (sarcosyl) to separate 
insoluble PHF-tau and native, normally phosphorylated soluble tau from supernatants of 
brain homogenates by high speed centrifugation. (Rubenstein et a l, 1986) However, 
Hanger and co-workers showed that high-speed centrifugation in the absence of the 
sarcosyl solubilisation step can achieve the same results. (Hanger et a l, 1998) These two 
methods have not previously been compared in studies that use protein
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dephosphorylation techniques. The greater efficiency of the Hanger method makes it 
preferable when large numbers of cases are being analysed. In the preparatory 
experiment (chapter 9.1) the Hanger method was compared to the modified Rubenstein 
method, using sarcosyl solubilisation to enrich the insoluble tau fraction. (Goedert et al., 
1992)
Tau isoform profiles in PSP
The majority of reports relating to the tau isoform profile in PSP have not used 
these dephosphorylation techniques. Insoluble tau from PSP has been characterised by a 
major doublet pattern of hyperphosphorylated tau on western blot of bands at 64 and 69 
kDa and a weaker band at 74 kDa, (Flament et a l, 1991) containing predominantly 4R- 
tau. (Sergeant et al., 1999) Biochemical mapping of neurofibrillary degeneration in PSP 
has shown that regional tau isoform composition of insoluble tau can vary, in particular 
in the entorhinal cortex where AD-type triplet bands have been found in cases where PSP 
doublet tau was found in the pre-motor and pre-frontal areas, caudate and GP. 
(Vermersch et a l, 1994; Schmidt et al., 1996) This finding is explained by coexisting 
age related NFTs.
Morris and colleagues reported the insoluble tau isoform composition in a series 
of 26 cases of PSP separated according to typical or atypical clinical features. (Morris et 
al, 2002a) Additional Alzheimer type pathological changes were present in 19 (74%). 
Tissue was taken predominantly from the GP and run on SDS-PAGE without 
dephosphorylation. A doublet pattern, described by the authors as a “normal PSP-tau 
protein electrophoretic pattern” was identified in 13 (50%) and the other cases 
demonstrated either a triplet pattern or six to eight protein bands, which appeared to 
migrate with the six recombinant tau bands. (Morris et a l, 2002a) These non-doublet 
banding patterns occurred more frequently in the clinically atypical group (66.7%) than 
the clinically typical group (27.3%), but did not correlate with the Alzheimer pathology. 
Definitive identification of the isoforms could not be made because the tissue 
homogenates were not dephosphorylated.
This tau protein heterogeneity in PSP was further investigated by a number of 
other authors who reported the presence of both 3R and 4R-tau isoforms in sporadic PSP,
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accounting for the presence of the uncharacteristic banding patterns in 50% of Morris’s 
cases. (Liu et al., 2001; Hanger et al., 2002; de Silva et a l, 2003) Gibb and colleagues 
used protein dephosphorylation to identify the individual tau isoform composition of 
clinically typical and atypical cases. (Gibb et a l, 2004) Samples from the pontine base in 
20 cases were analysed using insoluble tau extracts without dephosphorylation and run on 
SDS-PAGE. Similar to the findings in the GP reported by Morris and colleagues, they 
found two broad groupings of tau immunoreactivity. The first had the typical PSP-tau 
doublet in 12 (60%) and the second had a more diffuse staining. In 11 cases the tissue 
homogenate was solubilised in guanidine and dephosphorylated using the highly efficient 
and reproducible method of dephosphorylation with lambda phosphatase described by 
Hanger. (Hanger et a l, 2002; Gibb et a l, 2004) They found marked variation between 
different cases of the guanidine solubilised, dephosphorylated tau. All six tau isoforms 
were present to some degree, and in many 1N3R was present in the same proportion as 
4R isoforms. Taken together, these results showed that the banding pattern of 
hyperphosphorylated tau, derived from western blots of crude extracts of insoluble PSP- 
tau and probed with polyclonal pan-specific tau antibodies, cannot be used with any 
degree of certainty to identify the tau isoforms present in the PSP brain.
In the absence of a “typical” PSP-tau isoform profile, there remains the possibility 
that variability in the tau biochemical profile may account for some of the observed 
clinical or pathological heterogeneity.
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9.1. Comparison of methods for tau fractionation and dephosphorylation
Aims
The aim of this preparatory experiment was to compare two different methods of 
preparation of brain tissue for the isolation and analysis of insoluble tau (Rubenstein 
method: sarcosyl separation; and Hanger method: centrifugal separation). (Rubenstein et 
a l9 1986; Hanger et a l , 2002)
Materials and methods
Pathological material
Frozen brain tissue from the pontine base and temporal lobe of two cases of 
neuropathologically confirmed PSP and the temporal lobe of one case of 
neuropathologically diagnosed AD was obtained from the QSBB, London, UK.
Preparation o f  soluble tau
Human brain tissue weighing 0.4-1.0 g  was homogenised in 0.1M MES buffer, 
pH 6.5, containing 1M NaCl (homogenisation buffer) and clarified by centrifugation at
27,000 x g  for 30 minutes at 4°C.
For the Rubenstein method, 1% (w/v) sarcosyl was added to resulting supernatant, 
incubated with shaking for 1 hour at room temperature and centrifuged at 100,000 x g for 
1 hour at 4°C. The 100,000 x g  pellet containing the insoluble tau, was washed once by 
reconstituting in 0.1 M MES buffer, pH 6.5, containing 1M NaCl made up to 1% sarcosyl 
and re-centrifuged at 100,000 x g  for 1 hour at 4°C. The resulting 100,000 x g  pellet 
containing insoluble tangle-tau was retained.
For the Hanger method, the clarified supernatants from the first low-speed 
centrifugation were re-centrifuged at 100,000 x g  for 1 hour at 4°C. The pellets 
containing the insoluble tau were washed by adding homogenisation buffer and 
recentrifuging at 100,000 x g for 1 hour at 4°C. After decanting the supernatant, the pellet 
was reconstituted in 0.1M MES buffer, pH 6.5, containing 1M NaCl but without the 
addition of sarcosyl at any time.
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For both methods the resulting 100,000 x g supernatant contained soluble tau. The 
soluble tau was enriched further by heating for 10 minutes at 100°C and centrifuging at
15.000 x g for 30 minutes at 4°C. The supernatant, containing heat-stable soluble 
proteins, was made to 45% saturation with ammonium sulphate, maintained in ice for 15 
minutes, and centrifuged at 15,000 x g  for 30 minutes at 4°C. Precipitated proteins were 
re-suspended in 0.1 x vol. (relative to weight of starting brain material) 50mM Tris-HCl 
pH 7.5 and dialysed against the same buffer overnight at 4°C. The dialysate was clarified 
by centrifugation at 15,000 x g for 30 minutes at 4°C, and the supernatant, containing 
soluble heat-stable control brain tau, was retained.
Preparation o f  guanidine solubilised tau
The 100,000 x g  pellets were solubilised with guanidium hydrochloride 
(guanidine-HCl). (Hanger et al., 1998) For both the Hanger and Rubenstein methods the
100.000 x g pellet, containing insoluble tangle-tau, was solubilised in 50mM Tris-HCl, 
pH 7.5 containing 4M guanidine-HCl. The solution was agitated for 60 minutes at room 
temperature and the guanidine solubilised tau was then dialysed into 50mM Tris-HCl, pH 
7.5 overnight at 4°C and centrifuged at 7000 rpm for 1 minute to remove precipitated 
material.
Tau dephosphorylation
Soluble tau and guanidine-solubilised tau extracted from all three cases were each 
dephosphorylated with lambda protein phosphatase (New England Biolabs) as previously 
described (Hanger et a l , 2002). The tau preparations in 50mM Tris-HCl, pH 7.5, were 
dephosphorylated with 20 U/pl lambda protein phosphatase (New England Biolabs) for 3 
hours at 30°C. Reactions were stopped by the addition of 2x SDS-PAGE sample buffer 
and heating for 5 minutes at 100°C.
Purification o f  recombinant tau isoforms
The six isoforms of tau were each expressed in Escherichia coli BL21 cells and 
purified. (Mulot et al., 1994).
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Analysis o f  tau western blots
Proteins in the guanidine-solubilised brain extracts, with and without sarcosyl 
solubilisation, were separated on 10% (w/v) acrylamide SDS-PAGE. (Hanger et al., 
1998) A ladder o f  all six isoforms of recombinant tau and Cruz markers were run in 
adjacent wells. Resolved proteins were transferred onto PVDF membranes and probed 
with 1:20,000 TP70, a rabbit polyclonal antiserum that recognises all forms of tau. (Brion 
et a l , 1993) The immunoreactive bands were detected using standard enhanced chemi- 
luminescence (Amersham Pharmacia Biotech). For semi-quantitative analysis the 
detected bands o f dephosphorylated guanidine-solubilised and soluble tau were scanned, 
and the density o f each band was measured using ID Image Analysis Software (Version 
3.5, Kodak).
Results
The banding patterns from the temporal lobes were identical using the two methods 
of tissue preparation. (Figure 9.1) In both the PSP and AD brains all six tau isoforms 
were present in a 4R:3R ratio o f 1:1 with a predominance of the lower molecular weight 
bands. In the pontine base o f the PSP case, the Hanger method produced a higher yield 
of insoluble tau. In both methods the 4R bands were stronger, but 0N3R and 1N3R bands 
were visible only with the Hanger method. Even after prolonged exposure of the chemi- 
luminescence the Rubenstein method only showed a very faint 1N3R band.
A B C D E F G H I J K
Figure 9.1 Western blots of guanidine-solubilised tau, comparing two methods tau 
preparation. A Cruz marker; B recombinant tau; C pons (Hanger 
method); D pons (Rubenstein method); E temporal lobe (Hanger 
method); F temporal lobe (Rubenstein method); G temporal lobe 
(Hanger method); H temporal lobe (Rubenstein method); I coloured 
protein ladder; J Cruz marker; K recombinant tau
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Conclusion
In both methods guanidine solubilisation and dephosphorylation using lambda 
protein phosphatase was successful. The Hanger method, in which soluble and insoluble 
tau are separated using only centrifugation, was similar in efficacy to the Rubenstein 
method.
I l l
9.2. Biochemical heterogeneity in PSP
Aims
The aim of this experiment was to examine the heterogeneity of tau isoforms in 
pathological tau accumulation in PSP and to search for clinical correlations by comparing 
the tau isoform profiles amongst those cases clinically categorised RS and PSP-P.
Materials and methods
Pathological material
Frozen brain tissue was available from 69 cases with pathologically diagnosed 
PSP archived at the QSBB. In each case a portion of the pontine base, with the griseum 
pontis, was taken for tau isoform analysis. The pontine base was selected because it is 
considered to be free from Alzheimer tangles and age related tau pathology, (Parvizi et 
a l , 2001) and abnormal tau deposits are present in glial and neuronal cells of the basal 
pons in PSP. The composition of the insoluble tau isolated from this region was analysed 
by dephosphorylation of the guanidine-solubilised deposits followed by electrophoresis. 
The isoform profiles were compared to soluble tau that is ubiquitous in the human brain.
Precipitation o f  soluble and guanidine solubilised tau
Tau protein was extracted from the pontine base using the Hanger method 
described in chapter 9.1. (Hanger et al., 1998)
Tau dephosphorylation
Soluble tau and guanidine-solubilised tau extracted from the pontine base of all 69 
PSP brains, guanidine solubilised tau from the frontal lobe and pontine base of the 
Alzheimer brain and pontine base of the control brain was dephosphorylated with lambda 
protein phosphatase (New England Biolabs). (Hanger et al., 2002)
Purification o f  recombinant tau isoforms
The six isoforms of tau were each expressed in Escherichia coli BL21 cells and 
purified as described previously. (Mulot et al., 1994).
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Analysis o f  tau on western blots
Proteins in the soluble, insoluble and guanidine-solubilised brain extracts, with 
and without phosphatase treatment, were separated on 10% (w/v) acrylamide SDS-PAGE 
(Hanger et al., 1998). Resolved proteins were transferred onto PVDF membranes and 
probed with 1:20,000 TP70 a rabbit polyclonal antiserum that recognises all forms of tau 
(a generous gift from Dr Diane Hanger) (Brion et al., 1993). The immunoreactive bands 
were detected on X-ray film using standard enhanced chemiluminescence (Amersham 
Pharmacia Biotech). For semi-quantitative analysis the detected bands of 
dephosphorylated guanidine-solubilised and soluble tau were scanned, and the density of 
each band was measured using ID Image Analysis Software (Version 3.5, Kodak). For 
comparison the band with the highest density was given a value of 1 and the other bands 
were given a value equal to the ratio of their density compared to this band.
Statistical analysis o f  banding patterns
Cases were separated according to clinical subtype (RS or PSP-P). The relative 
values of the densities for each band in all cases were added and the mean in each clinical 
group was calculated. A Mann-Whitney U test was performed using SPSS for Windows 
(version 12.0.1) to check for statistical significance of the difference for each individual 
tau isoform and the ratio of 4R-tau to 3R-tau.
Results
Guanidine-solubilised tau extracts (i.e. the fraction containing the insoluble tau 
deposits) were examined in 68 cases (Figure 9.2) and soluble tau extracts were examined 
in 49. In one case guanidine-solubilised tau could not be detected in tissue homogenate. 
There was considerable heterogeneity in tau isoform profiles between individuals, 
including variation in all six tau isoforms. The 1N3R, 0N4R and 1N4R isoforms were 
most prominent in the guanidine-solubilised tau fractions, the other isoforms were present 
in only small quantities and were frequently not detectable at all. The soluble tau 
fractions were more homogenous, with all six isoforms represented in most individuals 
and 1N3R being present in large amounts.
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Figure 9.2
Richardson's syndrome PSP-P
Western blots of guanidine-solubilised, dephosphorylated tau from basal pons. 
RT = recombinant tau; C = control; AD = Alzheimer’s disease.
Results from semi-quantitative analysis of western blots were pooled according to 
clinical group and tau isoform. Different patterns of guanidine-solubilised tau isoforms 
were detected in the two clinical subgroups (figure 9.3A) but the profile of soluble tau 
expression did not differ (figure 9.3B). In the guanidine-solubilised fractions there were 
substantially more 4R-tau than 3R-tau isoforms in both groups. Pooled data from RS 
indicated that 1N4R and 0N4R were most prominent, 1N3R was present in smaller 
amounts and there were only small amounts of the other 3R-tau isoforms. In PSP-P, 
1N4R and 0N4R were also most prominent but an approximately equivalent amount of 
1N3R was present, significantly more so than in RS. The other 3R-tau isoforms were 
detected in higher amounts in PSP-P than in RS (0N3R p=0.015, 1N3R, p=0.002, 2N3R,
p=0.002).
In conclusion, there was no difference between total guanidine-solubilised 4R-tau 
between the two clinical groups but there was 57% more 3R-tau in PSP-P compared to 
RS (p=0.001) (figure 9.3C). The mean 4R-tau/3R-tau ratio in RS was 2.84 (standard 
deviation (SD), 1.64; standard error o f the mean (SEM), 0.26) and in PSP-P was 1.63 
(SD, 0.88; SEM 0.19; p<0.003). (Figure 9.4) 3R-tau predominant deposits were identified 
in the guanidine-solubilised extract from the pontine base o f the patient with AD. No 
insoluble tau was identified in the pontine base of the control patient. (Figure 9.2)
AD
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Figure 9.3
Black = RS; grey = PSP-P 
(A) Guanidine-solubilised tau isoforms 
according to clinical phenotype; (B) 
soluble tau isoforms according to 
clinical phenotype; (C) total 3R-tau and 
4R-tau according to clinical phenotype.
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Figure 9.4
Distribution, median, upper and lower 
quartiles of 4R/3R tau ratios according 
to clinical group
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Discussion
This study confirms the biochemical tau heterogeneity previously reported in 
smaller studies o f PSP. Substantial differences exist in the tau isoform composition 
amongst this group of 69 cases who satisfy the operational criteria for the pathological 
diagnosis of PSP. Furthermore the pathological tau profile in the pontine base appears to 
be different according to clinical phenotype as defined by factorial analysis. (Chapter 6)
PSP has been considered a 4R-tauopathy because of the predominance of 4R-tau 
isoforms in insoluble tau deposits. (Buee and Delacourte, 1999) Other tauopathies can 
also be defined by their pattern of insoluble tau isoform aggregation though the 
relationship between specific isoforms and aetiopathogenesis of these clinico- 
pathological entities is unclear. (Buee and Delacourte, 1999) This classification of 
tauopathies has been blurred by the demonstration of heterogeneity in aggregated 
insoluble tau in PSP. (Morris et a l , 2002a) Analysis using specific antibodies to 3R-tau 
and 4R-tau has shown that, to a variable degree, 3R-tau is a component of these insoluble 
deposits and that different 4R-tau:3R-tau ratios exist between cases, (de Silva et al., 
2003; Gibb et a l , 2004) These differences were not related to amount of soluble tau 
(Gibb et a l, 2004) and have not previously been related to clinical phenotype. Variations 
in the ratio of 4R-tau to 3R-tau in PSP and other neurodegenerative conditions have now 
been found by a number of authors using biochemical and immunohistochemical 
methods. (Chambers et a l, 1999; Liu et a l, 2001; Arai et a l, 2001; Takanashi et a l, 
2002; Gibb e ta l ,  2004)
There was diversity in the ratio of 4R-tau to 3R-tau, and in four cases it was less 
than 1. The clinical phenotypes of RS and PSP-P could be separated according to the 
ratio of 4R-tau to 3R-tau (figure 9.4) and the expression of soluble tau was not a factor in 
these differences (see figure 9.3C). It is of interest that the most “atypical” tau profiles, 
with relatively more 3R-tau, were from the PSP-P clinical subgroup. Another report 
found a three fold increase in 4R-tau/3R-tau ratio in the lentiform nucleus of all cases of 
PSP, without concurrent AD or neuropathological evidence of aging in other brain areas 
(Liu et a l, 2001). The cases were collected from an Alzheimer’s and PSP brain bank and 
selection bias may have limited the number of cases with PSP-P type presentations that 
would, according to the current results, favour a higher 4R-tau/3R-tau ratio. The absence
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of Alzheimer type pathology contributing to the banding patterns would also favour a 
higher 4R-tau:3R-tau ratio. The identification of cases with lower 4R-tau:3R-tau ratios in 
our series is unlikely to be due to coexistent Alzheimer pathology, as we extracted brain 
tissue from the pontine base, a region where AD NFTs do not generally occur and AD tau 
immunostaining has been found to be weak. (Parvizi et al., 2001) Nevertheless, tau in 
guanidine-solubilised brain extract from the case with AD was found to have a low 4R- 
tau to 3R-tau ratio. In the PSP cases coexistent AD was reported in only 3 (9.1%) of the 
PSP-P group and 1 (1.8%) of the RS group (p=0.1) and is therefore unlikely to account 
for the difference in tau isoform deposition between the groups. Age-related diffuse 
plaques were present in 11 (19.6%) of the RS cases and in 7 (21%) of the PSP-P cases 
(p=0.5).
Conclusions
Considerable heterogeneity occurs in insoluble, pathological tau in PSP. The 
classic reports of PSP as a 4R-tau disease do not encompass the diversity that exists in a 
large group of clinically heterogeneous patients. The greatest divergence from the 
classic view of PSP-tau occurs in patients with a clinical syndrome that is substantially 
different from Richardson’s classic description and suggests subtle differences in the 
aetiopathogenesis of tau accumulation in PSP-P and RS.
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Previous reports have suggested that atypical clinical phenotypes of PSP occur 
in familial disease, and might be associated with mutations of MAPT. We 
examined the association of PSP-susceptibility tau haplotypes in pathologically 
diagnosed PSP, dichotomised according to clinical features (Richardson’s 
syndrome (RS) and PSP-Parkinsonism (PSP-P)) and screened for mutations in 
exons 1 and 10 of MAPT in these patients. The association between APOE 
genotype and PSP was also examined. No mutations were found in 85 patients 
(21 PSP-P), and HI was associated with both RS and PSP-P compared to 
controls. There was no association between APOE and PSP, or RS and PSP-P 
separately. Routine screening for MAPT mutations in atypical PSP is not 
recommended.
Introduction
Although PSP is a sporadic disorder there are a few reports of familial 
aggregation (David et a l , 1968; Mata et al., 1983; Brown et al., 1993), in some cases 
with pathological confirmation (Ohara et al., 1992; Tetrud et a l, 1996; Ros et a l, 2005). 
In one clinical genetic study of familial PSP 44 patients from 12 pedigrees were studied 
and 34 had clinically typical PSP, but another 10 had unusual clinical phenotypes 
including features o f other neurological diseases, including postural tremor, dementia, 
dystonia with gaze palsy and tremor and isolated gait disturbance. (Rojo et a l, 1999) In 
these patients the inheritance was consistent with a dominant pattern with reduced 
penetrance. The authors suggested that the rarity of familial cases may be in part due to 
the lack of recognition of unusual clinical phenotypes and the difficulty finding a large 
enough number of affected individuals in a disease of the elderly.
In contrast to FTDP-17, MAPT is generally not mutated in RS. (Poorkaj et a l, 
2002; Morris et a l,  2002b) However there are several reports in the literature of 
mutations causing clinical and pathological phenotypes closely resembling typical PSP, 
and in some cases with the unusual clinical features predicted by Rojo and colleagues. 
(Rojo et a l, 1999) One patient reported with young onset PSP at 40 years of age, without 
a family history of neurological disease, had a tau exon 10+16 (intronic) mutation. 
Neuropathological examination confirmed the genetic diagnosis of frontotemporal
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dementia, with prolific tau deposition. (Morris et al., 2003) A silent mutation S305S in 
tau exon 10, was identified in another patient with a history of early dementia and 
abnormalities of gaze, without falls or axial rigidity but with pathological characteristics 
of PSP. Two other affected family members who presented with clinical features unusual 
for PSP, including prominent early dementia with falls late in the disease and early 
dystonia and gaze abnormalities without dementia. (Stanford et al., 2000)
Two brothers from a Spanish kindred, bom from a third-degree consanguineous 
marriage, developed dementia and supranuclear gaze palsy in the fourth decade and died 
within 5 years of disease onset. A homozygous deletion at codon 296 of MAPT was 
identified in one of the affected siblings. (Pastor et al., 2001) Among the heterozygous 
carriers, two members with PD were identified, but none of the heterozygotes developed 
PSP or atypical Parkinsonism. In another report of familial autosomal recessive PSP the 
clinical phenotype was more typical, but pathological examination revealed prominent 
neurofibrillary involvement of the limbic system. (Ohara et al., 1992)
One other area of genetic association has been reported in a large Spanish family 
with a PSP phenotype linked to a locus at 1 q31.1. (Ros et al., 2005) Typical pathological 
changes were reported in one member of this family.
Mutations of MAPT cause FTDP-17
To date more than 30 different pathogenic MAPT mutations have been described 
in more than 100 families with FTDP-17. These include missense mutations, silent 
mutations, in-frame single codon deletions and intronic mutations. (Rademakers et al.,
2004) Most mutations are clustered in exons 9-13 that encode the microtubule binding 
domains (see chapter 2). Depending on the type and location of the MAPT mutation, 
different pathogenic mechanisms are involved. (Hutton, 2001) All mutations in intron 10 
and the majority o f mutations in exon 10 disrupt the balance of exon 10 splicing, altering 
the ratio of 3R and 4R-tau protein. Most mutations result in increased 4R-tau, though in 
some cases 3R-tau is increased. In cases where the clinical picture is predominantly that 
of early frontal lobar dementia, even if ophthalmoplegia develops, FTDP-17 is the 
preferred nomenclature. (Morris et al., 2003) However, in cases with mutations of MAPT
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but the clinical picture and pathology are typical for Richardson’s syndrome, familial 
PSP is preferred. (Stanford et al., 2000)
Mutations of MAPT in sporadic PSP
Sequence analysis of MAPT in a series of 96 subjects with clinically diagnosed 
PSP identified one patient with a missense mutation in intron 1 of the tau gene, who was 
later found to have pathological changes characteristic of PSP. (Poorkaj et al., 2002) 
This mutation was not found in the other PSP subjects or in 198 additional controls. In 
contrast to FTDP-17, MAPT mutations in exons 9, 11, 12 and 13 have not been identified 
in any patients with a clinical or pathological diagnosis of PSP.
Genetic association of extended haplotypes at 17q21 with PSP
In 1997 Conrad and colleagues described the first evidence that there may be a 
genetic predisposition to PSP involving MAPT. (Conrad et al., 1997) They found that the 
ao allele and ao/ao genotype was significantly overrepresented in patients with PSP 
compared to normal controls. The allelic association of MAPT with PSP has been 
extended since then, and is known to cover a region of ~ 1.8 million base-pairs. (Pittman 
et al., 2004) MAPT is nested within the centre of the high linkage disequilibrium block. 
Other genes identified in this region include saitohin, corticotrophin releasing hormone 
receptor 1 and N-ethylmaleimide sensitive factor.
The frequency of the extended HI haplotype in Caucasian control populations is 
77% - 80%, but in PSP the allele frequency is increased to more than 93%. The odds 
ratio for the HI HI susceptibility genotype in PSP was found to be 4.08 (95 % confidence 
interval 1.89 to 8.79). (Baker et al., 1999) While the increased odds ratio for HI HI is 
significant, this genotype is neither necessary nor sufficient to cause PSP. In addition 
there is some evidence suggesting that the H2 allele is protective. (Pittman et a l, 2005) 
No associations between genotype and pathological phenotype have been identified. In 
one study tau biochemistry and neuropathology was examined in 25 patients with 
pathologically diagnosed PSP. The HI HI haplotype was not found to influence tau 
burden or tau isoform composition. (Liu et a l, 2001)
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A family of HI-derived sub-haplotypes have now been identified. (Pittman et a l, 
2005) A single specific variant of HI, designated the Hlc haplotype, was over­
represented in PSP and, importantly, other common HI derived haplotypes showed no 
association with the disease. The H2 haplotype was shown to be under-represented in 
PSP reinforcing its probable protective role (odds ratio 0.215, 95% confidence interval 
0.099 to 0.466). These findings imply that underlying variations in MAPT on the 
extended HI background are genetic risk factors for PSP.
ApoE in PSP
Apolipoprotein E e 4 (APOE c4) is a widely recognized genetic risk factor for 
AD, (Mayeux et a l,  1998; Tsuang et a l, 1999) affecting the rate and extent of amyloid 
deposition (Zubenko et a l, 1994; Gomez-Isla et a l, 1996; Hyman et a l, 1996; Berg et 
a l, 1998; Chen et al., 1999) with less consistent influence on neurofibrillary 
degeneration. (Ghebremedhin et a l,  1998; Ohm et a l, 1999; Mann et a l, 2001) There is 
little evidence to suggest that APOE e4 has a similar effect on PSP. Several small studies, 
usually based on relatively few cases and often including exclusively clinically diagnosed 
cases or a mixture of clinically and pathologically diagnosed cases, have addressed the 
role of APOE e4 in PSP. (Tabaton et a l, 1995; Schneider et a l, 1995; Anouti et a l, 
1996; Litvan and Saunders, 1998; Morris et a l, 2000; Morris et a l, 2001) None of these 
studies has found a strong relationship between APOE e4 and PSP.
Summary
The identification of genetic susceptibility in PSP and the similarities between 
patients with MAPT mutations and sporadic PSP raises the possibility that genetic factors 
account for differences between RS, PSP-P and PAGF. Furthermore, clinical genetic 
studies have suggested that atypical clinical syndromes occur more frequently in relatives 
of patients with PSP. To investigate the impact of known genetic factors on RS, PSP-P 
and PAGF, DNA from the group of pathologically diagnosed PSP archived at the QSBB 
was tested for mutations in MAPT and association studies were performed for tau 
haplotype and APOE genotype.
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10.1. MAPT gene mutations in PSP
Aims
The aim of this study was to determine if MAPT mutations in exon 1 and 10 
influence the clinical phenotype in patients with pathologically diagnosed PSP.
Methods
DNA from 79 patients archived at the QSBB with a pathological diagnosis of PSP 
was studied. There was no family history of neurological disease in 77, but in one there 
was a first degree relative with PSP and in another there was a family history of early 
onset AD. Patients were clinically categorised as RS, PSP-P or PAGF (chapter 6).
Tau exons (1 and 10) were amplified from genomic DNA from individuals with 
primers designed to flanking intronic sequences. (Andreadis et al., 1992; Hutton et al., 
1998; Poorkaj et al., 1998) Twenty-five nanograms of DNA were used in 40pl reaction 
mixture containing 20pmol of each primer, 0.2mM dNTPs, 1 U Taq polymerase (Qiagen, 
Crawley, West Sussex). Conditions were 35 cycles of 94°C for 30s, 58°C to 48°C touch 
down annealing for 30s, and 72°C for 45 s with a final extension of 72°C for 10 min.
The PCR product was cleaned up using 2 pi ExoSapIT (USB Amersham, 
Uppsala, Sweden) for 40 min at 37°C followed by 15 min at 85°C. The sequencing 
reaction was carried out using a Big Dye Terminator Cycle Sequencing Ready Reaction 
Kit (Applied Biosystems). The sequencing reaction was performed using forward and 
reverse primers separately with the following PCR conditions: 96°C for 1 min; 27 cycles 
of 96°C for 16 s, 54°C for 5 s and 60°C for 4 min. The sequencing products were 
precipitated with isopropanol, resuspended in 25 pi of water and loaded onto an ABI 
PRISM 3100 Genetic analyser (Applied Biosystems). The original data were analysed 
using Sequencing Analysis 3.7 software (Applied Biosystems) for base calling. The 
obtained sequences were aligned using BioEdit 7.0 software (Ibis Pharmaceuticals, 
Carlsbad, USA).
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Results
DNA was extracted from 79 patients (55 men) with a pathological diagnosis of 
PSP. The mean age of disease onset was 65.2 years (range 46-87), mean age at death was 
72.7 years (range 57-90) and mean disease duration was 7.6 years (range 1.2-20.9). 
Fifty-two patients were classified as RS, 19 as PSP-P and two as PAGF. In six patients 
clinical information was insufficient to assign a clinical phenotype. No mutations were 
identified in exons 1 or 10 of MAPT in any patient.
Conclusions
Mutations in exons 1 and 10 of MAPT are not responsible for the clinical 
differences observed in this group of pathologically diagnosed PSP, including patients 
with ‘atypical’ PSP phenotypes such as PSP-P and PAGF.
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10.2. Tau haplotype analysis in PSP
Aims
The aim of this study was to examine the associations between tau haplotype and 
PSP clinical, biochemical and pathological subtype.
Methods
DNA from 85 patients archived at the QSBB with a pathological diagnosis of PSP 
was studied. (Baker et al., 1999) Patients were clinically categorised as RS, PSP-P or 
PAGF (chapter 6).
Case-control allelic and genotypic association was calculated statistically in 
CLUMP software. (Sham and Curtis, 1995) The p  values were derived by standard 
Pearson’s % tests except in cases where cell counts in the contingency tables were less 
than 5. When cell counts were less than 5, p-values were determined empirically by 
10,000 simulations; the program uses a Monte Carlo approach that performs repeated 
simulations to generate random tables having the same marginal totals as the one under 
consideration and counting the number of times that a x, value associated with the actual 
table is achieved by the randomly generated tables.
Cases were separated according to tau genotype. Pathological severities, as 
described in chapter 8, and insoluble-tau isoform profiles, as described in chapter 9, were 
compared between these groups using %2 or Mann Whitney U tests as appropriate.
Results
The HI HI genotype was significantly associated with PSP, when compared to 
controls (OR 5.6, 95%CI 3.7-8.5, p<0.001). The association was different between the 
two clinical subtypes (RS OR 13.2, 95% Cl 3.0-57.2, p<0.001; PSP-P OR 4.5; 95%CI
1.3-16.0, p=0.018). In total 4 patients (5%) were heterozygous for the H2 allele and its 
overall frequency was 3.6%. The frequency of the minor allele was different between the 
groups, 2.8% in RS and 5.2% in PSP-P (p=0.108). The frequency of the H2 allele in both 
clinical groups was significantly less than in an unrelated control population (controls, 
7.0%, p<0.001). There was no significant difference in the clinical features of carriers of
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the H2 allele. The single patient who was homozygous for H2H2 was classified as PSP- 
P, and shared characteristics with that group.
There were no significant differences in guanidine-solubilised tau isoform profile 
or pathological tau distribution or severity between groups separated according to 
genotype or the presence of an H2 allele.
Conclusions
An association between MAPT (dys)-function and PSP has been confirmed by the 
OR of 5.6 for the HI HI genotype for PSP in this study. Morris and colleagues reported 
that patients homozygous for HI are more likely to present with clinically ‘typical’ PSP, 
and in their small group of ‘atypical’ PSP there was a higher frequency of the H2 allele. 
(Morris et a l , 2002a) We found a difference of H2 allele frequency between the two 
clinical subgroups, but the difference was not significant. The effect of the HI HI PSP 
susceptibility genotype was stronger in RS than in PSP-P (OR 13.2 versus 4.5). The 
difference in genotype frequencies between the clinical subgroups was not significant. 
There was no correlation between genotype and tangle-tau isoform profile or pathological 
tau distribution or severity.
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10.3. Apolipoprotein E
Aims
The aim of this study was to investigate the APOE genotype in a group of 
clinically well characterised patients with PSP and to examine for associations between 
genotype, clinical phenotype, biochemical profile and pathological profile.
Methods
In 72 patients archived at QSBB the APOE genotype was determined using a 
restriction digest assay as previously described. (Saunders et al., 1993) Case-control 
allelic and genotypic association was calculated an analysed as described in chapter 10.2.
Results
Results for 68 patients were available. ApoE allelic and genotypic distributions 
were examined and were compared to 134 pathologically normal controls. Tables 10.1 
and 10.2 show the genotype distributions and allelic distributions respectively. There 
were no significant differences between PSP and controls or between RS and PSP-P.
Conclusion
ApoE genotype does not appear to influence clinical phenotype or biochemical or 
pathological features in PSP.
Genotype
2.2 2.3 2.4 3.3 3.4 4.4
PSP 1(1.4) 11(16) 2(3) 43 (63) 10(15) 1 (1-4)
RS 1 (3) 4(13) 1 (3) 22 (69) 4(13) 0
PSP-P 0 3(16) 0 13(72) 1 (6) 1(6)
Controls 0 20 (15) 5(4) 78 (58) 30 (22) 1(1)
Table 10.1 ApoE genotype, number (percentage)
Allele
2 3 4
PSP 15(11) 107 (79) 14(10)
RS 6(11) 52 (81) 5(8)
PSP-P 3 (8) 30(84) 3(8)
C ontrols 25 (9) 206 (77) 37(14)
Table 10.2 ApoE alleles, number (percentage)
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Overall conclusions
The genetic risk factors that have been identified in PSP are present in both 
classic PSP (RS) and atypical PSP (PSP-P, PAGF). The associations found were stronger 
in RS than in PSP-P, but a larger number of PSP-P patients is required to determine if 
there is a statistically significant difference. Mutations in MAPT and APOE genotype do 
not appear to contribute to the clinical, biochemical or pathological differences between 
RS, PSP-P and PAGF.
Routine screening for mutations in MAPT in patients with sporadic PSP or 
atypical Parkinsonism with clinical features of PSP-P and PAGF is unlikely to yield a 
high number of abnormalities. Historically, MAPT mutations have been identified in 
patients with PSP who have an early age at onset with predominant early cognitive 
dysfunction or a family history of neurological disease. (Delisle et al., 1999; Stanford et 
al., 2000; Morris et al., 2003)
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The criteria for diagnosing PD do not have sufficient specificity to exclude 
many cases of PSP-P. A number of clinical features have been proposed to 
separate PSP from PD. Olfactory function testing (University of Pennsylvania 
Smell Identification Test), a visual hallucination inventory (Queen Square 
Visual hallucination Inventory) and a modified, simple protocol testing the 
startle response were used to test a series of patients clinically diagnosed with 
PSP, PD, MSA and other bradykinetic rigid syndromes. Using case notes from 
the QSBB, visual hallucinations and falls were assessed retrospectively in 
pathologically diagnosed cases. In addition clinical features were compared 
between patients with pathologically diagnosed PSP, PD, MSA and VP. Visual 
hallucinations rarely occurred in clinically diagnosed PSP, but were frequent in 
PD. Olfactory function was better preserved in PSP than PD and a score below 
the 11th percentile for age was not found in PSP. The auditoiy startle response 
was absent or reduced in all patients with PSP. The auditory blink response 
was abnormal in RS but not in PSP-P, suggesting less extensive PSP-tau 
pathology in PSP-P. Retrospective analysis in pathologically diagnosed 
patients confirmed the clinical specificity of visual hallucinations for PD, and 
their rarity in PSP. Falls occurred commonly in all bradykinetic rigid 
syndromes, but were significantly earlier in both RS and PSP-P than in PD. 
Fractures were more common in PSP than PD or MSA. Clinical features most 
specific for PD and MSA, when compared with PSP, were drug induced 
dyskinesias, autonomic failure and visual hallucinations. PSP can be identified 
by the absence of these features and the presence of falls within 6 years of 
disease onset, UPSIT scores above the 12th percentile for gender and age, and 
abnormalities in auditory startle response.
Introduction
RS has been recognised with increasing accuracy since the mid 1960s. (Steele, 
1975; Hughes et a l ,  2002) The classic phenotype of early falls (often backwards) and 
postural instability, ophthalmoplegia, pseudobulbar palsy and a dysexecutive syndrome is 
highly characteristic. The accuracy of clinical diagnosis in those with PSP-P is 
significantly less than RS and therefore the greatest challenge faced by neurologists in 
identifying patients with underlying PSP-tau pathology will be to differentiate PSP-P 
from PD, MSA and vascular PD. The diagnostic criteria for these other conditions have 
previously been reported and will be considered separately in the context of the 877 cases 
from the QSBB that have been reviewed for this project.
UKPDSBB Diagnostic Criteria
In 1988 the UKPDSBB proposed a set of clinical diagnostic criteria for PD using 
clinical details extracted from the records of a group of pathologically diagnosed 
cases.(Appendix, Gibb and Lees, 1988) In later, carefully studied pathological series the 
accuracy of these diagnostic criteria was found to be up to 90%. (Hughes et a l, 1992a; 
Hughes et al., 2001) In 100 consecutive cases of clinically diagnosed PD collected at the 
UKPDSBB the positive predictive value (PPV) and sensitivities of these criteria was 
found to be around 92%, and may even be higher in the hands of movement disorders 
specialists. (Hughes et al., 2001; Hughes et al., 2002) The inherent bias in this series, 
potentially favouring difficult to diagnose and extensively investigated cases, suggests 
that this is an underestimation of the predictive value of the criteria. (Maraganore et al, 
1999; Hughes et al., 2001) PD is by far the most common cause of a progressive, 
bradykinetic rigid syndrome in the community. It is 25 times more prevalent than PSP 
(Schrag et al., 1999; Nath et al., 2001; Porter et al., 2006) and MSA (Schrag et a l, 1999; 
Vanacore, 2005), the two conditions that it is most frequently confused with in specialist 
clinics. (Hughes et al., 2001) The high prevalence of PD and relatively low sensitivity of 
the diagnostic criteria (in relation to prevalence) makes the identification of non-PD 
bradykinetic rigid syndromes by a negative diagnosis of PD unreliable. That is, the 
number of false negative diagnoses of PD will exceed the number of true negative 
diagnoses including PSP and MSA. The specificity of these criteria has not been 
calculated, but unless it approaches 100% then a positive diagnosis of PD could not 
absolutely exclude PSP-P. Consequently a diagnosis of PD using UKPDSBB criteria 
would not exclude a proportion, potentially a large proportion, of PSP-P cases.
Consensus criteria for the diagnosis of MSA
In the QSBB database 78 patients with a clinical diagnosis of MSA before death 
were identified. The PPV of this group’s last clinical diagnosis was 81%; with 15 cases 
being incorrectly diagnosed MSA, including two with a pathological diagnosis of PSP. 
Of these two cases, one had been classified as PSP-P and the other as RS using the 
factorial analysis in chapter 6.1. The sensitivity of the clinical diagnosis of MSA was
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68%, as 23 cases were misdiagnosed clinically as PD and seven as PSP. A consensus 
statement on the diagnosis of MSA was published in 1999, after many of the final 
diagnoses of the QSBB series had been made.(Appendix, Gilman et al., 1999) These 
criteria were then validated in a retrospective, neuropathologically confirmed series at the 
QSBB. (Osaki et al., 2002) As a diagnostic aid early in the disease, the strictest category 
“probable MSA”, had sensitivity of 28%, but late in the disease the sensitivity was 63% 
and PPV 91%. In that study, amongst the 59 cases diagnosed with MSA, one (1.7%) had 
a pathological diagnosis o f PSP. The misdiagnosis of PSP as MSA reflects the overlap in 
clinical features even using the most stringent diagnostic criteria. The consensus criteria 
probably have a better PPV than the final clinical diagnosis in the QSBB series, although 
different methodologies make direct comparisons impossible. However, the relatively 
high PPV at the end of disease makes it unlikely that many patients would be 
misdiagnosed as PSP when these criteria are applied. (Osaki et a l , 2002)
Vascular PD criteria
Atypical “lower body” Parkinsonism with striking ‘gait apraxia’ occurs with 
subcortical white matter lesions due to small vessel disease. However, a clinical 
diagnosis of VP is still difficult to make as both lacunar infarction of the basal ganglia 
and leukoaraiosis occur very frequently in elderly people who do not have Parkinsonism. 
(Zijlmans et al., 2004a) Zijlmans has proposed diagnostic criteria for VP, but these have 
not yet been pathologically or prospectively validated. (Appendix, Zijlmans et al., 2004a) 
One community-based survey identified a prevalence of VP about 7 times less than PD in 
elderly patients. (Barbosa et al., 2006) In the QSBB archives 19 cases of Parkinsonism 
were identified in which only vascular pathology could be identified on histological 
examination. Of these only two were identified in life as VP, and the other 15 were 
misdiagnosed as PD or MSA (two cases). VP was not misdiagnosed as PSP and 
pathologically diagnosed PSP was not clinically diagnosed as VP. Given that the 
proposed diagnostic criteria include bilateral symptoms, the presence of an early 
shuffling gait and early cognitive dysfunction, a misdiagnosis of VP remains a 
possibility. (Zijlmans et al., 2004a) Furthermore cases closely resembling PSP have been
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reported due to vascular disease. (Tanner et al., 1987; Dubinsky and Jankovic, 1987; 
Josephs et al., 2002)
Diagnosing PSP-P
Historically the clinical diagnostic accuracy in PSP is lower than for PD, and 
patients with PSP-P appear to account for the majority of misdiagnoses. (Chapter 6) 
Together with estimates using the current operational diagnostic criteria and data from 
the QSBB, the greatest diagnostic dilemma appears to be between PD and PSP-P. The 
UKPDSBB criteria for PD do not have sufficient specificity to exclude many of these 
cases of PSP-P. Therefore a number of clinical features have been identified that have 
been proposed to separate PSP from other bradykinetic rigid syndromes, and have been 
predicted to increase the specificity of diagnostic criteria for PD and PSP. The clinical 
usefulness of these factors was explored, with a particular emphasis on clinical features 
that are easily assessed in the clinic. Olfactory function testing, a visual hallucination 
inventory and a modified, simple protocol testing the startle response were used in 
clinically diagnosed patients and visual hallucinations and falls were assessed 
retrospectively in pathologically diagnosed cases.
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11.1. Diagnostic experiments in clinically diagnosed patients
11.1.1. A visual hallucination inventory that differentiates Parkinson’s disease 
from atypical Parkinsonism 
Background
Visual hallucinations (VH) and disturbances of visual perception occur in PD and 
are a major diagnostic feature of DLB. In PD the prevalence of VH has been reported to 
be between 6% and 60%. (Cummings, 1991; Diederich et a l, 2005) In cases with Lewy 
body pathology, VH are thought to be secondary to pathology in the basolateral nucleus 
of the amygdala, parahippocampus and associated with a-synuclein pathology in the 
ventral temporal and frontal cortex. (Harding et a l, 2002a; Harding et a l, 2002b; Liang 
et al., 2005) The time from disease onset to first VH has been related to density of Lewy 
bodies (LB) in the parahippocampal and inferior temporal cortices. (Harding et a l, 
2002a) The presence o f VH is helpful in differentiating DLB from frontotemporal 
dementias and PSP, but not from AD. (Lopez et a l, 1999) This has led to the suggestion 
that VH might be helpful in the differential diagnosis of PD from atypical Parkinsonism. 
Patients with unclassifiable Parkinsonism make-up around 5% of patients in movement 
disorders specialist clinics, and most often the differential diagnosis lies between PD, 
MSA and PSP. (Katzenschlager et a l, 2003) By incorporating VH into the UKPDSBB 
operational clinical diagnostic criteria for PD the number of unclassifiable cases of 
Parkinsonism may be significantly reduced. Existing validated questionnaires that are 
used to screen for VH in PD, including the Unified Parkinson’s Disease Rating Scale 
(UPDRS) (Fahn et a l , 1987) and the Neuropsychiatric Inventory (NPI) (Cummings et a l, 
1994), probably underestimate the frequency of VH in PD. (Fenelon et a l, 2000)
Aims
A simple and short inventory capable of rapidly screening for VH, including 
minor forms, has been developed to determine the incidence of VH in an outpatient 
population with bradykinetic rigid syndromes. Its use in differentiating PD from PSP has 
been examined.
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Methods
Developing the Queen Square Visual Hallucination Inventory
On the basis of Fenelon’s description of VH in PD the Queen Square Visual 
Hallucination Inventory (QSVHI) was developed to determine the presence of minor and 
major visual hallucinations and illusions (appendix). (Fenelon et al., 2000) The 
questionnaire was designed to be read verbatim to patients in the context of a busy 
outpatient clinic. Question A is a general screening question asking about VH or unusual 
visual perceptions over the previous three months or earlier. Question B asks specifically 
for minor hallucinations: ‘presence’ hallucinations (the vivid sensation of the presence of 
somebody either in the room, or less often, behind him or her-extracampine 
hallucinations); ‘passage’ hallucinations (brief visions of a person, animal or object 
moving across the field of vision); and illusions (visual misinterpretation). (Fenelon et 
al., 2000) Question C asks if formed VH (consisting of people, animals or objects) were 
perceived and if they occurred in isolation or were associated with auditory 
hallucinations. Question D asks about isolated auditory hallucinations (sounds of people 
voices, music or other noises). The duration of all hallucinations was recorded. The 
physician was asked in question E to rate whether or not the hallucinations were likely to 
be related only to medications (VH started with initiation of medication and/or 
permanently disappeared on withdrawal of offending medication) or if the hallucinations 
occurred in the context of delirium.
Recorded data
The QSVHI was tested in three movement disorders clinics in London (National 
Hospital for Neurology and Neurosurgery and University College London Hospital). The 
study was approved by the local research ethics committee. The responses of consecutive 
patient’s responses were noted. Routine clinical assessment including motor function 
was assessed in the ‘on’ state using the Unified Parkinson’s Disease Rating Scale 
(UPDRS) activities of daily living and motor subscales and the modified Hoehn and Yahr 
staging. Cognitive function was assessed by Folstein’s mini-mental state examination 
(MMSE). (Folstein et al., 1975) Medication history, including antiparkinsonian 
treatments, antipsychotic treatment and antidepressant therapy was recorded. Dose and
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duration of treatment was recorded and calculation of a daily L-dopa equivalent unit 
(LEU) dose was based on theoretical equivalence to L-dopa (Graham et a l, 1997) as 
follows: bromocriptine (mg) x 10, cabergoline (mg) x 67, ropinirole (mg) x 25, 
pramipexole (mg) x 100, pergolide (mg) x 100, apomorphine (mg) x 8 as described 
previously. (Evans et al., 2004) The presence of depression, use of glasses and ocular 
pathology, including cataracts, retinal pathology and glaucoma was recorded.
Patients
One hundred and eighty-one patients were included. One hundred and fifteen 
(63.5%) patients met the UKPDSBB clinical diagnostic criteria for PD (Gibb and Lees, 
1988), five (2.8%) had DLB (McKeith et al., 1996), 23 (12.7%) met the NINDS-SPSP 
criteria for possible or probable PSP (3 PSP-P and 19 RS) (Litvan et a l, 1996a), 9 (5%) 
met the consensus criteria for MSA (3 MSA-P and 6 MSA-C) (Gilman et al., 1999), five 
(2.8%) had probable VP (Zijlmans et al., 2004a), one had CBD, two had Parkinsonism 
and an associated +29 tau mutation, one had a mitochondrial cytopathy, one had 
orthostatic tremor and in 19 (9.5%) a definitive diagnosis had not been reached. This 
group of patients with unclassified or undetermined Parkinsonism (UP) had either not 
satisfied any criteria for diagnosis or had overlapping features suggestive of more than 
one nosological entity. Fifteen disease-control patients with non-neurodegenerative 
neurological conditions selected from a different clinic (idiopathic cervical dystonia, 7; 
hemifacial spasm, 1; dopa responsive dystonia, 1; essential tremor, 6), and 14 control 
subjects, without neurological disease, were also included after written informed consent 
was obtained. A pathological diagnosis of CBD and Lewy body PD was made in one 
case which had been clinically diagnosed as CBD. Two patients with MSA and one with 
RS were pathologically confirmed.
VH were defined as being present if an affirmative response was given to 
questions A, B or C in the QSVHI. To determine the sensitivity and specificity of VH 
data from patients with a definitive diagnosis in the movement disorders clinic were used 
in a 2 x 2 table as illustrated below. This was also calculated for PD vs. PSP. For these 
calculations the pathologically diagnosed case and the tau+29 cases were included in the
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PD group, but DLB cases were excluded because of the arbitrary clinical definition which 
included the presence o f VH.
VH
present
VH
absent
Sensitivity = a/a+c 
Specificity = d/b+d 
PPV = a/a+b 
NPV = d/c+d
Results
The mean age of all patients was 66.8 years old (range 20-100; SD 11.7 years), 
63% were men, and mean disease duration was 9.3 years (0.3-55; SD 95.5). In PD the 
mean age was 65 and in PSP the mean age was 68.2 years (table 11.1). Amongst the UP 
patients two had early cognitive impairment and poor response to levodopa (diagnosis 
DLB vs. PSP), seven had a poor response to levodopa and no rest tremor (diagnosis PD 
vs. PSP vs. MSA), three had early autonomic symptoms, one of whom had eye 
movement abnormalities (PD vs. MSA vs. PSP), five had vascular risk factors, vascular 
changes on imaging not involving basal ganglia structures and poor response to levodopa 
or absence of rest tremor (PD vs. VP), and two had young onset Parkinsonism where 
metabolic and genetic causes had not been excluded.
There was no significant difference in frequency of ocular pathology, use of 
reading aids or depression between PD and the other main diagnostic groups. In PD, L- 
dopa and dopamine agonists were used more frequently than in the patients without PD. 
Compared to PSP there was no significant difference in the use of amantadine or 
anticholinergic medications. MMSE and Hoehn and Yahr scores indicated more severe 
abnormalities in PSP than PD, but UPDRS motor and ADL scores were comparable.
PD PD 
present absent
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PD PSP MSA VP DLB UP Disease Control
Number control115 22 9 5 6 19 15 14Age (range) yrs 65 68.2 60.5 74.8* 74.2 66.6 63.4 62.6
Disease duration yrs
(35-85) (58-78) (53-69) (62-92) (64-80) (20-82) (50-87) (42-76)
10.0 4.8* 6.7 6.6 6.9 7.9 20.8*
(range) (1-27) (2-15) (2-13) (3-13) (3-17) (0.3-22) (3-55) *
Men (%) 70 59 33f 20f 83 53 53 50
Spectacles (%) 15 14 14 20 17 11 80t 62 tOcular pathology (%) 5 9 0 20 17 12 7 0
Depression (%) 31 27 11 20 17 18 7 NR
Medications
L-dopa 82 5 2 t 44f 60 83 61 t 7f otDA 60 10 t 22f ot Of 28f ot otAntichol 5 5 0 20 0 6 7 0
Amantadine 41 32 44 40 17 6 f ot otSelegiline 8 5 0 0 0 0 0 0
Antipsych 5 0 0 0 17 6 0 0
ChE Inhib 4 5 0 0 0 6 0 0
BZD 0 0 0 0 0 0 27t 0
LEU 619 250 407 381 453
(range) (0-3000) (0-750) (0-1050) (0-1100) 0 (0-1100) 0 0
Clinical features
MMSE 27.7 25.9* 25.8* 28.5 21.8* 24.9* 28.4
(range) (13-30) (19-30) (22-230 (27-30) (17-28) (0-30) (26-30)
UPDRS II 13.1 15 22* 15 13.6 11.7 2*
(range) (2-30) (6-21) (10-32) (0-30) (8-24) (0-26) (0-8)
UPDRS III 28.8 33.9 35 33 36.2 28.4 4*
(range) (7-60) (14-60) (31-42) (3-55) (24-60) (4-74) (0-13)
H&Y 2.5 3.4* 4* 2.8 3 2.5 0.8
(range) (1-5) (2-4) (2-5) (1-4) (2-4) _ .(1-5) (0-2)
Table 11.1 Patient demographics* vs. PD t-test p<0.05; f  vs. PD x2 or Fisher’s exact p<0.05
Medication use expressed in %; DA, dopamine agonist; Antichol, anticholinergic 
medication; Antipsych, antipsychotic medication; ChE Inhib, cholinesterase 
inhibitor; BZD, benzodiazepine medication; MMSE, mini-mental state 
examination; UPDRS, unified Parkinson’s disease rating scale; H&Y, Hoehn and 
Yahr score; NR, not recorded
The screening question (QSVHI question Al) identified only 43 (38%) patients 
with clinically diagnosed PD who had VH, and none with PSP, MSA, VP or ET (table
11.2). Two (14%) control patients answered yes to this question, describing what 
transpired to represent visual auras associated with migraine. Eighty-five patients (75%) 
with PD, 3 patients (20%) with VP and three patients (14%) with PSP reported minor 
hallucinations and illusions (QSVHI question B), whereas none were reported in MSA. 
Amongst those with UP, nine patients (47%) experienced VH. Isolated auditory 
hallucinations (AH) occurred in 16% PD patients and none of the other movement 
disorders. VH were definitively related only to medications in 3% (two patients) of the 
PD hallucinators but medications were deemed responsible in 2 of 3 of PSP hallucinators. 
Delirium was associated with VH in 7% (5 patients) of PD hallucinators. In many
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patients the time of onset o f hallucinations could not be accurately recalled for example 
in the PD group only 68% of hallucinators could recall the time of onset of 
hallucinations.
QSVHI questions PD PSP MSA VP DLB UP Diseasecontrol Contr<
A General question 38 0* 0* 0 83 21 0* 14B1 Presence 46 9* 0* 20 100* 22* 7 0B2 Passage 52 5* 0* 0* 83 28* 20 7*
B3 Illusions 47 5* 0* 20 50 11* 20 0B Total 72 9* 0* 20 100* 37* 20 7*
C1 Formed VH 38 0* 0* 20 67 11* 0* 0
C2 VH, associated AH 6 0 0 0 17 0 0 0
Total VH 75 14* 0* 20 100* 47 33 7*
D Auditory hallucinations 16 0* 0 0 17 11 7 0
E1 Associated delirium 5 0 0 0 17 0 0 0
E2 Medication related 2 9 0 0 0 0 20 0
Total VH - E ■ De-novo VH 68 5* 0* 20 83 47* 13 7*
Current VH 78 67 _ 0 100 71 40 100
Past VH 22 33 - 100 0 29 60 0
VH Duration (range) mths 29 85 - 12 43 36 12 NR
(1-144) (6-240) (12) (6-130) (1-120) (1-28)
Table 11.2 Frequency of “yes” response to QSVHI questions. * vs. PD x2 or Fisher’s exact 
p<0.05. Results expressed as %; VH, visual hallucinations; AH, auditory 
hallucinations; NR, not recorded
De-novo VH, defined as VH not related to delirium or medications, were present 
in 78 (68%) PD patients but in only one (5%) patient with PSP. The PSP patient reported 
minor presence hallucinations that had been lifelong. Two patients with PD reported 
similar paranormal experiences going back to childhood. In disease controls the majority 
of VH were related to anticholinergic medications. Two (22%) disease control patients 
and one (7%) normal control reported presence hallucinations, limited to the months 
following the death o f their spouse.
In PD hallucinators the MMSE was not significantly different to non-hallucinators 
(27.5 vs. 28.2, t-test p=0.32). However, PD hallucinators had significantly worse mean 
UPDRS II (14 vs. 10.7, t-test p=0.02), UPDRS III (30.6 vs. 24.7, t-test p=0.04) and 
Hoehn and Yahr (2.6 vs. 2.2, t-test p=0.01) scores. Amongst those with PD, disease 
duration was significantly longer in the hallucinators (11.3 vs. 6.6 years, t-testp<0.001).
137
There was no difference in frequency or dose of medication use between PD 
hallucinators and non-hallucinators.
The sensitivity and specificity of a positive response to individual QSVHI 
questions is summarized in table 11.3. The screening question (A) was as good as asking 
specifically for formed VH (question C l) in identifying patients with clinically diagnosed 
PD. The addition of minor hallucinations and illusions to the inventory (question B) 
doubled the sensitivity for PD, at the expense of specificity and PPV. However, the 
overall specificity of de-novo VH remained above 90%. When compared in patients 
where the diagnostic dilemma was between PD and PSP, the specificity of de-novo VH 
was 95% and the PPV approached 100%.
QSVHI question PD vs. non-PD PD vs. PSPsens spec PPV NPV sens spec PPV NPV
A Screening question 36 100 100 38 36 100 100 23
B1 Presence 45 89 91 38 45 91 96 24
B2 Passage 50 98 98 43 50 95 98 26
B3 Illusions 45 91 93 39 45 95 98 24
B Total 72 89 94 55 72 86 97 37
C1 Formed VH 36 93 93 36 36 100 100 23
C2 VH, associated AH 8 100 100 29 8 100 100 17
Total VH 74 91 96 57 75 86 97 39
Total de-novo VH 62 91 95 48 62 95 99 32
Table 11.3 QSVHI in PD and other bradykinetic rigid syndromes. Sens, sensitivity; spec, 
specificity; VH, visual hallucinations; AH, auditory hallucinations
Discussion
The QSVHI is a sensitive and simple method for establishing the presence of 
minor and major VH in Parkinsonism. It doubles the sensitivity of standard clinical 
screening questions and can be used in routine clinical practice. VH, as assessed by the 
QSVHI, are highly specific for the clinical diagnosis of PD. Hallucinators were found to 
have longer disease duration and more severe motor symptoms than non-hallucinators in 
PD but MMSE and medication use did not differ.
138
The PPV for PD has been determined as 98.6% by examination of pathological 
material. (Hughes et al., 2002) In the present study the clinical diagnosis preceded the 
QSVHI implementation. De-novo VH assessed on the QSVHI were 91% specific for a 
clinical diagnosis of PD. Taken together this implies that patients who experienced VH 
according to the QSVHI have a 90% chance of having underlying Lewy body pathology.
Fenelon’s minor hallucinations and illusions are not examined in detail in the VH 
components of the UPDRS (Fahn et a l , 1987), NPI (Cummings et al., 1994) or other 
published questionnaires, including the Baylor PD Hallucination Questionnaire 
(Brandstaedter et al., 2005) and the Parkinson Psychosis Questionnaire. (Fenelon et al, 
2000; Ondo et al., 2005) Minor or “benign” hallucinations and illusions form part of the 
early spectrum of disorders of perception that eventually lead to formed VH in PD. (de 
Maindreville et al., 2005; Goetz et al., 2006) The QSVHI was designed to take into 
account the clinical observation that minor hallucinations and illusions occur frequently 
in PD but are not spontaneously reported (Fenelon et al., 2000) and may be missed using 
only screening questions. Specific questioning for Fenelon’s minor hallucinations 
(QSVHI questions B l, B2 and B3) substantially increased the number of VH reported 
compared to a typical screening that might be used in the UPDRS or NPI (QSVHI 
question A). This finding may prove particularly helpful in the UP group where QSVHI 
question A identified VH in 21%, but the complete QSVHI identified VH in 47% of UP 
patients. Given the specificity of VH for clinically diagnosed PD in this series, the 
majority of UP hallucinators are likely to have Lewy body pathology. For example, both 
patients in whom the differential diagnosis was between DLB and PSP reported VH on 
the QSVHI, favoring DLB as the underlying diagnosis. Of the seven UP patients with 
poor or no therapeutic levodopa response four reported VH on the QSVHI, favoring the 
diagnosis of PD rather than MSA or PSP. Two of the five patients where the diagnostic 
conundrum lay between PD and VP experienced hallucinations. The impact of the 
QSVHI on differential diagnosis is likely to be significant in the 4-5% of patients 
attending specialist clinics whose Parkinsonism remains unclassifiable. (Katzenschlager 
e ta l, 2003)
VH are known to occur in up to a third of patients with AD (Scarmeas et al.,
2005) and secondary to anticholinergic medications, and in these clinical contexts the
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inventory may be o f limited use. In controls minor VH were reported by one person, 
suggesting that question B may detect paranormal phenomena and in patients with visual 
loss and Charles Bonnet syndrome VH are likely to be reported. It follows that in an 
unselected population the “false positive” rate could be high and specificity is likely to be 
somewhat lower than found here.
The QSVHI does not replace detailed clinical evaluation and assessment of the 
patient but it can be included easily in the routine assessment of patients being followed 
up in neurology clinics and will pick up far more patients experiencing VH than would be 
spontaneously reported at the consultation by the patient or the family.
One of the potential weaknesses of this study is the selection bias inherent in a 
movement disorders clinic from a tertiary referral centre. Given that the community 
prevalence of PD is estimated to be more than 20 times higher than PSP and MSA 
(Schrag et a l, 1999; Porter et al., 2006), PD patients are probably under represented in 
this study. However, having more PD patients would have increased the PPV in this 
study. AD never presents with Parkinsonism but in any clinic with AD patients the PPV 
of QSVHI for PD would be lower than found in this study. The QSVHI was applied to a 
selected group of patients and is likely to be most useful where the diagnostic dilemma is 
between PD and PSP or MSA, a common diagnostic difficulty in specialist clinics. 
(Katzenschlager et a l, 2003) The lack of pathological confirmation also limits the 
conclusions that can be drawn from these findings, but the historical diagnostic accuracy 
in this clinic is known, so reasonable assumptions can be made. (Hughes et a l, 2001)
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11.1.2. Olfaction in PSP
Background
Olfactory dysfunction is a common early finding in PD. A number of studies 
have found that olfaction is normal in PSP and have proposed that smell identification 
testing can differentiate between PD and PSP. (Doty et al., 1993; Wenning et a l, 1995b) 
The underlying pathological substrate for hyposmia in PD is incompletely understood, 
but olfactory dysfunction can occur in other neurodegenerative disorders including PDC 
Guam (Doty et al., 1991), Alzheimer’s disease (Doty et al., 1991), Huntington’s disease 
and MSA. Previous studies using smell identification testing in PSP were performed 
prior to the publication of the NINDS-SPSP clinical diagnostic criteria and used data that 
was not adjusted for age or gender.
Aims
The aim of this study was to examine the diagnostic usefulness of smell 
identification testing using age and gender adjusted scores in a group of patients with PD 
and PSP diagnosed according to the UKPDSBB and NINDS-SPSP diagnostic criteria 
respectively. The diagnostic potential was also tested in a group of patients with 
unclassifiable Parkinsonism.
Methods
Data collection
Data was collected from patients attending the movement disorders clinic at the 
National Hospital for Neurology and Neurosurgery, London UK, where the University of 
Pennsylvania Smell Identification Test (UPSIT) is part of the routine clinic workup of 
new patients. Records from patients diagnosed with PD, according to the UKPDSBB 
criteria (Gibb and Lees, 1988), and clinically probable or possible PSP according to the 
NINDS-SPSP criteria (Litvan et al., 1996a) were examined. A third group of patients 
with “unclassifiable” Parkinsonism (UP) was also included. These patients had either not 
satisfied any criteria for the diagnosis of PD, PSP, MSA, VP or CBD, or had features of 
several different diseases. Some of these patients have previously been reported.
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(Katzenschlager et al., 2003) Data including patient demographics, disease duration, and 
disease severity (UPDRS II and III and MMSE), smoking history and UPSIT scores were 
recorded.
Statistical analysis
Clinical characteristics and UPSIT scores amongst different disease groups were 
compared. Percentile estimates for age and gender using published data from North 
American controls were used and compared between the groups. Univariable analyses 
using x2 for categorical and two-tailed t test or the Mann Whitney U test, as appropriate, 
for continuous variables were applied.
Further analysis was performed in subgroups of PD and PSP with MMSE >21 and 
disease duration <8 years. This separation was done to replicate the population in whom 
UPSIT testing might be most useful, that is those with disease duration within the mean 
disease duration of PSP, and who have the cognitive ability to accurately perform the test.
A cut-off percentile ranking of UPSIT scores was determined for the diagnosis of 
PD and its sensitivity and specificity was calculated in a 2 x 2 table as follows. This was 
also calculated for PD vs. PSP.
UPSIT 
<12th percentile 
UPSIT 
>11th percentile
Sensitivity = a/a+c 
Specificity = d/b+d 
PPV = a/a+b 
NPV = d/c+d
Results
Clinical details were recorded from 64 patients with PD, 12 with NINDS-SPSP 
probable PSP and four with NINDS-SPSP possible PSP. Three of these patients were 
classified as PSP-P and the remaining 13 as RS, according to the clinical features in the 
first two years of disease. All PSP-P patients were initially diagnosed as PD, had a good 
response to dopaminergic medications, rest tremor and developed falls and supranuclear
PD PD 
present absent
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gaze palsy more then five years after disease onset. One of these patients had previously 
been reported as unclassifiable Parkinsonism. (Katzenschlager et al., 2003) Eight 
patients with UP were included in the study. In three of these patients the principal 
diagnostic dilemma was between PD and VP and in two it was between PSP, MSA and 
PD. Amongst the 3 other unclassifiable patients in one, where the differential diagnosis 
was between CBD and PD, a post mortem examination revealed both pathological 
processes and in another a +29 tau mutation has been identified.
There were no significant differences between mean ages, UPDRS or MMSE 
scores in PD compared to PSP, but mean disease duration was significantly shorter in 
PSP (table 11.4).
PD PSP P PSP-P P
N 64 16 3
Male % 64 56 NS 0 0.026
Age yrs 63.6 (37-81) 68.2 (62-80) NS 69.9 (70-80) NS
Disease duration yrs 10.4(1.5-19) 5.2 (2-18) <0.001 10.5 (6-18) NS
UPDRS II 14 (2-27) 14(6-21) NS 17(10-21) NS
UPDRS III 30(12-62) 29 (14-46) NS 32 (18-39) NS
H&Y 2.6 (1-4) 3.2 (2-4) 0.03 3.7 (3-4) 0.035
MMSE 28.1 (19-30) 27.1 (19-30) NS 28.6 (27-30) NS
UPSIT raw-score 17.6 (8-36) 24.7 (14-35) <0.001 26 (22-27) 0.017
UPSIT percentile 9 (<5-23) 23 (<5-59) <0.001 27 (13-54) <0.001
Table 11A  Patient demographics, p, p value for Student’s t-test or x2; NS, not
significant; H&Y, Hoehn and Yahr
Mean UPSIT raw-scores were significantly lower in PD compared to PSP; 
however there was substantial overlap (figure 11.1). When adjusted for gender and age, 
using published percentile data, there was less overlap (figure 11.2). The differences 
between means for PD and PSP-P were also significant (table 11.4, figure 11.2).
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Figure 11.1
UPSIT raw-scores in PSP and PD. 
Mean, interquartile range, range and 
outliers
Figure 11.2
UPSIT age and gender percentile 
in PSP, PD and PSP-P.
Mean, interquartile range, range, 
and outliers.
Eleven PD patients and 14 PSP patients with disease duration <8 years and 
MMSE >21 and were compared. Mean UPSIT raw-score o f this PD sub-group was 
significantly less than the PSP sub-group (16.3 vs. 24.9, Mann Whitney U test =0.001). 
Mean percentile rankings were significantly different (5.7 vs. 21.0, p=0.002), but there 
was one patient whose scores overlapped with the PD range (figure 11.3). No PD patient 
in this subgroup had a UPSIT score ranked higher than the 11th percentile.
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Figure 11.3
UPSIT age and gender 
percentile in PD and PSP (only 
patients with disease duration <8 
years and MMSE >21).
Mean, interquartile range, range 
and outlier.
PD P SP
An UPSIT score below the 12th percentile for age was considered to be predictive 
of PD. In all patients with PD and PSP with MMSE >21, the specificity of an UPSIT 
score below the 12th percentile for PD was 88%, the sensitivity was 83%, the PPV was 
96% and NPV was 54%. Amongst the patients classified UP, six (1: +29 tau mutation 
PD; 3: PD vs. VP; 1: PSP vs. MSA vs. PD) had UPSIT scores below the 12th percentile 
and three patients (1: PD vs. VP; 1: PSP vs. MSA vs. PD; 1: path confirmed CBD and 
PD) had scores above the 11th percentile.
Discussion
Patients with clinically diagnosed PSP performed better on smell identification 
testing than those with PD. In this group of selected patients, without a pathological 
diagnosis, the mean UPSIT scores were significantly different between PD and PSP, and 
this difference was greater when raw-scores were adjusted for age and gender. A cut-off 
UPSIT score set at the 11th percentile for age and gender had a high PPV for the clinical 
diagnosis o f PD, but the specificity was only 88%. Most patients with a clinical 
diagnosis o f PSP scored above this cut-off suggesting that testing with the UPSIT may be 
clinically useful in separating PSP form PD when the MMSE is greater than 21. 
Furthermore in three patients clinically categorised as PSP-P, mean UPSIT scores were 
significantly higher than PD. The specificity o f this test means that in isolation it is 
unlikely to provide a highly accurate diagnosis but it may be helpful in certain clinical 
scenarios. For example this study predicts that in UP patients with an MMSE greater
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than 21 and an UPSIT score below the 12th percentile, PSP is unlikely to be the 
underlying pathological diagnosis. However, the converse is not true and an UPSIT 
score above the 11th percentile would be non-contributory to the diagnosis, because of the 
range of scores seen in PD.
One of the weaknesses of this study is the selection bias associated with the 
tertiary referral centre clinic where these patients were tested. The lack of pathological 
confirmation is another obvious limitation to the conclusions that can be drawn from 
these findings, but the historical diagnostic accuracy in this clinic is known, so reasonable 
assumptions can be made. (Hughes et al., 2001) A prospective study with pathological 
follow-up is needed to corroborate these findings.
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11.13. The auditory startle response in the diagnosis PSP
Background
Electrophysiological tests including the acoustic startle response (ASR) and 
auditory blink reflex (ABR) have been proposed as a method of distinguishing PSP from 
other Parkinsonian conditions. (Litvan et al., 1996a) The startle response is generated in 
the nucleus reticularis pontis caudalis which activates the reticulospinal tract inducing 
muscle responses in facial and spinal neurons. (Davis et al., 1982) Neuronal loss in 
patients with PSP affects these structures and specifically involves cholinergic neurons of 
the lower pontine reticular formation, including those of the pedunculopontine tegmental 
nucleus and the nucleus pontis caudalis. (Zweig et a l, 1987; Juncos et al., 1991; Malessa 
et al., 1991) This distribution of pathology does not occur in other Parkinsonian 
disorders. The ABR, on the other hand, is thought to originate from different brainstem 
structures, and a number of studies have found that in PSP it can be retained even when 
the ASR is absent. (Kofler et a l, 2001; Gironell et al., 2003) Animal studies of 
brainstem transections indicate that the pathway of ABR exists between the lower 
midbrain and the upper medulla, and the acoustic reflex pathway is postulated to include 
the superior olivary complex, the lateral lemniscus nuclei and the caudal colliculus in the 
midbrain. (Hori et al., 1986)
Measurement o f the ASR has been shown to differentiate NINDS-SPSP probable 
PSP from PD (Vidailhet et al., 1992) and MSA. (Valldeoriola et al., 1998) These studies 
suggested that ASR might be a useful diagnostic tool, particularly in differentiating the 
PSP from PD and other unclassifiable Parkinsonian syndromes. (Litvan et a l, 1996a) 
One prospective study assessed patients with MSA, CBD, VP as well as PSP. Patients 
were diagnosed using operational diagnostic criteria and sensitivity and specificity of 
ASR together with ABR and electro-oculography for the diagnosis of PSP were reported 
as 100% and 95% respectively. (Gironell et al., 2003) The ASR was absent in all the 
PSP cases, in contrast to other studies where a range of responses were found.
These studies have been limited to clinically diagnosed patients without 
confirmatory pathological examination. Furthermore, patients without a definitive
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diagnosis or with unclassifiable Parkinsonism have not been included, so the 
discriminatory ability o f these tests is unknown in patients where the clinical diagnosis is 
uncertain. Finally, no attempt has been made to distinguish between the ASR and ABR 
in orbicularis oculi in different conditions, even though the contrasting reflex circuits 
would argue for a differential sensitivity to pathological processes.
Aims
The ASR and ABR have been studied in patients with PSP, including those with 
the PSP-P/PAGF phenotype, and unclassifiable Parkinsonism, to determine the 
diagnostic usefulness.
Patients and methods
Patients
Thirty-nine patients were recruited from the movement disorders clinic at the 
National Hospital for Neurology and Neurosurgery, London UK. The study was 
approved by the local research ethics committee. In all cases written informed consent 
was obtained prior to testing. Ten patients were diagnosed with PD according to the 
UKPDSBB diagnostic criteria (Gibb and Lees, 1988), one with DLB (McKeith et al., 
1996), 14 with NINDS-SPSP probable PSP (RS), five with NINDS-SPSP possible PSP 
(with a clinical phenotype consistent with PSP-P or PAGF) and nine with unclassified or 
undetermined Parkinsonism (UP). In one patient with RS the pathological diagnosis of 
PSP was confirmed.
Seven PD patients were recorded OFF medication and three were only recorded in 
the ON state. In two patients recordings were taken both off medications and 90 minutes 
following medications. Comparisons between on and off treatment responses were not 
statistically different in preliminary Mann Whitney U tests (p > 0.05), and all PD results 
were subsequently pooled together. In each patient demographic details, disease duration, 
pharmacological therapy, MMSE and UPDRS activities of daily living and motor scores 
were recorded. Patients with a MMSE score less than 21 were excluded. Twelve age 
matched control subjects, without neurological disease, were also tested. Two 
neurologists working at QSBB and blinded to the electrophysiological findings were
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asked to rate, on a 10 point visual analogue scale, the likelihood of each patient with UP 
having PSP-tau pathology underlying their clinical disease. A mean grading of these 
results was used to classify the UP patients.
Methods
The patients were seated in a comfortable chair with arm and backrests, in a quiet 
room with an oil projector (Mathmos, London, UK) providing a relaxing visual stimulus 
to discourage sleep. A protocol modified from Brown (Brown et al., 1991) and from 
Gironell (Gironell et a l, 2003) was used to obtain the ASR and ABR. A startle stimulus 
was delivered when the subject was relaxed with eyes open. Subjects received an 
auditory tone burst of 1 KHz, 150 ms duration and 110 dB from a custom made gated 
tone generator and delivered binaurally through earphones at pseudo-random intervals 
during one 15 minute epoch. Stimuli were separated by at least 60 seconds and by no 
more than 180 seconds, giving 5 responses in one epoch.
Electromyographic (EMG) activity was recorded using bipolar surface silver- 
silver chloride electrodes applied to the orbicularis oculi (OO) and stemomastoid (Scm) 
muscles bilaterally. For the OO, the two recording electrodes were placed 1 cm below 
and 1 cm medially from the external canthus. For the Scm, the recording electrodes were 
placed 2 cm apart over the midbelly of the muscle. EMG activity was sampled at 1000 
Hz, amplified (X 5000) and filtered between 16 -  300 Hz using a D160 amplifier 
(Digitimer, Welwyn Garden City, UK) and 1401 analogue to digital (A-D) converter 
(Cambridge Electronic Design, Cambridge, UK). Raw EMG from each muscle was 
subject to DC removal (time constant 0.01s) before being rectified and averaged to the 
onset of the tone, with the 50 msec period before onset of the stimulus used as the 
baseline value in each of these sweeps.
Analysis o f  results
Analysis of results was performed blinded to clinical status. The presence of ASR 
in Scm and OO in the 5-trial average was examined. The ASR was considered to be 
absent if the amplitude of the EMG startle response was less than 5pV or 3 SD of the 
baseline mean (which ever was the greater). Onset latency (ASR) was measured as the
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time interval between onset of acoustic stimulus and the onset (sustained increase of at 
least 10 contiguous points above 3 SD of the baseline mean) of the averaged EMG 
response in OO or Scm muscles. The duration of responses was measured from response 
onset until EMG activity returned to a consistent level below 3 SD of the baseline mean 
(at least 10 contiguous points). The size and peak amplitude of responses were also 
measured as percentage increases from the baseline mean activity. The OO was later 
found to be compound; consisting of both an early ABR and a later true startle reflex 
beginning at approximately 100 ms after auditory stimulation. Response duration and size 
was also analysed for these two components. Habituation was examined for each muscle 
by comparing the amplitude of responses to the first two versus the last two stimuli.
Statistical analysis
The frequency of the presence of ABR and ASR was compared between 
diagnostic groups (PD, PSP and controls). Mean values for ASR and ABR latency, 
duration and amplitude were calculated and pair wise comparisons between groups were 
performed. Data for UP were plotted against PSP and PD. The UP groups was 
dichotomised (unlikely PSP, <4 and possible or likely PSP, >3) and mean values of all 
parameters were compared. Univariable analyses using Fisher’s exact test, for 
categorical and two-tailed t test or the Mann Whitney U test, as appropriate, for 
continuous variables were applied.
Results
Patient demographics
Table 11.5 shows the demographics of patients tested. There were significant 
differences in the MMSE, UPDRS and H&Y scores between the PSP and UP group. 
Overall the UP group had less severe disease. There was a significant difference in 
disease duration between RS (4.1 years) and PSP-P/PAGF (8.0 years, Student’s t-test,
p=0.002).
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Age (range) M en
(%)
D ise a se
duration
(range)
MMSE (range) UPDRS H&Y (range)
II
PD  6 3 .9 (4 1 - 7 8 )  9 0  8 .4 (1 -2 0 )  2 7 .7 (2 2 -3 0 )  1 2 .3 (8 -2 4 )  3 5 .3 (2 2 -6 0 )  2 .4  (2-4)
P S P /P A G F  6 8 .1  (5 2 -8 1 ) 5 6  4 .9 (1 - 1 1 )  26.1 (19 -30) 1 4 .8 (8 -2 0 )  3 4 .5 (1 4 -5 5 )  3.4* (2-4)
UP 6 3 .8 (5 1 - 7 6 )  7 0  6 .8 (2 - 1 9 )  2 9 .2 |  (27 -30) 5 .6 f  (3 -10) 1 8 .8 f (8 -2 7 )  2 f  (1-3)
Control 6 3 .4  (4 8 -7 4 ) 6 7  - -
Table 11.5 Demographics in clinically diagnosed patients, *(PD vs. PSP/PAGF, t-test 
p<0.05), t(PSP vs. UP, t-test p<0.05)
Orbicularis oculi responses
Orbicularis oculi responses to a startling stimulus in controls typically consisted 
of two components. The first had a mean latency of 45 (SD 11) ms and was most likely 
the ABR due to its lack of habituation (figure 11.4). Grand averages revealed a second 
component occurring at approximately 100 ms, which was thought to reflect the true 
ASR (figure 11.4B).
control
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_ /V _
UP
PSP-RS
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Controls
■UP
■PSP-P
■PSP-RS
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0  3 0 40.1 0201
Figure 11.4 A Representative OO EMG recording from each group B Grand average of OO 
EMG from control group C Grand average OO EMG according to group
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In controls both of these components were present in all but one person, in whom 
the OO ASR was absent (table 11.6). Both components were present in 9 (82%) PD 
patients. In PSP, both components were present in only four (21%) patients (2 (14%) RS 
and 2 (40%) PSP-P/PAGF, Fisher’s exact, p>0.05) (table 11.6).
PSP PD P Controls P UP RS PSP-P / 
PAGF
P
N 19 11 12 9 14 5
OO response
ABR present % 58 100 0.013 100 0.01 89 43 100 0.04
ASR present % 21 82 0.002 92 <0.001 67 14 40 NS
Scm response
ASR present % 11 45 0.043 50 0.022 67 7 20 NS
Table 11.6 EMG response according to clinical diagnosis. Fisher’s exact p value vs. 
PSP; NS, non significant difference
There were significant differences between mean ASR and ABR duration and 
amplitude in PSP and both controls and PD (figure 11.5; table 11.7). There were no 
significant differences between PD and controls.
PSP PD P Controls P
ABR duration 0.023 0.101 0.006 0.052 0.006
(0.026) (0.172) (0.019)
ASR duration 0.018 0.067 0.005 0.092 < 0.001
(0.047) (0.060) (0.080)
ABR amplitude 365 985 < 0.001 1334 < 0.001
(846) (874) (923)
ASR amplitude 73 409 0.002 679 < 0.001
(155) (305) (857) _
Table 11.7 Mean OO EMG parameters compared between groups. Duration ms, (SD); 
Amplitude % change from baseline; p, Mann Whitney U vs. PSP
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Figure 11.5A ABR and ASR duration (seconds) vs. clinical diagnosis. UP - grade of likelihood 
of PSP-tau pathology recorded next to case result (visual analogue scale 1-10)
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Figure 11.5B ABR and ASR amplitude (% change form baseline) vs. clinical diagnosis. UP - 
grade of likelihood of PSP-tau pathology recorded next to case result (visual 
analogue scale 1-10)
Sternocleidomastoid responses
Figure 11.6A shows typical Scm responses to startling stimuli in four subjects. 
The latency o f the Scm response was longer than the OO response, occurring at mean 94 
± 11 ms after tone presentation in control subjects. Scm response showed considerable 
variability within groups, but tended to be smaller and of shorter duration in patients than
153
in controls. Scm response was present in only 50% of controls and fewer patients (table 
11.6).
Figure 11.6B shows the grand averages for all groups normalized for baseline 
EMG activity. Scm ASR duration and amplitude values for PSP were significantly 
smaller on pair-wise comparisons with both controls and PD (table 11.8).
control
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PSP-RS
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Figure 11.6 A Representative SCM ASR EMG B Grand average EMG according to group; 
%amplitude vs. time (sec)
PSP PD p Controls
Scm ASR duration 0.015 0.056 0.034 0.135 0.010
(0.051) (0.066) (0.155)
Scm ASR amplitude 40 199 0.030 329 0.015
____________________ (145) (324)__________ (471)_________
Table 11.8 Mean Scm EMG parameters compared between groups. Duration, ms (SD); 
amplitude, % change from baseline; p, Mann Whitney U vs. PSP
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Unclassifiable Parkinsonism
Nine patients were graded according to the likelihood of PSP-tau pathology 
underlying their clinic syndrome. Four patients were graded 1 or 2 (extremely unlikely to 
have PSP-tau pathology underlying), one grade three, two grade 4 and one graded 8 
(likely to have PSP-tau pathology) and compared to PSP, PD and controls (figure 11.5). 
When dichotomised according likelihood of PSP there were no significant differences.
Discussion
Following a simple test protocol using a standardised acoustic startle the ABR and 
ASR were usually present in normal controls. The OO response was found to be 
complex, consisting of two peaks corresponding to the initial ABR and later OO ASR. In 
PSP both of these responses were usually absent, and, in particular, in RS both were 
present in only 14%. The OO ASR was almost universally absent in RS and PSP-P. In 
contrast the ABR was always present in PSP-P/PAGF, but was present in only 43% of 
RS. These findings imply that the extent of pathology in both PSP phenotypes extends to 
involve the ASR reflex circuits, but only in RS does it extend to structures in the ABR 
circuit. In PSP-P and PAGF the distribution of post mortem pathological tau is more 
limited than in RS, and the frequency of preserved startle and blink responses in PSP- 
P/PAGF compared to RS would support this (see chapter 8). In the PSP-P/PAGF group 
the mean duration of disease was twice that of RS, but the electrophysiological results 
imply the extent of pathological involvement was less in this group. Thus the nucleus 
reticularis pontis caudalis, where the ASR is generated, appears to be susceptible to 
damage in both RS and PSP-P/PAGF, but the midbrain structures involved in the ABR 
are significantly less susceptible in PSP-P/PAGF.
The SCM ASR was absent in some controls and PD, as well as PSP suggesting 
that neurodegeneration is not entirely responsible for these abnormalities. Qualitative 
analysis of OO and SCM responses showed significant differences between the means in 
patients with PSP, PD and controls. The amplitude and duration of ABR and ASR were 
consistently lowest in the PSP group, but the discriminatory ability of these findings is 
limited because of the degree of overlap between groups, and absent responses in 
controls. The diagnostic utility of the ABR and ASR can be estimated by examining the
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range of results for PSP, PD and controls and comparing them to patients with UP. By 
definition clinical diagnosis is difficult in these patients and the value assigned for 
“likelihood” of PSP-tau pathology underlying the clinical syndrome remains the best 
guess. There was no consistent pattern of abnormality in individual patients and the 
results in UP patients graded 1 (extremely unlikely to have PSP-tau pathology) were 
similar to those graded greater than 3 (possible to likely).
The place of ASR and ABR testing remains uncertain in the diagnosis of PSP. 
The electrophysiological characteristics of the two PSP phenotypes support the 
contention that brainstem pathology is more limited in PSP-P and PAGF than RS. A 
longitudinal study may be able to address this further by tracking the change in ASR, and 
more importantly ABR. Pathological confirmation and regional pathological comparison 
between RS, PSP-P and PAGF, where ABR differs, may provide further insights into the 
dynamics of PSP-tau pathological progression. According to the current findings other 
clinical parameters are likely to be more helpful in differentiating PSP from PD and UP.
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11.2. Retrospective studies of clinical features in pathologically diagnosed patients
11.2.1. Clinical differences between RS, PSP-P & other types of Parkinsonism 
Aims
To determine what factors might be helpful in the clinical diagnosis of PSP-P 
using data from the QSBB.
Methods
Patients
A retrospective analysis was performed using the clinical files of 877 patients 
archived at the QSBB. Patients were recruited from around the United Kingdom and 
died between 1988 and 2003. Seventy one patients were excluded who had a 
pathological diagnosis other than PD, MSA, PSP, CBD, cerebrovascular disease (CVD), 
AD or PEP and 48 patients (5.5% of total) could not be included in the analysis because 
of insufficient clinical data. The remaining 758 patients included PD and DLB, n = 490; 
PSP, n = 127; MSA, n = 90; CVD, n = 25; AD, n = 9; CBD, n = 9 and PEP, n=8. Of the 
25 patients with only CVD on histological examination four had essential tremor, with a 
positive family history, and two had other confounding factors (neuroleptic exposure and 
alcohol related dementia) and were removed from analysis of the VP group. PSP was 
further divided according to the number of clinical features associated with each clinical 
phenotype: 86 classified as RS (supranuclear gaze palsy, abnormality of saccadic eye 
movements, cognitive changes and falls in first two years), and 37 as PSP-P (in the first 
two years, asymmetric onset with a therapeutic response to levodopa and tremor).
Clinical data collection
A systematic chart review was performed on all the case notes using the same 
methodology as described in chapter 6.
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Analysis
The proportion of cases with each clinical feature was compared separately for 
cases with PSP-P and non-PSP-P, as well as individually with PD, MSA and VP, using 
the x^test for proportions for a two-by-two contingency table. Cases diagnosed with RS 
were not included. If an expected cell value was less than five, Fisher’s exact test was 
used. For each clinical feature the sensitivity, specificity, and positive (PPV) and negative 
predictive values (NPV) were calculated. A specificity of >0.85 or a PPV of >0.85 were 
considered good discriminators. Analyses were carried out using SPSS (version 12.0.1) 
software. To assess the influence of each feature on the diagnosis of PD, MSA and VP 
the sensitivities (1 -  [PSPP specificity]), specificities (1 -  [PSPP sensitivity]), PPV (1 -  
[PSPP NPV]) and NPV (1 -  [PSPP PPV]) were calculated.
Results
The mean age at disease onset of all patients was 61.3 years (range, 9.1 to 87.5) 
and the mean duration of disease was 13.3 years (range, 1.2 to 72.8); 459 patients were 
men and 299 were women (table 11.9). There were significant differences between PSP- 
P and other diseases for age of onset (MSA earlier and VP later), duration of disease (PD 
longer, MSA and VP shorter) and age at death (MSA earlier, PD and VP later) (table 
11.9). The diagnostic accuracy was significantly higher in PD and MSA than PSP-P
All cases 
(n=758)
PSP-P
(n=37)
Non-PSP-
P
(n=631)
PSP-P
vs.
non-
PSP-P
P
value
PD
(n=490)
PSP-P
vs.
PD
P
value
MSA
(n=90)
PSP-P
vs.
MSA
P
value
VP
(n=19)
PSP-P
vs.
VP
P
value
Male 440 19 409 309 41 11
(%) (61%) (51%) (64%) (63%) (46%) (58%)
Age at onset 61.1 64 61.3 0.035 61.0 0.100 56.3 <0.001 71.0 0.002
(yrs) (9.1-87.5) (44-85.3) (9.1-87.5) (28.6-84.2) (33.5-79.0) (59.4-81.3)
Duration of 13.3 12.7 13.3 0.078 15.0 0.020 8.1 <0.001 10.3 0.016
disease (yrs) (1.2-72.8) (5.3-29) (1.2-72.8) (1.4-39.9) (2.4-16.5) (2.6-18.2)
Age at death 74.4 76.6 74.5 0.002 76.1 0.730 64.4 <0.001 81.4 0.035
(yrs) (39.4-95.8) (50-92.6) (39.4-95) (49.8-93.4) (39.4-86.0) (72.4-90.8)
Clinical 588 14 496 <0.001 461 <0.001 61 0.002 2 0.015
diagnosis (78%) (38%) (79%) (95%) (68%) (11%)
correct (%)
Table 11.9 Demographics of patients in QSBB archives, including PSP (PSP-P only) and
non-PSP cases (PD, MSA and VP)
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Tables 11.10, 11.11 and 11.12 show the different proportions of PSP-P and non- 
PSP-P cases with each of the different clinical features. When comparing PSP-P with 
PD, the frequency of nine early features, 10 late features as well as hallucinations and 
grade of response to levodopa differed significantly (table 11.10). Individually none of 
these factors had a high sensitivity and PPV for PSP-P. However, three of these clinical 
features, when calculated with respect to a diagnosis of PD, appeared to be reasonable 
discriminators of PD. Late drug induced dyskinesias (specificity 0.92, PPV 0.99), late 
autonomic dysfunction (0.94, 0.99) and visual hallucinations (0.94, 0.99) occur in more 
than a third of PD patients and less than 10% of PSP-P patients.
When comparing PSP-P with MSA, the frequency of five early features and nine 
late features differed significantly (table 11.11). Late non-specific eye symptoms and 
supranuclear gaze palsy were good discriminators of PSP-P. Three other clinical features, 
when calculated with respect to a diagnosis of MSA, appeared to be reasonable 
discriminators of MSA. Early autonomic dysfunction (specificity 1.0, PPV 1.0), late 
autonomic dysfunction (0.94, 0.80) and late cerebellar signs (0.97,0.38) occurred in more 
than 50% of MSA patients and less than 10% of PSP-P patients.
When comparing PSP-P with VP, the frequency of two early features and six late 
features differed significantly (table 11.12). Pyramidal signs were more common 
throughout the disease in VP than PSP-P and postured instability was more frequent late 
in PSP-P but had a low specificity. Individually none of the other clinical factors had a 
high sensitivity and PPV.
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Criteria PSP-P PD
% %
Early features
Falls 3 5
Bradykinesia 89 85
Cognitive dysfunction 14 10
Tremor 51 75
Axial rigidity 27 7
Limb rigidity 66 80
Asymmetric onset 46 82
Postural instability 19 8
Vertical SNGP 0 4
Abnormal saccades 9 13
Dysarthria/dysphonia 30 11
Dysphagia 11 2
Non-specific eye symptoms 16 4
Limb dystonia 3 4
Pyramidal signs 8 2
Drug induced dyskinesias 0 <1
Alien limb 0 <1
Cerebellar signs 0 <1
Autonomic dysfunction 0 6
Cortical sensory loss 0 0
Late features
Falls 97 69
Bradykinesia 100 99
Cognitive dysfunction 60 69
Tremor 58 86
Axial rigidity 71 29
Limb rigidity 92 99
Postural instability 97 74
Vertical SNGP 68 13
Abnormal saccades 83 44
Dysarthria/dysphonia 89 75
Dysphagia 75 57
Non-specific eye symptoms 56 24
Limb dystonia 25 24
Pyramidal signs 14 8
Drug induced dyskinesias 8 53
Alien limb 0 0
Cerebellar signs 3 <1
Autonomic dysfunction 6 38
Cortical sensory loss 0 <1
Hallucinations 6 53
Levodopa Response
Grade 1 28 4
Grade 2 44 12
Grade 3 17 37
Grade 4 11 47
*X* Sensitivity Specificity PPV NPV
P
value
NS .03 .95 .04 .93
NS .89 .15 .08 .95
NS .14 .90 .10 .93
0.001 .51 .25 .05 .87
<0.001 .27 .93 .22 .94
0.048 .66 .20 .06 .89
<0.001 .46 .18 .04 .82
0.036 .19 .92 .14 .94
NS .00 .96 .00 .00
NS .09 .88 .17 .78
0.001 .30 .89 .18 .94
0.001 .11 .98 .33 .93
0.001 .16 .96 .23 .94
NS .03 .96 .05 .93
0.033 .08 .98 .21 .93
NS .00 .99 .00 .00
NS .00 1.00 .00 .00
NS .00 1.00 .00 1.00
NS .00 .94 .00 1.00
- .00 .00 .00 .00
<0.001 .97 .31 .10 .99
NS 1.00 .01 .07 1.00
NS .59 .31 .06 .91
<0.001 .58 .14 .05 .81
<0.001 .71 .71 .16 .97
0.004 .92 .01 .07 .70
0.003 .97 .26 .10 .99
<0.001 .68 .87 .50 .93
0.014 .83 .56 .32 .93
NS .89 .25 .10 .96
0.039 .75 .43 .11 .95
<0.001 .56 .76 .15 .96
NS .25 .76 .07 .93
NS .14 .92 .12 .93
<0.001 .08 .47 .01 .86
- .00 .00 .00 .00
NS .03 .00 .33 .93
<0.001 .06 .62 .01 .89
NS .00 .99 .00 1.00
<0.001 .06 .48 .01 .87
<0.001 0.28 0.96 0.37 0.94
<0.001 0.44 0.88 0.23 0.95
0.014 0.17 0.63 0.03 0.90
<0.001 0.11 0.53 0.02 0.88
Table 11.10 PSP-P vs. PD
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Criteria PSP-P
%
MSA
%
*x*
P
value
Sensitivity Specificity PPV NPV
Early features
Falls 3 22 0.010 .03 .78 .05 .66
Bradykinesia 89 79 NS .89 .21 .32 .82
Cognitive dysfunction 14 3 0.027 .14 .97 .63 .72
Tremor 51 42 NS .51 .58 .34 .74
Axial rigidity 27 15 NS .27 .85 .43 .74
Limb rigidity 66 68 NS .66 .32 .29 .69
Asymmetric onset 46 59 NS .46 .41 .24 .65
Postural instability 19 28 NS .19 .72 .20 .72
Vertical SNGP 0 2 NS .00 .98 .00 1.00
Abnormal saccades 9 24 NS .09 .76 .14 .66
Dysarthria/dysphonia 30 24 NS .30 .76 .35 .71
Dysphagia 11 7 NS .11 .93 .40 .70
Non-specific eye symptoms 16 1 0.001 .16 .99 .86 .74
Limb dystonia 3 6 NS .03 .94 .17 .69
Pyramidal signs 8 16 NS .08 .84 .18 .68
Drug induced dyskinesias 0 2 NS .00 .98 .00 1.00
Alien limb 0 0 - .00 .00 .00 .00
Cerebellar signs 0 13 0.03 .00 .88 .00 1.00
Autonomic dysfunction 0 54 <0.001 .00 .46 .00 1.00
Cortical sensory loss 0 0 - .00 .00 .00 .00
Late features
Falls 97 78 0.012 .97 .22 .34 .95
Bradykinesia 100 96 NS 1.00 .04 .30 1.00
Cognitive dysfunction 60 26 0.006 .59 .74 .49 .81
Tremor 58 61 NS .58 .39 .28 .69
Axial rigidity 71 48 0.04 .71 .53 .37 .82
Limb rigidity 92 93 NS .92 .07 .30 .67
Postural instability 97 94 NS .97 .06 .31 .83
Vertical SNGP 68 10 <0.001 .68 .90 .72 .89
Abnormal saccades 83 72 NS .83 .28 .30 .82
Dysarthria/dysphonia 89 95 NS .89 .05 .29 .50
Dysphagia 75 90 0.027 .75 .10 .27 .47
Non-specific eye symptoms 56 10 <0.001 .56 .90 .69 .83
Limb dystonia 25 35 NS .25 .65 .23 .68
Pyramidal signs 14 57 <0.001 .14 .43 .10 .52
Drug induced dyskinesias 8 23 NS .08 .77 .13 .67
Alien limb 0 1 NS .00 .99 .00 1.00
Cerebellar signs 3 35 <0.001 .03 .65 .03 .62
Autonomic dysfunction 6 90 <0.001 .06 .10 .03 .20
Cortical sensory loss 0 1 NS .00 .99 .00 1.00
Hallucinations 6 9 NS .06 .91 .20 .71
Levodopa Response
Grade 1 28 40 NS .28 .59 .25 .63
Grade 2 44 30 NS .47 .70 .44 .73
Grade 3 17 26 NS .17 .74 .24 .64
Grade 4 11 4 NS .11 .96 .57 .70
Table 11.11 PSP-P vs. MSA
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Criteria PSP-P VP *X* Sensitivity Specificity PPV NPV
% % P
value
Early features
Falls 3 21 0.040 .03 .79 .20 .29
Bradykinesia 89 79 NS .89 .21 .69 .50
Cognitive dysfunction 14 21 NS .14 .79 .56 .32
Tremor 51 53 NS .51 .47 .66 .33
Axial rigidity 27 17 NS .27 .83 .75 .38
Limb rigidity 66 94 NS .66 .06 .58 .08
Asymmetric onset 46 58 NS .46 .42 .59 .30
Postural instability 19 39 NS .19 .61 .46 .31
Vertical SNGP 0 0 - .00 .00 .00 .00
Abnormal saccades 9 0 NS .09 .00 1.00 .00
Dysarthria/dysphonia 30 11 NS .30 .89 .85 .40
Dysphagia 11 5 NS .11 .95 .80 .35
Non-specific eye symptoms 16 0 0.045 .16 .00 1.00 .00
Limb dystonia 3 0 NS .03 .00 1.00 .00
Pyramidal signs 8 33 0.044 .08 .67 .33 .27
Drug induced dyskinesias 0 0 - .00 .00 .00 .00
Alien limb 0 0 - .00 .00 .00 .00
Cerebellar signs 0 0 - .00 .00 .00 .00
Autonomic dysfunction 0 0 - .00 .00 .00 .00
Cortical sensory loss 0 0 - .00 .00 .00 .00
Late features
Falls 97 67 0.003 .97 .33 .74 .86
Bradykinesia 100 94 NS 1.00 .06 .69 1.00
Cognitive dysfunction 60 53 NS .59 .47 .66 .41
Tremor 58 58 NS .58 .42 .66 .35
Axial rigidity 71 33 0.02 .71 .67 .79 .57
Limb rigidity 92 100 NS .92 .00 .65 .00
Postural instability 97 76 0.037 .97 .24 .72 .80
Vertical SNGP 68 20 NS .68 .80 .93 .40
Abnormal saccades 83 100 NS .83 .00 .91 .00
Dysarthria/dysphonia 89 53 0.014 .89 .47 .80 .64
Dysphagia 75 47 NS .75 .53 .79 .47
Non-specific eye symptoms 56 5 0.004 .56 .95 .95 .53
Limb dystonia 25 16 NS .25 .84 .75 .37
Pyramidal signs 14 47 0.020 .14 .53 .36 .24
Drug induced dyskinesias 8 16 NS .08 .84 .50 .33
Alien limb 0 0 - .00 .00 .00 .00
Cerebellar signs 3 0 NS .03 .00 1.00 .00
Autonomic dysfunction 6 21 0.14 .06 .79 .33 .31
Cortical sensory loss 0 0 - .00 .00 .00 .00
Hallucinations 6 5 NS .06 .95 .67 .35
Levodopa Response
Grade 1 28 28 NS .28 .72 .67 .33
Grade 2 44 22 NS .47 .78 .81 .42
Grade 3 17 33 NS .17 .67 .50 .29
Grade 4 11 17 NS .11 .83 .57 .32
Table 11.12 PSP-P vs. VP
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Conclusions
Clinically PSP-P is often difficult to distinguish from PD and DLB, MSA and VP. 
PSP-P shares many clinical features with PD and DLB, but visual hallucinations, drug 
induced dyskinesias and autonomic dysfunction are very uncommon in PSP-P and are 
helpful exclusion criteria.
Cardiovascular autonomic failure does not occur in PSP-P and this probably 
accounts for the rare false positive diagnoses of MSA in this series. There were no 
particularly strong clinical discriminators between VP and PSP-P, although this study did 
not include imaging findings which are an essential part of the diagnostic criteria for VP. 
(Zijlmans et al., 2004a)
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11.2.2. Falls in PSP
Background
The diagnoses of PSP and PD are contingent on the presence of postural 
instability and falls. (Hughes et a l, 1992a; Litvan et a l, 1996c) In patients with 
disturbances of gait due to parkinsonism, fractures are more common than in those with 
gait disturbances due to other neurological conditions such as peripheral neuropathies. 
(Syijala et al., 2003) Despite the greater frequency of falls in PSP, falls and their 
proclivity to cause bone fractures has not been systematically analysed. (Wenning et a l , 
1999; Wielinski et a l, 2005) Falls occur frequently in Parkinsonian conditions and are 
associated with a poorer quality of life. (Schrag et a l, 2001; Bloem et a l, 2004) The risk 
of bone fracture increases with a history of falls, impairment of mobility, low body mass 
index and low bone mineral density. (Greenspan et a l, 1998; Sato et a l, 2001)
Falling within the first year of disease is required by the NINDS-SPSP criteria for 
the diagnosis of probable PSP, although in the QSBB series less than two-thirds of 
patients with pathologically diagnosed PSP had fallen in the first year of disease. (Osaki 
et a l, 2004) Falls occur frequently in PSP-P, but usually later in the disease than RS. 
The stringent NINDS-SPSP diagnostic criteria use falls within the first 12 months of 
disease because of its high specificity for RS. (Litvan et a l, 1996a)
A number of factors contribute to falls in bradykinetic rigid syndromes and may 
help to distinguish them from PSP-P. Gait unsteadiness and cognitive impairment 
contribute to falls in CBD and DLB. In MSA, on the other hand, orthostatic hypotension 
and cerebellar or Parkinsonian gait disorder are important precipitants. (Wenning et a l, 
1995a)
Aims
The aims of this study were to quantify the temporal evolution of falls in RS, 
PSP-P, PD, MSA, CBD, DLB, VP and AD and to analyse the relationship between time 
from disease onset to first fall (latency) and pathological diagnosis, specifically to
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determine if latency is helpful in distinguishing PSP-P from PD. The relationship 
between pathological diagnosis and fractures was also investigated.
Patients and methods
Patients
A retrospective analysis was performed using the clinical files of 774 patients 
with a lifetime diagnosis of a bradykinetic rigid syndrome or Parkinsonism with a 
pathologically confirmed diagnosis (PD, n = 474; PSP, n = 127; MSA, n = 91; DLB, n = 
46; VP, n = 19; AD, n = 9; CBD, n = 8) archived at the QSBB. A few cases (2% of total) 
could not be included in the analysis because of insufficient clinical data (10 PD, 3 PSP, 
1 MSA, 1 AD, 1 VP). The PSP group were further divided according to the number of 
clinical features reported associated with each clinical phenotype, not including falls in 
this designation: RS (supranuclear gaze palsy, abnormality of saccadic eye movements, 
cognitive changes in first two years), PSP-P (tremor and non-axial dystonia in the first 
two years, asymmetric onset and response to levodopa).
Data collection
A systematic chart review was performed on all the case notes using the same 
methodology as described in chapter 6.
Statistical analysis
The report and timing of any falls from the time of disease onset until death or 
fractures was the primary outcome measure. Descriptive statistics were used to analyse 
the latency to first fall and frequency of different skeletal bones fractured in each 
diagnostic group. Clinical characteristics amongst different diseases were compared. 
The proportion of PD and PSP-P cases within latencies either side of a nominated cut-off 
according to findings on the descriptive statistics were compared using the chi-square test 
for proportions for a two-by-two contingency table. The sensitivity, specificity, and 
positive (PPV) and negative predictive values (NPV) were calculated. The association 
between bradykinesia, rigidity, tremor, cognitive dysfunction, speech disturbance, 
dysphagia, dystonia, dyskinesias, autonomic dysfunction, gender, symmetry of clinical
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features, visual hallucinations and age at disease onset with falls and fractures in all 
diseases was investigated. Univariable analyses using x2 for categorical and two-tailed 
t-test or the Mann Whitney U test, as appropriate, for continuous variables were applied. 
In PSP univariable analysis was performed on falls in the first two years (i.e. early falls, 
rather than any falls) because of the high frequency of falls. In PSP, RS and PSP-P the 
effect of falls on prognosis was assessed by calculating the mean disease duration in 
patients who fell in the first two years of disease and comparing it to those who fell after 
two years. Kaplan-Meier plots were used to graphically assess survival. Cox multiple 
stepwise regression analysis was performed in all diseases for latency to first fall, using 
clinical factors present around disease onset (within the first two years) and gender as 
categorical covariates and age at onset as a continuous variable.
Results
Amongst the 782 cases the incidence of falls from disease onset to death was 
77.5%. It was highest in CBD (100%) and PSP (97.5%) and lowest in MSA (77.6%) and 
PD (73.3%). (Table 11.13) Falls occurred earlier in those with PSP (median 17 months; 
range 0-244 months) than all other diseases (figure 11.7).
PD PSP MSA DLB CBD VP AD
Number 474 127 91 46 8 27 9
Mean age at onset, 60.4 65.7 56.4 66.7 66.2 69.6 69.4
yrs (range) (28.6-84.2) (40.1-87.5) (33.5-79) (43.0-82.6) (55.6-76.1) (39.5-81.3) (59.6-84.8)
Mean age at death, 76.4 73.7 64.4 74.9 73.0 82.5 80.2
yrs (range) (49.8-93.4) (45.4-95.8) (39.4-86.0) (54.9-88.3) (65.8-81.6) (72.4-93.6) (71.0-94.6)
Women (%) 39.9 37.3 53.8 20 20 48 44.4
Falters (%) 73.3 98.3 77.6 58.1 100 73.9 85.7
Median time to first 108 16.8 42 54 30 40.8 66.6
fall, months (range) (0-384) (0-244) (0-165) (0-158) (0-90) (0-304) (36-228)
Fractures (%) 16.9 28.6 11 4.3 0 11.1 22.2
Table 11.13 Characteristics of patients according to pathological diagnosis
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Figure 11.7 Latency to first fall according to disease, showing interquartile range
Median time to first fall was significantly shorter in RS (12; range 0-95) 
compared to both PSP-P (47; 0-228, p<0.001), PD (108; 0-384, p<0.001) and MSA (42; 
0-165). A cut-off o f 70 months was used to test the usefulness of falls in separating PSP-
P from PD. In PSP-P 49% of patients fell within 70 months and in PD 19% fell within
that time. For the diagnosis o f PSP-P the sensitivity of this clinical feature was 0.48, the 
specificity was 0.81, the PPV was 0.18 and the NPV was 0.96.
In PSP univariable analysis showed an association between early falls (within the 
first two years o f disease) and symmetrical disease onset and early cognitive dysfunction, 
axial rigidity, postural instability, eye movement abnormalities and speech disturbance 
(occurring within 2 years o f disease onset). (Table 11.14) In common with PD, in those 
with early falls, tremor was less frequent. In PD there was also an association between 
the occurrence of falls and the late clinical features of cognitive dysfunction, speech 
disturbance, dysphagia, autonomic dysfunction and hallucinations and a negative 
association between the falls and early and late tremor. In MSA falls at any time were 
associated with the late clinical features o f limb rigidity, speech disturbance, dysphagia 
and pyramidal tract signs. There were no significant associations between falls and 
clinical features in VP, DLB, CBD and AD; this may be due to the small sample sizes for 
these diseases.
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Parkinson’s Disease PSP MSA
Fallers Non- P- Early Early P- Fallers Non- P-
fallers value Fallers non-
fallers
value fallers value
Number 313 114 75 49 66 19
Gender (% female) 43.1 27.2 0.002 36 40.8 NS 59 36.8 NS
Early clinical features
Cognitive dysfunction 0 0 NS 70.7 28.6 <0.001 4.8 0 NS
Tremor 72.4 86.2 0.004 6.8 35.4 <0.001 42.2 42.1 NS
Axial rigidity 5.6 8.1 NS 54.7 32.5 0.024 16.7 5.9 NS
Limb rigidity 75 81.9 NS 63.9 61.4 NS 61.1 68.9 NS
Asymmetric onset 84.8 88.2 NS 34.8 83.1 <0.001 60.3 50 NS
Postural instability 8.7 1.9 0.017 91.9 41.9 <0.001 28.6 21.1 NS
Vertical gaze palsy 6.2 0 NS 54.9 11.5 <0.001
Abnormal saccades 12 0 NS 83.3 45.0 0.002
Speech disturbance 9.6 6.5 NS 66.7 41.7 0.006 19.3 38.9 NS
Dysphagia 0.7 2.9 NS 26.7 12.5 NS 4.9 17.6 NS
Pyramidal signs 3.3 0 NS 12.3 15.2 NS 17.4 16.7 NS
Dyskinesias 0.7 0.9 NS 0 0 NS 0 1.6 NS
Autonomic dysfunction 5.7 3.6 NS 1.4 2.0 NS 55.6 58.9 NS
Late clinical features
Cognitive dysfunction 71.7 49.5 <0.001 31.6 12.5 NS
Tremor 85.7 93.6 0.018 60.3 68.4 NS
Axial Rigidity 30.1 22.3 NS 47.5 41.2 NS
Limb rigidity 98 98.2 NS 96.7 77.8 0.008
Postural instability 45.6 83.8 <0.001 94.7 88.2 NS
Speech disturbance 78.8 59 <0.001 98.4 82.4 0.007
Dysphagia 59.7 46.9 0.033 94.9 68.8 0.003
Dyskinesias 58.1 53.3 NS 22.2 22.2 NS
Autonomic dysfunction 46.9 21.5 <0.001 88.9 100 NS
Pyramidal signs 5.4 9.4 NS 66.7 33.3 0.018
Hallucinations 53.3 37.5 0.004 10.6 5.9 NS
Table 11.14 Clinical features in fallers and non-fallers according to pathological diagnosis. 
Percentage, X2
Multivariate analyses were performed using the Cox multiple stepwise regression 
model on early clinical features, age and gender. This identified several clinical factors 
which independently influence time to first fall (table 11.15).
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PD HR 
(95% Cl)
P PSP HR 
(95% Cl)
P MSA HR 
(95% Cl)
P
Age of onset 1.07 <0.001 Age of 1.05 0.007 Age of 1.04 0.003
(1.05-1.08) onset (1.01-1.09) onset (1.02-1.08)
Symmetrical 1.86 0.002 Early 3.4 0.001 Early 2.08 0.03
onset (1.25-2.77) postural
instability
(1.7-6.8) postural
instability
(1.07-3.94)
Early 2.56 0.005
autonomic (1.32-4.98)
dysfunction
Female 1.39 0.021
gender (1.05-1.83)
Table 11.15 Factors affecting time to first fall in PD, PSP and MSA: Independent predictors 
from Cox multiple regression analysis on early clinical features, age and sex. 
HR, hazard ratio; Cl, confidence interval
In PD female gender, older age, symmetrical onset and autonomic dysfunction 
were all independent predictors of earlier falls. Age of onset was also an important 
independent factor predicting time to first fall in PSP and MSA, as was postural 
instability.
Almost all patients with PSP had falls at some point in their clinical history; 
patients with falls in the first two years had a mean life expectancy 3.3 years lower than 
other PSP patients (table 11.16). This difference was greater in the PSP-P group, and 
there was no difference in the RS group. This is illustrated graphically by the Kaplan- 
Meier plot (figure 11.8).
Falls <2 y Falls >2 y p value
PSP Duration, y 6.4 9.7 <0.001
Onset, y 66.7 64.7 NS
RS Duration, y 6.2 6.8 NS
Onset, y 66.1 64.6 NS
PSP-P Duration, y 7.1 11.0 0.005
Onset, y 69.1 64.7 NS
Table 11.16 Disease duration (time from onset until death) and age at onset in early (<2
years) and late (>2 years) fallers in PSP, RS and PSP-P (Mann-Whitney U Test)
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Figure 11.8 Kaplan-Meier plot illustrates the effect of early or late falls upon survival in 124 
cases of (a) PSP in total, and separated into subgroups (b) RS (72 cases) and 
(c) PSP-P (54 cases)
There were 166 fractures recorded in 134 (17.1%) patients. Thirty six (28.6%) 
patients with PSP sustained a total of 52 fractures, 80 patients (16.9%) with PD sustained 
96 fractures, and 10 (11%) patients with MSA sustained a fracture. Hip fractures 
comprised 46.9% of all fractures in PD and one third of fractures occurred in the upper 
limb. In PSP the proportion of hip fractures was less than in PD (30.7% vs. 46.9%, 
p=0.053 t-test), and the proportion of “other upper limb fractures” (including the clavicle, 
scapula and bones in the hand) was higher than in PD (p=0.109, t-test) (table 11.17). 
Comparing all patients (with and without fractures), multiple fractures were significantly 
more common in PSP than in both PD (6.4% vs. 1.9%, p=0.007 t-test) and MSA (6.4% 
vs. 0%, p=0.014 t-test). Skull fractures (3.2% vs. 0.8%, p=0.43 t-test) and truncal 
fractures (5.6% vs. 1.9%, p=0.24 t-test) were also more common in PSP than in PD. 
There were no substantial or significant differences in fracture site between RS and 
PSP-P.
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PD PSP RS PSP-P MSA VP DLB AD
Forearm 17(17.7) 7(13.5) 5 (16.7) 2(9.1) 3(30) 1(33)
Humerus 10(10.4) 5 (9.6) 2 (6.6) 3(13.7) 1 (10) 1(33)
Other upper limb 6 (6.3) 8(15.4) 5 (16.7) 3(13.7) 0 1(33) 1 (50)
Hip 45 (46.9) 16 (30.7) 10(30.0) 7(31.8) 4(40) 2(100)
Distal leg 5(5.2) 4 (7.7) 3(10) 1 (4.5) 0 1 (50)
Pelvis 1 (1.0) 1 (1.9) 0 1 (4.5) 0
Trunk 8 (8.3) 7(13.5) 3(10) 4(18.2) 1 (10)
Skull 4 (4.2) 4(7.7) 3(10) 1 (4.5) 1 (10)
Multiple 9 8 7 5 0
Total fractures 96(100) 52 (100) 30 (100) 22 (100) 10(100) 3(100) 2(100) 2 (100)
Table 11.17 Distribution of fracture location in bradykinetic rigid syndromes: 
Number (percentage of all fractures)
In PSP early bradykinesia (28.6% with fractures vs. 8% with fractures, %2 
p=0.027), early limb rigidity (47% vs. 68.7%, x2 p=0.028) and early pyramidal signs 
(2.5% vs. 18.8%, x2> p=0.02) occurred less frequently in those with fractures. Gender 
distribution was not significantly different between fracture and non-fracture groups in 
PSP (34% women and 44% women respectively, x2 p=0.275). In contrast, women were 
over represented in PD fracture groups (28.6% vs. 11.3%, x2 p<0.001) and amongst the 
10 MSA patients with fractures (90% vs. 49.4%, x2 p=0.015). The clinical features that 
were significantly associated with fractures in PD were early falls (9.3% with fractures 
vs. 3.2% no fractures, x2 p=0.024), late falls (100% vs. 66.7%, x2 p<0.001) and late 
postural instability (88.4% vs. 71%, x2 p=0.003). VP patients with fractures did not have 
bradykinesia (0% vs. 83% VP without fractures, x2 p=0.017) or limb rigidity (0% vs. 
100% VP without fractures, x2 p=0.02).
Discussion
Using the “gold standard” of pathological diagnosis and retrospective case notes 
review methodology, several important factors related to falling have been identified 
which help to distinguish the most common neurodegenerative, bradykinetic rigid 
syndromes. Falls occurred within the first 3 years of disease onset in a majority of 
patients with PSP, within 4 years in MSA, 5 for those with DLB and a median of 9 years 
for those with PD.
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There was a significant difference between the time to first fall in RS and PSP-P, 
when these clinical phenotypes were separated using the clinical features identified by 
factor analysis in chapter 6.1, but excluding falls. There was substantial overlap between 
the mean latency to first fall in PSP-P and MSA and VP, but there was a significant 
difference when compared to PD (see figure 11.7) Despite this, the sensitivity and PPV 
of falls before 70 months for PSP-P was low and in isolation unhelpful in separating 
these patients in the clinic.
Overall the incidence of falls and fractures was high (77.6% and 17.1% 
respectively). 73% of patients with PD had falls and 16.9% sustained fractures. A 
previous prospective survey of PD and elderly patients predicted a higher incidence of 
fractures caused from falls in PD. (Genever et al., 2005) Studies have estimated an 
incidence of falls as high as 69% in PD and 32% in elderly patients. (Tromp et a l , 1998; 
Wood et al., 2002) However, falls and fractures are likely to have been underestimated 
in the present study because it relied entirely on the accuracy and completeness of clinical 
notes. Patients with other bradykinetic rigid syndromes, including PSP, CBD and MSA, 
fall more frequently and earlier in the disease than in PD, and it has been suggested that 
these patients have a higher incidence of fractures. (Wenning et al., 1999) More than 
three-quarters of patients with PSP (97%), MSA (77%) and CBD (100%) fell during their 
disease, though only 53% of patients with VP and 58% of patients with DLB fell. 
Compared to PD, the incidence of fractures was higher in PSP, but lower in MSA, CBD, 
VP, DLB and AD, partially reflecting the differences in disease duration and emphasising 
one of the strongest clinical characteristics of PSP-tau pathology.
Falls in PSP, RS and PSP-P
In PSP early falls were associated with symmetrical disease onset, early cognitive 
dysfunction, axial rigidity, dysphagia and eye movement abnormalities. These clinical 
factors reflect the importance of axial symptoms in balance and gait disturbance. 
Prognosis in PSP has previously been related to early falls, speech and swallowing 
problems and time to PEG tube insertion. (Nath et a l, 2003) There was a significant 
difference in disease duration between early fallers and late fallers in PSP and PSP-P. 
This difference was not found in RS. The Kaplan-Meier curves suggest that early falls in
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PSP predict mortality, particularly in the PSP-P subgroup. In the general population the 
risk of falling increases with age and so too in PSP the age of onset had the greatest effect 
on the latency to first fall in the multiple regression analysis. Postural instability was also 
a significant factor, although given the retrospective nature of the study; it is possible that 
the recording of this clinical feature was more likely in those who had fallen than those 
who had not. Patients were selected on the basis that they died during a specified period 
of time. If the method or accuracy of diagnosis is changing over time, then this too may 
cause some bias in the type of patients included in this study. Furthermore, people 
diagnosed more recently would need to die sooner after diagnosis to be included.
Falls in PD
This study has confirmed previous reports of a high incidence of disturbances of 
higher cortical functions in PD fallers (Wood et al., 2002; Marchese et a l , 2003), as 
indicated by the clinical parameters identified here, including: cognitive dysfunction and 
hallucinations, and axial symptoms, such as speech disturbance and dysphagia. 
Autonomic dysfunction and absence of tremor in PD were also found to be more frequent 
in those who fell. The lower incidence of tremor in PD fallers has previously been 
reported. (Koller et a l, 1989; Wood et al., 2002)
Age of onset, gender, symmetrical disease onset and autonomic dysfunction were 
identified as independent significant factors contributing to latency to first fall in PD. 
Both older age and female gender are well recognised risk factors for falls in the general 
population (Campbell et a l, 1989; Lord et a l, 1993; Tromp et a l, 1998) and have 
been identified as risk factors for falls in some, but not all reports in PD. (Bloem et a l, 
2001; Ashbum et a l, 2001; Wielinski et a l, 2005) This study also suggests that falls 
occur more frequently in women and they tend to fall significantly earlier than men.
Falls in MSA
The clinical factors that were more common in fallers with MSA were similar to 
those found in PD, in particular axial symptoms and signs (early axial rigidity, speech 
disturbance and dysphagia) and early pyramidal tract signs. Less than 15% of cases in 
this study presented with prominent cerebellar symptoms (MSA-C) accounting for the
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lack of association with cerebellar signs. Interestingly autonomic dysfunction, which was 
present in more than 50% of patients in the first two years of disease, was not 
significantly associated with the risk of falling. The clinical features which significantly 
and independently influenced latency to first fall were the same as PSP: age of disease 
onset and postural instability.
Fractures
More than one quarter of patients with PSP (28.6%) fractured at least one bone 
and the frequency of fractures was significantly higher than in the other diseases (Fisher’s 
exact test: p<0.02). The clinical features that were more frequent in those with fractures 
and PSP were also different to other diseases. Whereas in PD, MSA and control 
populations women were more at risk of fracture (Nordell et al., 2000) in PSP there was 
no association with female gender. In PSP only the absence of early bradykinesia, limb 
rigidity and pyramidal signs were significantly associated with fractures. When early 
bradykinesia, limb rigidity and pyramidal signs are present, patients maybe less likely to 
attempt to independently mobilise and therefore there maybe fewer opportunities of 
succumbing to the sequelae of poor balance and “motor recklessness” making fractures 
less frequent. Among the elderly in residential care facilities men fall more than women 
but fractures are more frequent in women. (Sadigh et al., 2004) In contrast, men with 
PSP had a similar propensity to fracture bones perhaps reflecting the nature of falling 
associated with the disease and the frontal cognitive deficits in many patients. There was 
no difference between clinical phenotypes in gender distribution. A similar pattern was 
seen in patients with VP, who often had some associated cognitive impairment.
The proportion of hip fractures was higher in PD than in PSP and MSA. (Table
11.17) There were a significantly smaller proportion of fractures at the ankle and foot in 
MSA than in PD and PSP. Fractures of the trunk (ribs, vertebrae and sternum) were 
proportionally more in PSP and MSA than in PD. In contrast to previous reports 
(Wielinski et al., 2005) rib and vertebral fractures were proportionally less than hip and 
proximal upper limb fractures in PSP. These studies have different methodology and the 
discrepancy may be explained if rib and vertebral fractures occur earlier in the disease,
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and hip and arm fractures later. In other respects, the location of fractures was similar 
between disease groups.
Nordell and colleagues reported that in a residential population of 65 to 74 year 
olds fractures of the arms, and in particular the distal radius, were most common with 
fractures of the proximal femur or hip being half as common as radial fractures. (Nordell 
et al., 2000) In all bradykinetic rigid syndromes diagnosed in this study this ratio was 
reversed, probably reflecting a common disturbance of postural reflexes. Bradykinesia 
prolongs reaction times following a postural challenge thereby compromising the 
protective responses, including outstretching of the arm, and thus limiting fractures of the 
forearm and wrist.
Conclusions
Falls and fractures are frequently associated with bradykinetic rigid syndromes. 
The disease burden associated with disturbances of posture, resulting in falls and factures 
appears to be highest in PSP. The significant difference between RS and PSP-P in 
latency to first fall supports a division of these clinical syndromes. While the mean 
latency to first fall is shorter in PSP-P than PD, the differences are not sufficiently 
discriminatory on their own to be helpful in the diagnosis of PSP-P. Patients with PSP, 
PD, MSA, DLB and VP should be assessed for the independent risk factors identified in 
this study.
The presence of early supranuclear gaze palsy, cognitive change and a lack of 
response to levodopa predict early falls and bone fractures in PSP. Patients with RS, and 
those with other bradykinetic rigid syndromes with symmetrical disease onset, postural 
instability, autonomic dysfunction and cognitive disturbance, and in particular women, 
may benefit from early assessment for osteoporosis, treatment of decreased bone mineral 
density and physiotherapy intervention to limit falling related morbidity. (Sato et al., 
2001)
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11.2.3. VH in pathologically diagnosed bradykinetic rigid syndromes
Background
VH are considered rare in bradykinetic rigid syndromes other than PD, and have 
not been systematically studied in pathologically diagnosed series that include these 
patients. There are, however, some clinical reports of VH in MSA, PSP and CBD. (Lees 
and Bannister, 1981; Aarsland et a l , 2001; Shimo et a l , 2001; Nagaoka et al., 2004) In 
these conditions LB do not usually occur in the frontal or temporal cortices, implying that 
when present VH are not due to Lewy body accumulation in the cortex. This distinction 
may be helpful when clinically diagnosing bradykinetic rigid syndromes, particularly 
when attempting to distinguish idiopathic PD from non-Lewy body Parkinsonism.
Aims
The aims of this study were to evaluate the relationship between pathological 
diagnosis and VH, specifically to determine if the presence of VH is helpful in 
distinguishing PSP-P from PD, and to quantify the temporal evolution of VH in each 
disease and analyse the relationship between VH and other clinical factors including 
medications.
Patients and methods
Patients
A retrospective analysis was performed using the clinical files of 788 patients 
with a lifetime diagnosis of a bradykinetic rigid syndrome or parkinsonism with a 
pathologically confirmed diagnosis (PD, n = 473; DLB (where cognitive dysfunction was 
recorded within the first year of disease onset), n = 44; PSP, n = 127; MSA, n = 91; 
VP, n = 27; AD, n = 9; CBD, n = 9; PEP, n=8) archived at the QSBB. All cases met the 
currently accepted pathological criteria for the diagnosis of these conditions. (Kosaka, 
1990; Mirra et a l, 1991; McKeith et a l, 1996; Litvan et a l, 1996b; Gilman et a l, 1999; 
Lantos, 2000) A number of cases could not be included in the analysis because of 
insufficient clinical data (28 PD, 7 PSP, 5 MSA, 2 AD, 2 VP). PD and DLB groups were 
combined (Lewy body Parkinsonism, LBP) for analysis because of the similar
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pathological substrate and arbitrary clinical definition which relies, in part, on the 
presence of VH in early disease to differentiate them.
Data Collection
A systematic chart review was performed as described in chapter 6. VH were 
recorded as present if they were specifically recorded, including formed VH and 
Fenelon’s minor form (presence, passage or illusion). (Fenelon et al., 2000) Time from 
disease onset to first VH (latency) was also recorded. Patients with isolated auditory or 
tactile hallucinations were not included. Visual acuity and field loss were not recorded in 
most patient files. Complete medication history was obtained, including latency to 
initiation and maximum dose for all medications except apomorphine and time to 
maximum dose for levodopa. The rate of levodopa increase after initiation, designated 
Tevodopa gradient’ (LG), was calculated: LG = maximum dose/time to reach maximum 
dose. Dopamine agonists (DA) were sub-divided into ergot and non-ergot groups in a 
further attempt to establish if a difference exists between their hallucinogenic potential. 
(Brunt et al., 2002) Calculation of a daily levodopa equivalent unit (LEU) dose was 
based on theoretical equivalence to levodopa (Evans et a l , 2004) as follows: 
bromocriptine (mg) x 10, cabergoline (mg) x 67, pergolide (mg) x 100.
Statistics analysis
The report of any VH from the time of disease onset until death was the primary 
outcome measure. The ability to predict LBP (PD and DLB) by the presence of VH was 
examined by calculating sensitivity, specificity, PPV and NPV against all the other 
diseases where Lewy bodies are not considered the pathological hallmark. Clinical 
characteristics in different diseases were compared. We investigated the associations 
between falls, bradykinesia, rigidity, tremor, cognitive dysfunction, speech disturbance, 
dysphagia, dystonia, dyskinesias, autonomic dysfunction, gender, symmetry of clinical 
features and age at disease onset with time to hallucinations in LBP. Univariable 
analyses using x2 for categorical and two-tailed t test for continuous variables were 
applied. Cox survival analysis was performed for LBP with latency to first VH and 
clinical factors present around disease onset (within the first two years) and gender as
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categorical covariates and age at onset as a continuous variable. The influence of 
medications on VH was investigated using Spearman’s correlation calculations for 
latency to medication initiation as a percentage of total disease duration versus latency to 
first VH as a percentage of disease duration in an attempt to correct for variability in 
disease length and severity. The maximum levodopa dose and LG were also compared to 
latency to first VH. The time from VH to death, expressed both as absolute time and 
percentage of disease duration, was compared amongst PD hallucinators.
Results
Amongst the 744 cases the incidence of VH was 36.6%. In PD, VH were 
reported in 221 (49.7%) patients and in DLB in 32 (72.7%). (Table 11.18) Eight patients 
(6.8%) with PSP experienced VH. In four, these were caused by dopaminergic 
medication and ceased on withdrawal of the offending medication and in a fifth there was 
a long history of alcohol dependence and post traumatic stress disorder. These patients 
were included in further analysis. Eight patients (9%) with MSA experienced VH and in 
three they occurred only after starting dopaminergic medications and did not persist after 
medication withdrawal. VH were reported in only one patient with VP (4%) and one 
with PEP (13%), but in none with AD or CBD. Table 11.18 shows the list of anti­
parkinsonian medications used in the different disease groups.
The specificity of VH for LBP was 92.9% and the PPV was 93.4% (95% Cl 89.7 
to 95.8), but sensitivity was 51.7% and NPV was 50.1% (95%CI 45.62 to 54.6). In LBP 
VH occurred a mean of 11 years after disease onset (PD mean 11.9 years, range 4.0-37.0, 
standard deviation(SD) 6.2; DLB mean 4.6, range 0.1-14.0, SD 3.5 ). There was no 
difference in disease duration between hallucinators and non-hallucinators. (Table 11.19). 
In PD hallucinators, VH occurred a mean of 53 months prior to death (standard deviation 
31.7 months; interquartile range (IQR) 25%-75%, 26-73 months), which corresponded to 
VH onset at 70% of total disease duration (IQR 25%-75%, 60-84%). (Figure 11.9). 
Correspondingly, those who experienced hallucinations earlier died earlier.
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PD DLB PSP MSA
Number 445 44 120 86
Mean age at onset 60.4 66.7 65.7 56.4
(range) (28.6-82.4) (43.0-82.6) (40.1-87.5) (33.5-79)
Mean age at death 76.2 74.9 73.7 64.4
(range) (49.8-93.4) (54.9-88.3) (45.4-95.8) (39.4-86.0)
Disease duration (years) 15.8 8.2 8.0 8.0
(range) (1.4-37.0) (3.7-15.8) (1.2-23.8) (2.4-16.5)
Women (%) 169(38) 9(20) 45(37) 49(55)
Hallucinators (%) 221 (49.7) 32 (72.7) 8 (6.8) 8 (9)
Latency to VH (years) 11.9 4.6 4.5 6.9
(range) (0.9-34.0) (0.1-14.0) (2.0-11.0) (4.0-11.0)
Medications
Levodopa (%) 99.8 93 76
Mean maximum 935 683 667
dose, mg/day (range) (125-4400) (250-1500) (125-1500)
Ergot DA (%) 50 25 17
Not-ergot DA (%) 10 7 7
Selegiline (%) 72 41 24
Amantadine (%) 29 25 28
Anticholinergic (%)_________ 55__________ 27   22
CBD VP AD PEP
9 25 7 8
66.2 70.5 68.1 26.9
(55.6-76.1) (59.4-81.3) (60.5-75.4) (9.1-38.1)
73.0 82.6 80.2 80.3
(65.8-81.6) (72.4-93.6) (71.0-94.6) (71-84.6
6.8 12.1 8.3 53.5
(3.6-10.2) (2.6-26.2) (1.3-17.0) (41.4-72.8)
6(33) 11 (44) 2(29) 4(50)
0 1(4) 0 1 (13)
10.5 28
66 88 92 82 75
973 833 684 647 759
(375-3000) (440-1125) (250-1250) (375-825) (500-1375)
45 22 24 22 38
7 11 0 0 0
50 33 44 33 13
26 22 8 0 38
42 11 28 22 63
Table 11.18 Clinical features according to pathological diagnosis
Patients
Hallucinators Non-hallucinators p value
Number 253 236
Women (%) 82 (37) 95 (40)
Age of onset 60.2 (30-82.6) 61.7 (28.6-82.3) 0.11
Disease duration (years) 14.6 (4.0-37.0) 15.6(1.4-41) 0.11
Levodopa
Number (%) 250 (99) 233 (99) 0.71
Latency (months) 34(1-216) 38(1-217) 0.32
Mean dose (mg) 944 (125-4400) 895 (250-2750) 0.32
Levodopa gradient 12.0 (0-25) 10.4 (0-18) 0.23
Ergot DA
Number (%) 135 (53) 100 (42) 0.015
Latency (months) 117 (10-401) 122 (26-390) 0.58
Mean dose (LEU) 579 (15-1400) 622 (15-1300) 0.62
Non-ergot DA
Number (%) 28(11) 16(7) 0.10
Latency (months) 166 (56-343) 185(41-432) 0.47
Selegiline
Number (%) 185 (73) 152 (64) 0.032
Latency ( months) 98 (6-324) 104 (7-341) 0.41
Mean dose (mg) 8.9 (5-20) 8.8 (5-15) 0.74
Amantadine
Number (%) 90 (36) 48 (20) <0.001
Latency (months) 94 (2-330) 87 (2-264) 0.65
Mean dose (mg) 220 (100-400) 184(100-300) 0.005
Anticholinergic
Number (%) 136 (54) 121 (51) 0.58
Latency (months) 57 (2-396) 61 (2-400) 0.62
Table 11.19 Medication use in patients with LB pathology (mean, (range), *)? or Student’s t- 
test)
179
°  >-----------— — i
0% 20% 40% 60% 80% 100%
D isease onset Death
Figure 11.9 Time of VH onset as a function of total disease duration in PD, median, 
interquartile range, outlier
LBP hallucinators were significantly more likely to be taking ergot derived DA, 
selegiline and amantadine (table 11.19). There was no association between 
anticholinergic medication and VH. Levodopa was used equally by hallucinators and 
non-hallucinators and there was no difference between these groups in maximum dose or 
time to reach maximum dose. In PSP, MSA, CBD, PEP and VP there was no difference 
in medication use between hallucinators and non-hallucinators.
In patients with LBP, univariable analysis showed an association between VH and 
cognitive dysfunction (x2, p=0.002), falls (p=0.005), postural instability (p=0.007), 
speech disturbance (p<0.0001), dysphagia (p=0.015), and autonomic dysfunction 
(p=0.041). Latency to first VH as a percentage of disease duration only weakly correlated 
with time to initiation of ergot dopamine agonists (Spearman’s rho 0.24, p=0.006) and 
selegiline (0-22, p=0.005) expressed as percentages of disease duration, but not time to 
maximum levodopa dose (0.11, p=0.15), amantadine (0.17, p=0.14), or anticholinergic 
drugs (0.14, p=0.11; table 10.20). The levodopa gradient and the maximum dose of 
levodopa were not correlated with latency to onset of VH. The assumptions for covariates 
used in multivariate analyses were found to be correct. The survival curves showed 
several early clinical factors that were independent predictors of onset of VH in patients 
with LBP (table 11.21).
180
Onset of hallucinations and time to: Spearman scorrelation r
Maximum levodopa dose 0.11 0.146
Initiation of ergot dopamine agonist 0.24 0.006
Initiation of selegiline 0.22 0.005
Initiation of amantadine 0.17 0.139
Initiation of anticholinergic medication 0.14 0.114
Table 11.20 Spearman’s correlation coefficient between time to onset of VH in LBP and time 
to initiation of medication expressed as a percentage of disease duration
Early clinical Hazard
features Ratio
Cognitive 5.62
dysfunction
Autonomic 3.13
dysfunction
Axial rigidity 2.22
Age of onset 1.05
Asymmetric onset 0.60
95% Cl P
3.37-9.35 <0.001
1.77-5.52 <0.001
1.26-3.85 0.006
1.03-1.07 <0.001
0.40-0.91 0.015
Table 11.21 Factors predictive of VH in LBP: multiple Cox regression analysis
Discussion
VH are common in PD and very uncommon in unmedicated PSP and MSA. VH 
are a frequent clinical accompaniment of LB pathology and are very infrequently seen in 
PSP and other bradykinetic rigid syndromes. The presence of VH predicted LBP with 
93% accuracy. VH occurred in 49.7% (221) of patients with PD and in nearly all cases 
VH occurred in the second half of the disease course. VH only weakly correlated with 
use of selegiline and ergot DA and not with levodopa use, amantadine or anticholinergic 
medications. They occurred earlier in patients with early cognitive dysfunction, 
prominent axial rigidity and autonomic dysfunction. Of the 15% of patients with LB 
pathology who experienced VH within 5 years of disease onset, most had a clinical 
syndrome consistent with DLB and the associated pathological features. Less than 4% of 
hallucinators with PD developed VH in the first 5 years.
In this study, the incidence of VH in PD was higher than previous cross sectional 
and longitudinal studies of shorter duration, (de Maindreville et a l, 2005) The
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retrospective methodology, using case notes without screening specifically for VH, 
means that this figure is also likely to be an underestimate of the true incidence. The 
proportion of patients in this study with non-LBP is higher than would be predicted by 
most community estimates of prevalence. (Schrag et al., 1999) Predictive values of VH 
for LBP are dependent on the prevalence of the diseases in the test population and 
therefore the PPV is likely to be higher than we have reported because of the over 
representation of non-LBP in this clinicopathological series and limits the generalisation 
of these findings. (Maraganore et al., 1999) Nonetheless these limitations applied 
equally to the different diseases, and should not influence the specificity of the results. 
We chose to record the first experience of VH in an attempt to clarify the clinical 
relevance of VH to the progression of disease and it was not possible to distinguish 
persistent VH from a single acute episode related to drug changes in many cases.
Once established, VH tend to be stable (de Maindreville et a l , 2005), probably 
reflecting encroachment of a-synuclein pathology into central visuoperceptual systems. 
(Diederich et al., 2005) In the context of pathological progression in Parkinson’s disease, 
this progression would correspond to Braak stage 4 or 5. (Braak et al., 2003) Although 
the onset of VH does not suggest a poorer prognosis than if there were no VH, 
progression to the second half of the course of PD is suggested. (Figure 11.9)
The relationship between dopaminergic therapy and the onset of VH is complex, 
(de Maindreville et a l , 2005) The facilitating role of dopaminergic treatment is well 
established, but VH are not an invariable complication of treatment and rarely occur in 
other conditions where dopaminergic treatment is used such as hyperprolactinaemic 
infertility and Ekbom’s syndrome. We found that the total dose and frequency of 
exposure to levodopa was similar between our LBP and non-LBP groups (see table
11.18). In most published clinical studies in PD levodopa dose did not correlate with the 
frequency or severity of VH. (Fenelon et a l , 2000; de Maindreville et a l , 2005) This is 
further supported by our findings that total levodopa dose, rate of levodopa increase and 
maximum levodopa dose do not independently correlate with VH or the time to first 
hallucination in PD or DLB. Ergot DA, selegiline and anticholinergic medications were 
used more often in LBP than PSP, MSA and other non-LBP. Amongst the LBP 
hallucinators, DA, selegiline and amantadine were prescribed more frequently than in
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non-hallucinators (see table 11.19) but the time to onset of VH did not correlate with 
exposure to the later and only weakly with ergot DA and selegiline when corrected for 
disease duration at the time of VH onset. While these medications may be more 
hallucinogenic than others, these results support the notion that the pathological substrate 
has a greater influence on the development of VH than the medications alone. (Holroyd 
et a l, 2001) Anticholinergic drugs are known to be a potent cause of hallucinations in 
patients without clinical evidence of neurodegenerative disease. (Perry and Perry, 1995) 
Extensive neocortical cholinergic deficits exist in DLB that are thought to contribute to 
VH and fluctuations of cognition, as well as to the sensitivity of these patients to 
anticholinergic and dopaminergic medications. (Perry and Perry, 1995) It is surprising 
that we have not found a correlation between time to VH onset and cholinergic 
medication use in LBP and may reflect patient selection. Because anticholinergic drugs 
have a mild effect on the motor features of PD and the tendency for cognitive dysfunction 
increases with disease progression, treating physicians are more likely to withdraw drugs 
or never prescribe them in patients at highest risk, which may explain the lack of 
correlation.
The association between VH and cognitive dysfunction and axial symptoms, 
including falls and dysphagia, is well established, (Levy et a l, 2000) and this 
combination may help to discriminate PSP-P from PD. Cognitive dysfunction was shown 
to have the largest influence on time to VH using Cox survival analysis (table 11.21). 
We found that autonomic dysfunction (see definition above) was also associated with VH 
and significantly influenced latency to first hallucination. Cognitive dysfunction, axial 
symptoms and autonomic dysfunction imply widespread LB pathology and are all 
common findings in DLB. (McKeith et a l, 1996) The risk of VH increased with 
increasing age of disease onset which may reflect the incidence of dementia in older 
patients and the superimposed effects of ageing. Ocular disorders are known to influence 
VH in PD (Diederich et a l, 2005) and are more likely to occur in older patients. 
(Teunisse et a l, 1996) REM sleep behaviour disorder and altered sleep-wake cycles have 
also been linked with VH in PD (Pappert et a l, 1999) but were not assessed. VH were 
less likely to develop in those patients with asymmetrical disease and those with tremor 
or dyskinesias. These clinical features may reflect the limited extent of pathological
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burden, or specific alterations in the dopaminergic or serotonergic systems, (Bibbiani et 
al., 2001; Diederich et al., 2005) that may reduce the risk of developing VH.
Conclusions
In patients with Parkinsonism, VH are highly specific for LBP and, when they 
occur in PD, indicate that, in that individual, more than half of the disease course has 
passed. The emergence of VH is not caused directly by dopaminergic medications but is 
influenced by the interaction of these medications with progressive a-synuclein 
pathological involvement of visuoperceptual systems. These findings need to be 
confirmed with a prospective cohort of clinically, and then pathologically diagnosed 
group of patients.
VH are a useful clinical sign associated with underlying LB pathology in 
Parkinsonism, and should be specifically asked for in the clinic. Minor and major 
hallucinations, as defined by the QSVHI, are very rarely reported in clinically and 
pathologically diagnosed PSP. In patients with unclassifiable Parkinsonism the presence 
of VH is highly suggestive of PD or DLB, rather than PSP-P or MSA. If however, VH 
precede the onset of Parkinsonism or completely disappear on withdrawal of 
hallucinogenic medications, non-LB pathology remains possible.
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The effect of separating the clinical phenotypes of PSP on the sample size 
needed to detect a treatment effect in prospectively studied patients was 
examined. Sample sizes required to detect the effect of a proposed disease- 
modifying treatment were estimated for all clinically diagnosed patients, for 
those with the correct clinical diagnosis of PSP and those clinically categorised 
as RS. For a treatment effect equivalent to a 20% (14 months) improvement in 
longevity, fewer PSP subjects would be required in each treatment arm when 
recruiting only those patients who fit the RS clinical phenotype (252 cf. 284).
Power calculations based on RS and PSP-P clinical subgroups confirm that this 
designation has the potential to improve the ability of clinical trials to evaluate 
the efficacy of a disease modifying treatment in PSP.
Introduction
Progressive supranuclear palsy (PSP) is diagnosed by identifying a symmetric 
bradykinetic rigid syndrome with early falls, a supranuclear gaze palsy (SNGP) and axial 
rigidity. (Steele et a l , 1964) The definitive diagnosis of PSP can only be made 
pathologically, as the accuracy in antemortem diagnosis is likely to be less than 90%. 
(Litvan et al., 1996a; Osaki et al., 2004) In the patients used for analysis in chapter 6.1 
the mean disease duration in RS was 5.9 years and in PSP-P was 9.1 years, compared to 
all PSP cases where disease duration was 7.0 years. The difference in disease duration 
between each clinically diagnosed group may be helpful in trial design, by improving 
homogeneity in treatment groups.
Aims
The aim of this study was to determine the effect of identifying these phenotypes 
for clinical trials where disease duration is the primary outcome measure.
Methods
A retrospective analysis was performed using the clinical files of 758 patients 
archived at the QSBB, and included PD/DLB, n = 490; PSP, n = 127; MSA, n = 90; 
CVD, n = 25; AD, n = 9; CBD, n = 9 and PEP, n=8. All patients clinically diagnosed as
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PSP and all pathologically diagnosed as PSP were included and separated according to 
the clinical phenotypes (RS and PSP-P).
Sample size requirements were estimated for number of events (deaths) needed to 
establish a 20% treatment effect on disease duration. The following standard formula 
was applied to estimate sample sizes in patients clinically diagnosed with PSP (Machin et 
al., 1997) (including path proven PSP and other pathological diseases), patients correctly 
diagnosed clinically as PSP (all pathologically proven) and patients correctly diagnosed 
with PSP and RS clinical phenotype:
Number o f  events needed (E) = 4(u + vf /lo g  (M /M 2)2
where u = 1.28 (the one sided percentage point of the normal distribution corresponding 
to 100%- the power) to provide 90% power and v = 1.96 (the percentage point of the 
normal distribution corresponding to the two-sided significance level) to test at the 5% 
level; Mi is median disease duration following final diagnosis in treatment group and M2 
is median disease duration following diagnosis in placebo group and therefore 
Mi/M2=HR. Numbers needed for different trial durations were calculated according to 
the following: E=(Mi+M2/2)x(trial durations). All calculations were performed based on 
the requirement that a trial should have 90% power to detect the specified treatment effect 
when a 2-sided 5% level of significance is used.
Results
Of the 758 cases reviewed, 114 had been clinically diagnosed with PSP. This 
diagnosis was confirmed in 93 (82%), and incorrect in 21 (18%, 12 (11%) with PD, 7 
(6%) MSA and 2 (2%) CBD). The median time to final clinical diagnosis was lowest in 
RS (table 12.1). In the clinically diagnosed cases the median disease duration was 6.5 
years (range 1.2-16.5; SD, 3.1 years). Eighty six of these patients were categorised as RS 
according to clinical features (median disease duration of 6.0 years, 1.2-13.5; SD, 2.4), 
including 76 with pathological PSP (89%), seven with pathological PD (8%), one with 
MSA (1%) and two with CBD (2%). The mean duration of disease was not significantly
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different between correctly and incorrectly diagnosed patients categorised RS (6.4 vs. 6.7 
t-test p=0.76).
In pathologically diagnosed patients the disease duration SD of RS was 
substantially lower than the PSP group as a whole. The sample size needed if only RS 
cases were to be included was around 25% less than if all PSP patients were included.
The results of the power calculations can be interpreted as follows: to have 90% 
power to detect the effect of a drug or intervention with an anticipated ability to increase 
disease duration by 20% (14 months) in all clinically diagnosed PSP patients, in a clinical 
trial with a 3 year follow-up period, 567 patients would be needed in total (table 12.2). 
To have the same power in a trial lasting 3 years in all clinically diagnosed PSP patients 
with only a RS phenotype, 504 patients would be needed in total.
Median time Median disease SD
to final diagnosis duration
(range) yrs (range) yrs
Clinical diagnosis of PSP
All n=114 3.2 6.5 3.1(0.4-14.5) (1.2-16.5)
Correct diagnosis n=93 3.1(0.4-14.5)
6.4
(1.6-16.5)
3.1
RS phenotype only n=86 2.9 6.0 2.4(0.5-8.5) (1.2-13.5)
Pathological diagnosis of PSP
All n=127 2.8(0.3-14.5)
7.4
(1.2-23.8)
4.7
RS n=86 2.8(0.5-12.4)
6.1
(1.2-14.5)
2.5
Table 12.1 Homogeneity in clinical phenotypes of PSP
Number of events Trial duration (yrs)
needed 2 3 4 5 6
Clinical diagnosis 
of PSP 
All 436 850 567 425 340 283
Correct diagnosis 436 850 567 425 340 283
RS phenotype 403 756 504 378 302 252
only 
Pathological 
diagnosis of PSP 
All 781 1134 756 567 453 378
RS 436 850 567 425 340 283
Table 12.2 Effects of clinical phenotype on sample size in clinically diagnosed PSP
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Discussion
Power calculations based on RS and PSP-P clinical subgroups confirm that this 
designation has the potential to improve the ability of clinical trials to evaluate the 
efficacy of a disease modifying treatment in PSP.
The few therapeutic trials in PSP have failed to demonstrate consistent clinical 
benefits or disease modification. (Ghika et a l, 1991; Kompoliti et al., 1998; Litvan et a l, 
2001; Bum and Warren, 2005) With the development of several agents that have the 
potential to modify the natural history and even the pathophysiology of PSP (Bum and 
Warren, 2005), the scene is set for the development of appropriate research strategies to 
test these agents. However, in the absence of validated, sensitive clinical tools designed 
specifically for PSP, future trials for symptomatic and putative neuroprotective 
interventions risk type II error. Measures of functional status and quality of life in PSP 
have been proposed but have not been assessed prospectively. (Goetz et a l, 2003; Schrag 
et a l, 2005) In the absence of reliable markers of disease progression one strategy for 
testing disease modifying agents is survival analysis of treatment versus placebo. The 
sample sizes needed to perform this type of trial have been estimated using data from 
pathologically confirmed cases.
The shorter disease duration in RS compared to PSP-P reduces the sample size to 
detect a significant difference in survival. One of the other important factors in 
determining sample size is the heterogeneity (SD) of the studied disease group. This 
variability arises as a result of natural differences between individuals or as a result of 
pathophysiological or anatomical differences in disease. The more homogeneous the 
study population, the easier it is to detect a small treatment effect. By separating RS and 
PSP-P the homogeneity, and therefore the power of clinical trials using any marker of 
disease progression is likely to be enhanced, and it is recommended that these 
considerations are included in future trial designs.
The prevalence of PSP is around 5 per 100,000 (Schrag et a l, 1999; Nath et a l, 
2001), and compared to PD it is relatively rare, suggesting a small pool of available 
potential participants for any clinical trial. Sample size calculations indicate that by 
identifying and recruiting RS patients, 504 patients would need to be included in a
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clinical trial to detect significant improvement in longevity, compared to 567 for 
clinically diagnosed PSP. The resources needed for this type of trial would be substantial 
and argue for the development of some validated surrogate marker for disease 
progression.
Several limitations are acknowledged in these findings. Firstly archived brain 
bank cases are not entirely representative of community based cases. (Maraganore et al., 
1999) Ascertainment bias from autopsy series favour patients with shorter disease 
durations, however the long recruitment period and consistency with other clinical reports 
suggest that this effect is likely to be small and outweighed by the strength of 
pathological confirmation. Finally the clinical designation was based on principal 
components factor analysis, and has not been confirmed prospectively.
Time to death is a reliable end point for the design of trials in PSP, and the 
numbers needed to power the trials are less if patients with only RS are included. Even if 
techniques for confirming the presence of PSP-tau pathology in life are developed, or 
surrogate markers of disease progression are validated, the stratification of RS and PSP-P 
will increase the homogeneity of clinical trials and therefore limit the likelihood of type II 
error.
Conclusions
Conducting a large multi-centre trial using time to death as a reliable end point, 
might be practical if patients with RS are identified. Such a trial would require 504 
patients and could be complete within 5 years of recruitment.
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In 1963 Richardson described a distinctive clinical syndrome that was found to be 
associated with subcortical gliosis and pathological tau accumulation in a number of 
subcortical regions. Richardson called it progressive supranuclear palsy and it is now 
recognised as the second most common cause of neurodegenerative Parkinsonism.
The pathological characteristics of this distinct clinical syndrome have broadened 
with technological advances in immunohistochemistry, electron microscopy and protein 
analysis. PSP-tau pathology shares much in common with other tauopathies, and in 
particular CBD, PEP and PDC-Guam, but can be defined by relatively severe tau 
pathology in subcortical nuclei and the presence of tufted astrocytes. Pathological 
differentiation, however, in individual cases is sometimes difficult. Regional 
pathological heterogeneity has previously been identified but the lack of apparent clinical 
correlations has confounded efforts to improve clinical and pathological diagnostic 
criteria.
It has become evident that the pathological diagnosis of PSP can be made in 
patients who do not develop many of the clinical features described by Richardson. 
These patients have previously been referred to in the literature as “atypical” PSP.
This thesis has explored the clinical and pathological heterogeneity in PSP and 
two other clinical syndromes have been identified that allow for a more refined 
classification of this prototypic primary tauopathy. The continuum of clinical and 
pathological features in PSP and the overlap with CBD, PEP and PDC Guam, makes 
absolute distinction between these clinicopathological entities impossible.
Richardson’s syndrome, identified by onset of falls, supranuclear eye movement 
abnormalities and cognitive dysfunction within the first two years of disease, is distinct 
from other forms of Parkinsonism. It is recognised with high accuracy in movement 
disorders clinics and is characterised by relentless deterioration to death within six or 
seven years. The pathological hallmarks of RS are neuronal and glial tau pathology in 
specific nuclei in the brainstem, cerebellum and, contrary to original reports, in some
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areas of the cerebral cortex. Tau accumulation in the pontine base is made of 
predominantly 4R-tau.
The clinical syndrome of PSP-Parkinsonism differs from RS. Clinical features 
within the first two years of disease have more in common with PD than RS, often with 
asymmetric onset o f tremor and moderate response to levodopa. The supranuclear gaze 
palsy, cognitive dysfunction and falls occur later, if at all, and the mean disease duration 
to death is about 10 years. Pathological differentiation of PSP-P from RS is not straight 
forward, and the substantial pathological overlap between these syndromes implies a 
common aetiopathologenetic substrate. While in both syndromes the STN and SN are 
most severely affected, in PSP-P the distribution of pathology outside of these structures 
is more limited. A difference in pathological tau biochemistry hints at some modification 
of the pathological process involved in PSP-P compared to RS. Trends in the odds ratios 
for the PSP-susceptibility tau haplotype suggest that genetic factors could be responsible 
for the differences, but tau mutations appear not to be.
Pure akinesia with gait freezing is a further distinct clinical entity and the absence 
of rigidity and other signs of RS and PD distinguish this syndrome. It appears to rarely 
be associated with Lewy body pathology and may be confused with vascular 
Parkinsonism. Patients with PSP-PAGF have longer disease duration than RS. In 
general the pathological-tau severity is less and is more limited in its extent than in PSP- 
PAGFthaninRS.
The accuracy of applying operational diagnostic criteria in movement disorders 
clinics is skewed by differences in the prevalence of different diseases. The specificity of 
the criteria for diagnosing PD is not sufficiently high to reliably exclude PSP-P. 
Identifying the presence of visual hallucinations increases the specificity for PD, and is 
an important exclusion criterion for the diagnosis PSP. In both RS and PSP-P the mean 
time to first fall is significantly less than PD, emphasising the importance of this clinical 
feature in the clinical prediction of underlying PSP-tau pathology. However, the 
specificity of falls before 6 years is not sufficiently high to separate PSP-P from PD. 
Olfaction is not always normal in PSP, but is much more likely to be preserved than in 
PD. A severely abnormal result on UPSIT testing is suggestive of underlying Lewy body 
pathology, increases the specificity for PD and makes PSP unlikely. Electrophysiological
191
testing of the auditory startle response is usually abnormal in established RS and PSP-P, 
and the degree of abnormality probably reflects the extent of pathological involvement in 
the midbrain and pons. Abnormalities in both ASR and ABR suggest RS rather than PD.
The extension of clinical observations in these studies challenges the classic view 
of PSP and, according to Charcot’s anatomoclinical approach, argues for a nosological 
separation of RS, PSP-P and PAGF. All three conditions are clearly linked by the 
presence of characteristic pathological lesions in STN, SN and GP, but are separated by 
the extent and distribution of that pathology, their natural history and biochemical profile.
The clinical differences between RS, PSP-P and PAGF are sufficient to warrant 
separation from ‘PSP’, in the same way that PEP and PDC Guam are considered 
separately. These differences should be acknowledged and a modified understanding of 
what, exactly, constitutes PSP may improve efforts to discover aetiological factors and 
disease modifying therapies. Problems with the nosology of PSP are not unusual, and the 
same issues confound the understanding of PD, AD and MND. (Caine, 2005) In these 
conditions conventional clinical and anatomoclinical definitions of disease are being 
adapted to incorporate advances in molecular biology and aetiopathogenesis. A sub­
classification of the extent and distribution of PSP-tau pathology would also provide a 
plausible framework for considering further clinicopathological correlations. The 
pathological overlap with PDC Guam, PEP and pallidonigro-luysian atrophy needs 
further clarification and, if a definitive classification is to be achieved, future studies need 
to critically evaluate the pathological differences between these diseases and RS, PSP-P 
and PAGF.
A proportion of patients with unclassifiable Parkinsonism will go on to develop 
PSP-P, and a small proportion of patients with clinically diagnosed PD will prove to have 
PSP-tau as the underlying pathology. These patients can be identified by the absence of 
drug induced dyskinesias, autonomic failure and visual hallucinations, the presence of 
falls within 6 years of disease onset, UPSIT scores above the 12th percentile for gender 
and age, and abnormalities in ASR. Even if the diagnosis of PSP is made late in the 
disease these patients should be stratified separately in clinical trials because the 
underlying pathology is likely to be less extensive and less severe and the clinical 
features and prognosis are different to RS. Patients whose clinical features fit the profile
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of PSP-P, and where PAGF, corticobasal syndrome or progressive non-fluent aphasia is 
diagnosed, an accurate ante-mortem diagnosis of PSP-tau pathology may be best served 
by the development of a biomarker for the presence of tau pathology. An understanding 
of the genetic and environmental factors that contribute to clinical and pathological 
heterogeneity in PSP is likely to shed further light on the mechanisms that lead to tau 
pathology.
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The genetics the easel, 
and proteins the paint; 
History the brush strokes, 
first symptoms health’s feint.
With science and series, 
a picture is made;
After death the answer? 
Charcot’s method to sate.
This picture we see, 
is just words in a  book;
For disease, this is not, 
ask the patient, then look.
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UKPDSBB Criteria for the diagnosis of PD (Gibb and Lees, 1988)
Step 1: Diagnosis of Parkinsonian syndrome
• Bradykinesia (slowness of initiation of voluntary movement with progressive reduction in speed 
and amplitude of repetitive actions)
And at least one of the following:
• Muscular rigidity
• 4-6 Hz rest tremor
• Postural instability not caused by primary visual, vestibular or proprioceptive dysfunction
Step 2: Exclusion criteria for PD
• History of repeated strokes with stepwise progression of Parkinsonian features
• History of repeated head injury
• History of definite encephalitis
• Oculogyric crises
• Neuroleptic treatment at onset of symptoms
• More than one affected relative
• Sustained remission
• Strictly unilateral features after 3 years
• Supranuclear gaze palsy
• Cerebellar signs
• Early severe autonomic involvement
• Early severe dementia with disturbances of memory, language and praxis
• Bab inski’s sign
• Presence of cerebral tumour or communicating hydrocephalus on computed tomography
• Negative response to large dose of levodopa
• MPTP exposure
Step 3: Supportive prospective positive criteria for PD (three or more required for diagnosis of definite PD)
• Unilateral onset
• Rest tremor present
• Progressive disorder
• Persistent asymmetry affecting side of onset
• Excellent response to levodopa (70-100%)
• Severe levodopa induced chorea
• Levodopa response for 5 years or more
• Clinical course of 10 years or more
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Consensus criteria for the diagnosis of multiple system atrophy (Gilman et aL, 
1999)
Clinical domains, feature and criteria used ia  the diagnosis of MSA. A feature (A) is a characteristic of die disease and a criterion (B) is a Arfmmg feature 
or composite of features required for diagnosis
1 Autonomic and urinary dysfunction 
A. Autonomic and urinary features
1. Orthostatic hypotension (by 20 mmHg systolic ot 10 mmHg diastolic)
2. Urinary incontinence or incomplete bladder emptying
B Criterion for autonomic failure or urinary dysfunction in MSA
Orthostatic fall in blood pressure (by 30 mmHg systolic a  15 mmHg diastolic) or 
urinary incontinence (persistent, involuntary partial or total bladder emptying, accompanied 
by erectile dysfunction in mm) or both 
H  Parkinsonism
A. Parkinsonian features
1. Bradykinesia (slowness of voluntary movement with progressive reduction in 
speed and amplitude during repetitive actions)
2. Rigidity
3. Postural instability (pot caused by primary visual vestibular, cerebellar, or 
proprioceptive dysfunction)
4. Tremor (postural resting ot both)
B Criterion for parkinsonism in MSA
Bradykmesia plus at least one of items 2 to 4 
IE. Cerebellar dysfunction 
A  Cerebellar features
1. Gait ataxia (wide based stance with steps of irregular length and direction)
2. Ataxic dysarthria
3. Lamb ataxia
4. Sustained gaze-evoked nystagmus
B. Criterion for cerebellar dysfunction in MSA 
Gait ataxia phis at least one of hems 2 to 4
IV. Corticospinal tract dysfunction 
A. Corticospinal tract features
1. Extensor plantar responses with hypeneflexaa 
B Corticospinal tract dysfunction in MSA no corticospinal tract features are used 
in defining the diagnosis of MSA
Exclusion criteria fin die diagnosis o f MSA 
L History
Symptomatic onset under 30 years of age 
Family history of a similar disorder
Systemic diseases or other identifiable causes for features listed in Table 1 
Hallucinations unrelated to medication 
II Physical examination 
DSM criteria for dementia
Prominent slowing of vertical saccades or vertical supranuclear gaze palsy'
Evidence of focal cortical dysfunction such as aphasia, alien limb syndrome, and parietal dysfunction 
IH Laboratory investigation
Metabolic, molecular genetic and imaging evidence of an alternative cause of features listed in Table 1
Tn practice. MSA is most frequently confused with Parkinsons disease or progressive supranuclear palsy (PSP) [14]. Mild limitation of upward gaze alone 
is nonspecific, whereas a prominent (>  50%) hzmtatien of upward gaze ot any limitation of downward gaze suggests PSP [13] Before die onset of vertical 
gaze limitation, a clinically obvious slowing of voluntary vertical saccades is usually easily detectable in PSP and assists in tire early differentiation of these 
two disorders [13]
Diagnostic categories of MSA The features and criteria for each clinical domain are shown m Table 1
L Possible MSA: one criterion plus two features from separate other domains. When the criterion 
is parkinsonism, a poor levodopa response qualifies as one feature (hence only one additional 
feature is required).
II Probable MSA: criterion tor autonomic failure urinary dysfunction phis poorly levodopa 
responsive parkinsonism or cerebellar dysfunction.
HI Definite MSA pathologically confirmed by the presence of a high density of ghai cytoplasmic 
inclusions in association with a combination o f degenerative changes in the mgrostriatal and 
olivopontocerebellar pathways.
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Possible criteria for the clinical diagnosis of vascular Parkinsonism (Zijlmans et ah, 
2004a)
A. Parkinsonism:
• bradykinesia
• and at least one of the following:
o  rest tremor, 
o  muscular rigidity,
o  postural instability not caused by primary visual, vestibular, cerebellar or proprioceptive 
dysfunction
B. Cerebrovascular disease:
• defined by evidence of relevant cerebrovascular disease by brain imaging (CT or MRI)
•  or  the presence of focal signs or symptoms that are consistent with stroke
C. A relationship between the above two disorders. In practice:
• An acute or delayed progressive onset with infarcts in or near areas that can increase the basal 
ganglia motor output (GPe or substantia nigra pars compacta) or decrease the thalamocortical 
drive directly (VL of the thalamus, large frontal lobe infarct). The Parkinsonism at onset consists 
of a contralateral bradykinetic rigid syndrome or shuffling gait, within 1 year after a stroke (VPa).
• An insidious onset of Parkinsonism with extensive subcortical white matter lesions, bilateral 
symptoms at onset, and the presence of early shuffling gait or early cognitive dysfunction (VPi).
Exclusion criteria for VP:
• History of repeated head injury,
• History of definite encephalitis
• Neuroleptic treatment at onset of symptoms
• Presence of cerebral tumor or communicating hydrocephalus on CT or MRI scan
• Other alternative explanation for Parkinsonism.
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Queen Square Visual Hallucination Inventory
MMSE: UPDRSII (on): UPDRS III:
H&Y: 1 1.5 2 2.5 3 4 5
Psychiatric history:____________________________________________________
Ocular pathology: □ None □ Cataracts □ Retinal disease □ Glaucoma □ Spectacles
A “Have you had any unusual visual experiences or hallucinations in the past 3 months?” YES NO
i f  YF.S “In relation to these experiences in the last 3 months ” - > G O  T O  B
I f  N O “Have you had any unusual visual experiences more than 3 months ago?”
if  YTS “In relation to these experiences ” T i i O  ' I O B
I f  N O  - X i O  I O  B a n y w a y  t o  c o n f i r m  a b s e n c e  o f h a i i u e i n a t i o n s  ' i l lu s i on s
B Minor hallucinations/Ulusions:
“Have you had the vivid sensation of the presence of somebody in the room with you, 
when in fact there was no one there?”
“Have you experienced a brief vision of movement past you, of perhaps an animal or 
person, when in fact there was nothing there? -> If yes, also complete page 2
“Have you looked at something and it appeared as something else for a time?”
“For example spots in the wall appearing as insects, or faces in patterns on fabrics or 
the carpet?”
C Formed visual hallucinations:
“Have you had visions of people, animals or objects that were in fact not there?”
“Did you hear these people/animals/objects make any noise?”
D Auditory hallucinations:
“Have you heard sounds of people talking, music or other noises when in fact there 
was no sound?”
E Details:
“When did these unusual experiences start?” M M  Y Y  “...and finish?” \ i \ f Y Y  
“Were they related ONLY to medications?”
Were the visual experiences related to delirium (as defined by DSM-IV)?
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